Research activity information

• May 2026 Springer Nature, Springer Nature Editor of Distinction Awards 2026


• Jun. 2021 The Japan Society of Transfusion Medicine and Cell Therapy, Excellent Poster Award, 本邦の細胞治療(造血幹細胞採取等)に関する実態調査 (細胞治療合同委員会 造血幹細胞移植関連委員会からの報告) その1


• Mar. 2015 神戸大学医学部, ベストティーチャー賞, 神戸大学医学部附属病院 医師

  Yakushijin Kimikazu, 倉田啓史, 高谷具史

  Others

• Letermovir prophylaxis and risk of bacterial or fungal infection after allogeneic hematopoietic cell transplantation.

  Shun-Ichi Kimura, Shunto Kawamura, Takashi Toya, Keiji Okinaka, Hiroki Hosoi, Naoyuki Uchida, Noriko Doki, Tetsuya Nishida, Masatsugu Tanaka, Yuta Hasegawa, Yoshinobu Kanda, Noboru Asada, Naoki Kurita, Hirohisa Nakamae, Tetsuya Eto, Makoto Yoshimitsu, Makoto Onizuka, Takahiro Fukuda, Marie Ohbiki, Yoshiko Atsuta, Kimikazu Yakushijin

  BACKGROUND: Previous reports have suggested an association between cytomegalovirus (CMV) infection and bacterial or fungal infections after allogeneic hematopoietic cell transplantation (HCT). This study aimed to examine the relationship between letermovir (LTV) prophylaxis and the incidence of bacteremia and invasive fungal infections. METHODS: Using a Japanese transplant registry database, we analyzed 19,531 patients who underwent their first allogeneic HCT from 2011 to 2022. Patients who initiated LTV prophylaxis within the first week post-transplantation were classified as the LTV group. RESULTS: A total of 4915 patients in the LTV group and 14,616 in the No LTV group were analyzed. The incidence of bacteremia by day 100 was significantly lower in the LTV group compared to the No LTV group (17.4 % vs. 21.7 %, P < 0.001). In the multivariate analysis, LTV prophylaxis (HR 0.75, 95 %CI: 0.69-0.81) was found to be significantly associated with a reduced risk of bacteremia, along with neutrophil engraftment. Age >50 years, male, non-remission status, alternative donors, higher values of the hematopoietic cell transplantation-comorbidity index, poor performance status, and grade II-IV acute graft-versus-host disease were associated with an increased risk of bacteremia. LTV was associated with a reduced risk of bacteremia both within 30 days (HR 0.74, 95 %CI: 0.68-0.81) and beyond 30 days (HR 0.76, 95 %CI: 0.66-0.89) after HCT. Conversely, it was not associated with the risk of invasive aspergillosis or candidemia. CONCLUSIONS: LTV prophylaxis significantly reduced the risk of bacteremia. However, it was not associated with the risk of invasive fungal infections.

  Jan. 2026, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 32(1) (1), 102888 - 102888, English, International magazine

  Scientific journal


• Humoral immunity after hematopoietic stem cell transplantation: evaluation by B-cell receptor repertoire analysis.

  Sakuya Matsumoto, Yohei Funakoshi, Kimikazu Yakushijin, Takaji Matsutani, Yuri Okazoe-Hirakawa, Goh Ohji, Taiji Koyama, Yoshiaki Nagatani, Keiji Kurata, Shiro Kimbara, Naomi Kiyota, Hironobu Minami

  Immunity acquired before hematopoietic stem cell transplantation (HSCT) may decrease or disappear following HSCT, and it is unclear whether the first vaccination after HSCT in patients with an antigen exposure history before HSCT elicits a primary or secondary immune response. The Quantification of Antigen-Specific Antibody Sequence (QASAS) method enables real-time assessment of responses to SARS-CoV-2 antigen exposure through B-cell receptor (BCR) repertoire analysis. Using this method, we evaluated the disappearance of immunological memory after HSCT. First, in individuals without hematologic disorders, primary SARS-CoV-2 antigen exposure elicited no immune response at 7 days post-exposure but demonstrated activation between 14 to 21 days. In contrast, repeated exposure elicited early responses (secondary immune responses) at 7 days post-exposure. We then enrolled HSCT patients with pre-HSCT SARS-CoV-2 antigen exposure history and collected samples before and after vaccination. Despite prior exposure history, patients receiving their first vaccination after HSCT showed no response around 7 days post-exposure but responded at 14 days. In conclusion, even with pre-HSCT antigen exposure, the first vaccination after HSCT induced a primary immune response. This demonstrates that first vaccination after HSCT should be considered to induce a primary immune response, regardless of previous infection or vaccination history.

  Dec. 2025, International journal of hematology, 122(6) (6), 877 - 884, English, Domestic magazine

  Scientific journal


• Plateletpheresis for treating essential thrombocythemia that developed during pregnancy: A case report.

  Naohisa Masuko, Kenji Tanimura, Koki Moriuchi, Tomomi Kita, Kenta Obata, Sonoko Suda, Hitomi Imafuku, Masashi Deguchi, Keiji Kurata, Kimikazu Yakushijin, Keiji Kono, Takuya Kawakatsu, Yoshito Terai

  OBJECTIVE: Essential thrombocythemia (ET), a life-threatening disease, is associated with increased risks of hemorrhagic and thromboembolic complications. In particular, ET during pregnancy is rare and associated with an increased risk of obstetric complications. Drug therapies are frequently administered for managing pregnant women with ET, and plateletpheresis is considered to reduce platelet (PLT) counts rapidly. CASE REPORT: A 28-year-old pregnant woman was referred to our hospital at 37 + 0/7 gestational weeks (GWs) due to severe thrombocythemia. She underwent plateletpheresis at 37 + 4/7 GWs because thrombocythemia was exacerbated. She delivered vaginally at 38 + 0/7 GWs without hemorrhagic or thromboembolic complications. She was diagnosed with ET based on a bone marrow biopsy, and ET gradually improved with medication. Thus, she and her baby were discharged without complications. CONCLUSION: Plateletpheresis is useful for preventing hemorrhagic and thromboembolic complications at delivery in pregnant women with ET and severe thrombocythemia during the antepartum period.

  Jul. 2025, Taiwanese journal of obstetrics & gynecology, 64(4) (4), 703 - 706, English, International magazine

  Scientific journal


• Heterogeneity of Survival Benefit Conferred By Letermovir

  Yu Akahoshi, Hideki Nakasone, Katsuto Takenaka, Takahide Ara, Yuma Tada, Noriko Doki, Naoyuki Uchida, Masatsugu Tanaka, Yuta Hasegawa, Wataru Takeda, Tetsuya Nishida, Jun Ishikawa, Naoki Kurita, Masashi Sawa, Makoto Onizuka, Shinichi Kako, Shin-Ichiro Fujiwara, Keisuke Kataoka, Koji Kawamura, Takahiro Fukuda, Yoshiko Atsuta, Kimikazu Yakushijin, Yoshinobu Kanda

  Elsevier BV, Jul. 2025, Transplantation and Cellular Therapy, 31(7) (7), 461.e1 - 461.e12

  Scientific journal


• Importance of E/e' and BNP for early detection of late cardiotoxicity in long-term follow-up of childhood hematologic cancer survivors: a retrospective cross-sectional study.

  Yuri Okazoe-Hirakawa, Kimikazu Yakushijin, Keiji Kurata, Sakuya Matsumoto, Hiroya Ichikawa, Rina Sakai, Taku Nose, Shiro Kimbara, Yoshiaki Nagatani, Taiji Koyama, Yumiko Inui, Yohei Funakoshi, Naomi Kiyota, Mitsuhiro Ito, Keiko Hatazawa, Hidekazu Tanaka, Nobuyuki Yamamoto, Hironobu Minami

  BACKGROUND: Childhood cancer survivors (CCS) often develop late complications after their primary disease is cured. Cardiovascular disease is one of the most frequent and serious complications that significantly affects prognosis and quality of life. Early detection and appropriate intervention are expected to improve their prognosis. However, the risk factors for late cardiotoxicity in CCS are not well defined, and biomarkers that can detect cardiac dysfunction prior to the development of heart failure have not yet been established. METHODS: Medical records of childhood hematologic cancer survivors referred to our department for transitional care between January 2016 and October 2023 were reviewed for this cross-sectional study. The relationships between the most recent cardiac function at the review and history of cancer treatment were analyzed. RESULTS: This study included 34 patients and the median elapsed time since cancer diagnosis was 16.5 years (range, 5-30 years). None of the patients had symptomatic cardiac complications. The E/e' ratio was significantly higher in survivors with a history of hematopoietic stem cell transplantation (HSCT) than in those who did not undergo HSCT (median, 8.4% vs. 6.25%, P = 0.040), while no intergroup differences were observed in ejection fraction (EF), global longitudinal strain (GLS), or the brain natriuretic protein (BNP) level. In addition, the E/e' ratio was positively correlated with years elapsed since cancer diagnosis (ρ = 0.38, P = 0.034). While there was no clear correlation between years since cancer diagnosis and the BNP level in the overall cohort, a strong correlation was found in patients with a history of HSCT (ρ = 0.73; P < 0.01). No significant differences were observed in EF, E/e' ratio, GLS, and BNP level by cumulative anthracycline dose or history of chest irradiation. CONCLUSIONS: In this study, no patient had late symptomatic cardiac complications. However, in those who had survived for a long time since their cancer diagnosis, particularly those with a history of HSCT, there were significant elevations in the E/e' ratio and the BNP level. Continuous follow-up is required to determine whether these abnormalities lead to symptomatic cardiotoxicity and whether they serve as useful markers for the early detection of cardiac complications.

  Jun. 2025, Cardio-oncology (London, England), 11(1) (1), 55 - 55, English, International magazine

  Scientific journal


• Impact of center volume on outcomes in allogeneic hematopoietic cell transplantation for children.

  Motohiro Kato, Hideki Nakashone, Keitaro Matsuo, Yuri Ito, Atsumi Yanagisawa, Marie Ohbiki, Ken Tabuchi, Tatsuo Ichinohe, Yoshiko Hashii, Junya Kanda, Hideki Goto, Koji Kato, Makoto Yoshimitsu, Atsushi Sato, Moeko Hino, Kimikazu Matsumoto, Kimikazu Yakushijin, Yoshiko Atsuta, Takahiro Fukuda

  The impact of center volume on outcomes in pediatric hematopoietic cell transplantation (HCT) is not well established. We retrospectively analyzed data from a nationwide registry, including 6966 pediatric patients who underwent their first allogeneic HCT at 123 centers in Japan between 2001 and 2020. Centers were categorized by transplant volume as low volume centers (C1, the smallest number of transplantation), medium-low volume centers (C2), medium-high volume centers (C3), and high volume centers (C4, the greatest number of transplantation), and outcomes were compared across these categories. The analysis revealed no statistically significant differences in HCT outcomes among center categories. The 5-year OS by center category was 66.8% (95% CI 64.4-69.0%) for C1, 66.8% (95% CI 64.5-69.0%) for C2, 67.9% (95% CI 65.6-70.2%) for C3, and 68.3% (95% CI 65.9-70.6%) for C4. These results were consistent even when analysis was restricted to malignant and nonmalignant diseases. Our findings suggest that, unlike in adult HCT, outcomes for pediatric HCT are not significantly affected by center volume. These results indicate the consistent quality of care across centers, supporting the accessibility of HCT at various institutions for pediatric patients.

  Jun. 2025, Bone marrow transplantation, 60(6) (6), 851 - 856, English, International magazine

  Scientific journal


• A Rare Case of Pseudohypercalcemia Associated with Multiple Myeloma.

  Chiharu Mishima, Kimikazu Yakushijin, Hidenori Fukuoka, Ruri Takahashi, Yuri Okazoe, Miki Joyce, Sakuya Matsumoto, Rina Sakai, Yumiko Inui, Keiji Kurata, Hironobu Minami

  We report a rare case of pseudohypercalcemia associated with multiple myeloma in a 77-year-old woman. Despite elevated albumin-corrected calcium levels (12.6 mg/dL), ionized calcium levels remained normal (1.25 mmol/L). Differential diagnoses excluded common causes of hypercalcemia, and the findings suggested calcium binding to negatively charged immunoglobulins and confirmed pseudohypercalcemia due to IgG-type myeloma. Treatment with isatuximab plus dexamethasone normalized albumin-corrected calcium levels as IgG levels decreased. This report highlights the importance of recognizing pseudohypercalcemia to prevent misdiagnosis of true hypercalcemia due to myeloma. Measuring ionized calcium levels is crucial for accurate diagnosis when hypercalcemia is suspected without corresponding clinical symptoms.

  May 2025, The Kobe journal of medical sciences, 71(2) (2), E46-E49, English, Domestic magazine

  Scientific journal


• Impact of Conditioning Intensity on Clinical Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Relapse After First Transplantation

  Kazuki Yoshimura, Hideki Nakasone, Masaharu Tamaki, Hiroki Hosoi, Kazuaki Kameda, Naoyuki Uchida, Noriko Doki, Takahiro Fukuda, Satoshi Yoshihara, Yasuo Mori, Hirohisa Nakamae, Masatsugu Tanaka, Yuta Katayama, Tetsuya Eto, Yuta Hasegawa, Shuichi Ota, Satoshi Takahashi, Makoto Yoshimitsu, Fumihiko Ishimaru, Junya Kanda, Yoshiko Atsuta, Kimikazu Yakushijin

  ABSTRACT Although second allogeneic hematopoietic cell transplantation HCT (HCT2) is a potentially curative treatment for patients relapsing after their first HCT (HCT1), it is associated with higher non‐relapse mortality (NRM) compared with HCT1. Furthermore, while reduced‐intensity conditioning (RIC) in HCT2 might decrease NRM, there is no consensus on which patients may benefit from RIC. We retrospectively analyzed 2478 patients who underwent HCT2 for relapse of hematologic malignancies after HCT1. In a multivariate analysis, older recipient age, short duration between HCT1 and HCT2, RIC in HCT1, HCT‐CI ≥ 2, and ECOG PS ≥ 2 were associated with an increased risk of NRM. RIC in HCT2 was associated with better NRM compared to myeloablative conditioning (MAC) (hazard ratio [HR] 0.83, 95% confidence interval [CI]: 0.72–0.97; p = 0.018), but was not significantly associated with overall survival (OS) (HR 0.91, 95% CI: 0.82–1.01; p = 0.075). We observed a significant interaction for NRM between extensive cGVHD in HCT1 and the conditioning intensity of HCT2 (interaction p < 0.001), meaning that the benefit of RIC in HCT2 was seen in patients with extensive cGVHD in HCT1, but not in those without cGVHD. RIC in HCT2 was also associated with superior OS in patients with extensive cGVHD in HCT1 (HR 0.68, 95% CI: 0.49–0.93; p = 0.02), with significant interaction between the conditioning intensity and the prior history of extensive cGVHD (interaction p = 0.01). This study suggests that RIC in HCT2 reduces NRM for HCT2 and improves OS, especially in patients with a history of extensive cGVHD.

  Last, Wiley, May 2025, American Journal of Hematology, 100(7) (7), 1185 - 1195

  [Refereed]

  Scientific journal


• Ring Chromosomes 7 in Two Cases of Myelodysplastic Syndrome: Isolated Abnormality and Complex Karyotype Including idic(21)(p11.2) Duplication

  Katsuya Yamamoto, Keiji Kurata, Kimikazu Yakushijin, Hironobu Minami

  Wiley, May 2025, International Journal of Laboratory Hematology, 47(5) (5), 791 - 793

  Scientific journal


• Classical and Late‐Onset SOS//VOD After Allogeneic HSCT: A Japanese Transplant Registry Analysis

  Kyoko Masuda, Keisuke Kataoka, Masatoshi Sakurai, Yuho Najima, Naonori Harada, Shoko Ukita, Naoyuki Uchida, Noriko Doki, Takahiro Fukuda, Masatsugu Tanaka, Hiroyuki Ohigashi, Jun Ishikawa, Satoshi Yoshihara, Masashi Sawa, Shuichi Ota, Yoshinobu Kanda, Tetsuya Nishida, Makoto Onizuka, Yoshiko Atsuta, Hideki Nakasone, Kimikazu Yakushijin

  ABSTRACT Sinusoidal obstruction syndrome/veno‐occlusive disease (SOS/VOD) is a lethal complication of allogeneic hematopoietic stem cell transplantation (allo‐HSCT). According to the 2016 European Society for Blood and Marrow Transplantation criteria, SOS/VOD is classified into classical SOS/VOD and late‐onset SOS/VOD, but their similarities and differences remain unclear. Here we retrospectively investigated the incidence, risk factors, and impact on transplant outcomes of classical and late‐onset SOS/VOD in 16 518 allo‐HSCT recipients using the Japanese nationwide registry data. The cumulative incidences of classical and late‐onset SOS/VOD were 2.5% and 2.2%, with a median onset of 13 and 42 days after transplantation, respectively. Both patients with classical (hazard ratio [HR], 3.45; 95% CI, 3.07–3.87) and late‐onset (HR, 3.98; 95% CI, 3.51–4.51) SOS/VOD had a significantly worse overall survival compared with those without. The risk factors for classical and late‐onset SOS/VOD are different. Hepatic comorbidities, high‐risk diseases, use of melphalan (MEL), and myeloablative conditioning are associated with both types of SOS/VOD. Whereas poor performance status, a prior history of transplantation, and positive hepatitis C virus are associated with only classical SOS/VOD, allo‐HSCT from cord blood or related human leukocyte antigen‐haploidentical donors, use of total body irradiation and busulfan (BU), and tacrolimus‐based graft‐versus‐host disease prophylaxis are associated with only late‐onset SOS/VOD. In particular, the incidence of late‐onset SOS/VOD is much higher in patients receiving both BU‐ and MEL‐containing conditioning regimens. These findings suggest that different monitoring and treatment approaches are necessary for allo‐HSCT recipients at high risk for classical and late‐onset SOS/VOD.

  Last, Wiley, May 2025, American Journal of Hematology, 100(8) (8), 1283 - 1294

  [Refereed]

  Scientific journal


• Adverse Impact of Pre-Transplant Liver Dysfunction in Allogeneic Hematopoietic Cell Transplantation.

  Yukiko Misaki, Masaharu Tamaki, Ryu Yanagisawa, Noriko Doki, Naoyuki Uchida, Masatsugu Tanaka, Tetsuya Nishida, Masashi Sawa, Yuta Hasegawa, Shuichi Ota, Makoto Onizuka, Sakata-Yanagimoto Mamiko, Yuta Katayama, Noboru Asada, Junya Kanda, Takahiro Fukuda, Yoshiko Atsuta, Yoshinobu Kanda, Kimikazu Yakushijin, Hideki Nakasone

  Although the hematopoietic cell transplantation (HCT)-comorbidity index (HCT-CI) score is associated with an increased risk of mortality after allogeneic HCT, it remains unclear how pre-HCT liver dysfunction affects clinical outcomes. We retrospectively compared clinical HCT outcomes among four groups stratified according to the presence of HCT-CI liver and other organ scores, using a Japan transplant registry database between 2010 and 2020. Of the 14235 recipients, 1527 tested positive for an HCT-CI liver score including HBV or HCV hepatitis (n = 503). The 5-year overall survival (OS) was significantly lower in the HCT-CI liver(+) other(+) and HCT-CI liver(-) other(+) groups compared to the HCT-CI liver(+) other(-) and HCT-CI liver(-) other(-) groups [49.9% vs. 59% vs. 66.5% vs. 68.3%, p < 0.001]. A multivariate analysis showed that both the HCT-CI liver(+) other(+) [HR 1.62, p < 0.001] and HCT-CI liver(-) other(+) groups [HR 1.21, p < 0.001] were significantly associated with inferior OS. Similarly, both the HCT-CI liver(+) other(+) [HR 1.89, p < 0.001] and liver(-) other(+) groups [HR 1.26, p < 0.001] were significantly associated with an increased risk of NRM. On the other hand, the HCT-CI liver(+) other(-) group was not associated with either OS or NRM. Separately analyzing the subcohorts with or without HCT-CI other scores, the presence of an HCT-CI liver score alone did not affect survival, while the co-presence of pretransplant liver dysfunction seemed to synergistically increase the adverse impact on OS and NRM among recipients with other organ comorbidities. Further studies will be needed to identify optimal strategies for recipients with pretransplant liver dysfunction.

  May 2025, American journal of hematology, 100(5) (5), 821 - 829, English, International magazine

  Scientific journal


• Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study

  Ayumi Fujimoto, Kana Miyazaki, Kimikazu Yakushijin, Takahiro Fujino, Wataru Munakata, Yasuo Ejima, Dai Maruyama, Nobuko Kubota, Takeshi Maeda, Jun Takizawa, Nobuhiro Hiramoto, Masahiro Takeuchi, Rika Sakai, Noriko Fukuhara, Senzo Taguchi, Naoko Asano, Motoko Yamaguchi, Ritsuro Suzuki

  Abstract A retrospective study of extranodal natural killer/T-cell lymphoma (ENKL) patients diagnosed between 2014 and 2021 in Japan was conducted. Among 351 patients with sufficient data, 116 (33%) were in the advanced stage (5 in stage III and 111 in stage IV) at diagnosis, and were further analyzed. The median age was 60 years (range: 19–90), and 68 (59%) were male. Ninety-four (85%) of stage IV patients had two or more extranodal involvements. The most common first-line regimen was SMILE (steroid, methotrexate, ifosfamide, L-asparaginase, and etoposide; 52%). The 2-year overall survival (OS) for all patients was 38.5%, which was significantly improved after 2017 (25.2% for 2014–2017 vs. 50.7% for 2018–2021; P = 0.008). Patients treated with SMILE showed better OS than those treated with DeVIC or CHOP (2y-OS: 57.1%, 35.8%, and 0%, respectively; P < 0.001). The prognosis was significantly better in patients who received hematopoietic stem cell transplantation (HSCT) than in those who did not (2-year OS: 68.3% vs. 17.6%, P < 0.001). Multivariate analysis showed SMILE and HSCT were significant factors for OS. In conclusion, the prognosis of advanced-stage ENKL has improved in recent years. The L-asparaginase-containing chemotherapy and subsequent HSCT is considered the recommended strategy.

  Springer Science and Business Media LLC, Feb. 2025, Leukemia, 39(4) (4), 909 - 916

  [Refereed]

  Scientific journal


• Female-to-male allogeneic transplantation affects outcomes differently according to the type of haplo-transplantation.

  Masaharu Tamaki, Shunto Kawamura, Kosuke Takano, Hirohisa Nakamae, Noriko Doki, Hiroyuki Ohigashi, Yumiko Maruyama, Shuichi Ota, Nobuhiro Hiramoto, Tetsuya Eto, Satoshi Yoshihara, Ken-Ichi Matsuoka, Masayoshi Masuko, Makoto Onizuka, Yoshinobu Kanda, Takahiro Fukuda, Yoshiko Atsuta, Ryu Yanagisawa, Kimikazu Yakushijin, Hideki Nakasone

  Allogeneic hematopoietic stem cell transplantation from a female donor to a male recipient (female-to-male allo-HCT) is a well-established risk factor for chronic graft-versus-host disease (GVHD) and non-relapse mortality (NRM). The inferior outcomes of female-to-male allo-HCT are considered to be due to allo-immunity against H-Y antigens. However, the influence of minor histocompatibility antigens in haplo-identical allo-HCT remains to be elucidated. We investigated the impact of female-to-male allo-HCT according to the haplo-HCT subtype. In the post-transplant cyclophosphamide (PTCY) cohort (n = 660), a female-to-male sex-mismatch was significantly associated with a decreased risk of relapse (HR: 0.70 [95% CI: 0.49-0.99], P = 0.045), but not with overall survival (OS) or NRM (HR: OS 0.89 [95% CI: 0.68-1.16], P = 0.40; NRM 0.98 [95% CI: 0.68-1.41], P = 0.90). On the other hand, in the non-PTCY cohort (n = 219), a female-to-male sex-mismatch was associated with inferior risks of OS and NRM, but was not associated with relapse. These results suggested that the survival impact of the haplo-HCT subtype differed according to the presence of a sex-mismatch. PTCY might be feasible for overcoming the inferiority of female-to-male allo-HCT and might preserve a GVL effect against H-Y antigens.

  Feb. 2025, Cytotherapy, 27(2) (2), 213 - 221, English, International magazine

  Scientific journal


• Lower-dose post-transplant cyclophosphamide in haploidentical hematopoietic cell transplantation.

  Shigeo Fuji, Hirohisa Nakamae, Junichi Sugita, Yuho Najima, Tatsuya Konishi, Takashi Tanaka, Yasuhiro Nakashima, Mitsutaka Nishimoto, Hiroshi Okamura, Kazutaka Nakayama, Ayumu Ito, Makoto Yoshimitsu, Masayuki Hino, Takahiro Fukuda, Yoshiko Atsuta, Kimikazu Yakushijin

  Nov. 2024, Bone marrow transplantation, 59(11) (11), 1628 - 1630, English, International magazine


• 日常的に計算可能な臨床的指標と、類洞閉塞症候群(SOS/VOD)の病勢進行との関連

  市川 大哉, 藥師神 公和, 倉田 啓史, 岡副 結梨, 高橋 瑠理, 松本 咲耶, 坂井 里奈, 北尾 章人, 宮田 吉晴, 齊藤 泰之, 川本 晋一郎, 山本 克也, 伊藤 光宏, 村山 徹, 松岡 広, 南 博信

  (一社)日本血液学会, Oct. 2024, 日本血液学会学術集会, 86回, O2 - 3, English


• B細胞リンパ腫に対するマクロファージ標的療法のヒト化マウスモデルを用いた前臨床評価

  齊藤 泰之, Tania Afroj, 小森 里美, 高井 智子, 小谷 武徳, 船越 洋平, 村田 陽二, 藥師神 公和, 松岡 広, 南 博信, Markus Manz, 的崎 尚

  (一社)日本血液学会, Oct. 2024, 日本血液学会学術集会, 86回, O2 - 4, English


• Association between human herpesvirus-6 encephalitis and antiviral prophylaxis after allogeneic hematopoietic stem cell transplantation in the letermovir era.

  Toshiki Terao, Ken-Ichi Matsuoka, Shigeo Fuji, Shunto Kawamura, Takashi Toya, Noriko Doki, Naoyuki Uchida, Masatsugu Tanaka, Takahiro Fukuda, Masashi Sawa, Jun Ishikawa, Tetsuya Nishida, Hiroyuki Ohigashi, Yumiko Maruyama, Shin-Ichiro Fujiwara, Yoshinobu Kanda, Shuichi Ota, Fumihiko Ishimaru, Yoshiko Atsuta, Junya Kanda, Masao Ogata, Kimikazu Yakushijin, Hideki Nakasone

  The impact of letermovir (LTV)-an anti-cytomegalovirus (CMV) drug-on human herpesvirus-6 (HHV-6) encephalitis is unclear. We hypothesized that LTV prophylaxis may increase the incidence of HHV-6 encephalitis by reducing anti-CMV therapies after allogeneic hematopoietic stem cell transplantation (HSCT). To evaluate the association between HHV-6 encephalitis and antiviral prophylaxis, 7985 adult patients from a nationwide registry who underwent their first HSCT between January 2019 and December 2021 were analyzed. The incidence of HHV-6 encephalitis on day 100 after HSCT was 3.6%; 11.5% for the broad-spectrum antiviral group (foscarnet, ganciclovir, or valganciclovir); 2.8% for the LTV group, and 3.8% for the other antiviral group (p < 0.001). These differences persisted when cord blood transplantation (CBT) was analyzed separately (14.1%, 5.9%, and 7.4%, p < 0.001). In the multivariate analysis, CBT (hazard ratio [HR]: 2.90), broad-spectrum antiviral prophylaxis (HR: 1.91), and grade II-IV acute graft-versus-host disease requiring systemic corticosteroids (HR: 2.42) were independent risk factors for encephalitis (all p < 0.001). The findings of this large modern database study indicate that broad-spectrum antiviral prophylaxis, rather than LTV prophylaxis, is paradoxically associated with HHV-6 encephalitis in the LTV era. This paradoxical finding needs to be further explored in future studies.

  Sep. 2024, Bone marrow transplantation, 59(9) (9), 1224 - 1231, English, International magazine

  Scientific journal


• Analysis of B-cell receptor repertoire to evaluate immunogenicity of monovalent Omicron XBB.1.5 mRNA vaccines.

  Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Takaji Matsutani, Kazuhiko Doi, Hironori Sakai, Tomoki Sasaki, Takahiro Kusakabe, Sakuya Matsumoto, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Taiji Koyama, Yoshiaki Nagatani, Keiji Kurata, Shiro Kimbara, Yoshinori Imamura, Naomi Kiyota, Mitsuhiro Ito, Hironobu Minami

  Monovalent Omicron XBB.1.5 mRNA vaccines were newly developed and approved by the FDA in Autumn 2023 for preventing COVID-19. However, clinical efficacy for these vaccines is currently lacking. We previously established the quantification of antigen-specific antibody sequence (QASAS) method to assess the response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination at the mRNA level using B-cell receptor (BCR) repertoire assay and the coronavirus antibody database (CoV-AbDab). Here, we used this method to evaluate the immunogenicity of monovalent XBB.1.5 vaccines. We analyzed repeated blood samples of healthy volunteers before and after monovalent XBB.1.5 vaccination (BNT162b2 XBB.1.5 or mRNA-1273.815) for the BCR repertoire to assess BCR/antibody sequences that matched SARS-CoV-2-specific sequences in the database. The number of matched unique sequences and their total reads quickly increased 1 week after vaccination. Matched sequences included those bound to the Omicron strain and Omicron XBB sublineage. The antibody sequences that can bind to the Omicron strain and XBB sublineage revealed that the monovalent XBB.1.5 vaccines showed a stronger response than previous vaccines or SARS-CoV-2 infection before the emergence of XBB sublineage. The QASAS method was able to demonstrate the immunogenic effect of monovalent XBB.1.5 vaccines for the 2023-2024 COVID-19 vaccination campaign.

  Aug. 2024, EJHaem, 5(4) (4), 661 - 668, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Near‐triploidy with four Philadelphia chromosomes in adult B‐lymphoblastic leukemia with BCR::ABL1 fusion

  Katsuya Yamamoto, Yuri Hirakawa, Sakuya Matsumoto, Kimikazu Yakushijin, Hironobu Minami

  Wiley, Jun. 2024, International Journal of Laboratory Hematology, 46(6) (6), 988 - 990

  Scientific journal


• Superiority of BM over PBSC for recipients with pre-transplant lung dysfunction in HLA-matched allogeneic HCT.

  Shunto Kawamura, Masaharu Tamaki, Takaaki Konuma, Makoto Onizuka, Emiko Sakaida, Hiromi Hayashi, Noriko Doki, Tetsuya Nishida, Masashi Sawa, Hiroyuki Ohigashi, Takahiro Fukuda, Jun Ishikawa, Ken-Ichi Matsuoka, Toshiro Kawakita, Masatsugu Tanaka, Fumihiko Ishimaru, Tatsuo Ichinohe, Yoshiko Atsuta, Yoshinobu Kanda, Kimikazu Yakushijin, Junya Kanda, Hideki Nakasone

  Jun. 2024, Cytotherapy, 26(11) (11), 1353 - 1361, English, International magazine

  Scientific journal


• Utility of the refined EBMT diagnostic and severity criteria 2023 for sinusoidal obstruction syndrome/veno-occlusive disease.

  Hiroya Ichikawa, Kimikazu Yakushijin, Keiji Kurata, Takahiro Tsuji, Naoko Takemoto, Miki Joyce, Yuri Okazoe, Ruri Takahashi, Sakuya Matsumoto, Rina Sakai, Akihito Kitao, Yoshiharu Miyata, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Tohru Murayama, Hiroshi Matsuoka, Hironobu Minami

  Sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is a life-threatening complication of hematopoietic stem cell transplantation (HSCT). Early diagnosis of SOS/VOD is associated with improved clinical outcomes. In 2023, the refined European Society for Blood and Marrow Transplantation diagnostic and severity criteria (refined EBMT criteria 2023) have been advocated. The revision has introduced new diagnostic categories, namely; probable, clinical, and proven SOS/VOD. In addition, the Sequential Organ Failure Assessment (SOFA) score has been newly incorporated into the SOS/VOD severity grading. We performed a retrospective analysis to evaluate the utility of these criteria. We analyzed 161 cases who underwent allogeneic HSCT. We identified 53 probable, 23 clinical, and 4 proven SOS/VOD cases. Probable SOS/VOD was diagnosed a median of 5.0 days earlier (interquartile range: 2-13 days, P < 0.001) than that of clinical SOS/VOD. The development of probable SOS/VOD alone was associated with a significantly inferior survival proportion compared to non-SOS/VOD (100-day survival, 86.2% vs. 94.3%, P = 0.012). The SOFA score contributed to the prediction of prognosis. Consequently, the refined EBMT criteria 2023 demonstrated the utility of SOS/VOD diagnosis and severity grading. Further investigations and improvements in these criteria are warranted.

  Apr. 2024, Bone marrow transplantation, 59(4) (4), 518 - 525, English, International magazine

  Scientific journal


• Analysis of risk factors for fatal renal complications after allogeneic hematopoietic cell transplantation.

  Ryu Yanagisawa, Hiroaki Koyama, Kimikazu Yakushijin, Naoyuki Uchida, Atsushi Jinguji, Wataru Takeda, Tetsuya Nishida, Masatsugu Tanaka, Tetsuya Eto, Hiroyuki Ohigashi, Kazuhiro Ikegame, Ken-Ichi Matsuoka, Yuta Katayama, Yoshinobu Kanda, Masashi Sawa, Toshiro Kawakita, Makoto Onizuka, Takahiro Fukuda, Yoshiko Atsuta, Akihito Shinohara, Hideki Nakasone

  Various complications can influence hematopoietic cell transplantation (HCT) outcomes. Renal complications can occur during the early to late phases of HCT along with various factors. However, studies focusing on fatal renal complications (FRCs) are scarce. Herein, we analyzed 36,596 first allogeneic HCT recipients retrospectively. Overall, 782 patients died of FRCs at a median of 108 (range, 0-3,440) days after HCT. The cumulative incidence of FRCs was 1.7% and 2.2% at one and five years, respectively. FRCs were associated with older age, male sex, non-complete remission (non-CR), lower performance status (PS), and HCT comorbidity index (HCT-CI) associated with renal comorbidity in multivariate analysis. The risk factors within 100 days included older age, multiple myeloma, PS, and HCT-CI comorbidities (psychiatric disturbance, hepatic disease, obesity, and renal disease). Older age and male sex were risk factors between 100 days and one year. After one year, HCT-CI was associated with the presence of diabetes and prior solid tumor; total body irradiation was identified as a risk factor. Non-CR was a common risk factor in all three phases. Furthermore, acute and chronic graft-versus-host disease, reactivation of cytomegalovirus, and relapse of underlying disease also affected FRCs. Systematic follow-up may be necessary based on the patients' risk factors and post-HCT events.

  Mar. 2024, Bone marrow transplantation, 59(3) (3), 325 - 333, English, International magazine

  Scientific journal


• The Efficacy of Bepotastine Besilate Compared With Hydroxyzine Pamoate for Preventing Infusion Reactions to the First Dose of Rituximab in Patients With Non-Hodgkin Lymphoma: Protocol for a Phase II, Double-Blind, Multicenter Randomized Trial.

  Yumi Kitahiro, Kazuhiro Yamamoto, Kimikazu Yakushijin, Takeshi Ioroi, Masaaki Tanda, Kotaro Itohara, Tomohiro Omura, Hironobu Minami, Ikuko Yano

  BACKGROUND: Rituximab, an anti-CD20 monoclonal antibody, can cause infusion reactions (IRs), especially during the initial rituximab infusion therapy. Generally, patients are administered a histamine H1-receptor antagonist before the rituximab infusion, along with an antipyretic analgesic, to prevent or reduce IRs. Multiple retrospective case-control studies indicate that the second generation of histamine H1-receptor antagonists might be more effective than the first generation in suppressing IRs caused by the rituximab infusion. OBJECTIVE: This study aimed to assess the efficacy of first- and second-generation histamine H1-receptor antagonists for preventing IRs resulting from the initial infusion of rituximab in patients diagnosed with non-Hodgkin lymphoma. METHODS: This is a phase II, double-blind, active-controlled randomized trial. It will be a multicenter study conducted across 3 facilities that aims to enroll a total of 40 patients diagnosed with non-Hodgkin lymphoma who will receive their initial rituximab infusion. Participating patients will be administered hydroxyzine pamoate or bepotastine besilate, representing first- or second-generation histamine H1-receptor antagonists, respectively. This will be combined with 400-mg acetaminophen tablets taken approximately 30 minutes before the first infusion of rituximab. The primary end point of this trial is to assess severe IRs, equivalent to grade 2 or higher as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0, that occur within a 4-hour period after the initiation of rituximab infusion. The secondary end points include assessing the severity of the initial IR, the maximum severity of the IR, and the duration between rituximab infusion initiation and the onset of the first IR within a 4-hour period. Additionally, the trial will evaluate histamine H1-receptor antagonist-induced drowsiness using the visual analogue scale, with each patient providing their individual response. RESULTS: This study began with patient recruitment in April 2023, with 17 participants enrolled as of November 12, 2023. The anticipated study completion is set for February 2026. CONCLUSIONS: This study is the first randomized controlled trial comparing the effects of oral first- and second-generation histamine H1-receptor antagonists in preventing IRs induced by the initial administration of rituximab. The findings from this study hold the potential to establish the rationale for a phase III study aimed at determining the standard premedication protocol for rituximab infusion. TRIAL REGISTRATION: Japan Registry of Clinical Trials jRCTs051220169; https://jrct.niph.go.jp/latest-detail/jRCTs051220169. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/54882.

  Feb. 2024, JMIR research protocols, 13, e54882, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Irreversible Intrathecal Chemotherapy-induced Myelopathy in a Patient with Diffuse Large B-cell Lymphoma.

  Yuri Hirakawa, Akihito Kitao, Marika Watanabe, Sakuya Matsumoto, Ryohei Komaki, Rina Sakai, Kohei Morimoto, Kimikazu Yakushijin, Hironobu Minami

  Intrathecal chemotherapy is often administered for prophylaxis and treatment of central nervous system involvement in hematological malignancies. However, it may rarely cause neurotoxicity as a side effect. We herein report a 74-year-old woman with diffuse large B-cell lymphoma including a spinal lesion. She received systemic and intrathecal chemotherapy. After five doses of intrathecal chemotherapy, she developed intrathecal chemotherapy-induced myelopathy. Intrathecal treatment was discontinued, and she was administered vitamin B12 and folic acid, along with steroid pulses. However, her symptoms did not improve. Intrathecal chemotherapy-induced myelopathy is rare, but may be irreversible; therefore, clinicians should be aware of this potential complication.

  Feb. 2024, Internal medicine (Tokyo, Japan), 63(4) (4), 547 - 551, English, Domestic magazine

  Scientific journal


• Outcomes of cessation of the administration of nucleos(t)ide analogues on HBV reactivation after allogeneic hematopoietic stem cell transplantation: A nationwide retrospective study.

  Masahiro Onozawa, Shigeru Kusumoto, Yuho Najima, Hiroya Hashimoto, Kohei Okada, Masaharu Tamaki, Masatsugu Tanaka, Takayuki Sato, Tsutomu Takahashi, Kaoru Hatano, Koichi Onodera, Yukiyoshi Moriuchi, Kimikazu Yakushijin, Junya Kanda, Koji Nagafuji, Masao Ogata, Nobuaki Nakano, Akihiro Tamori, Masashi Mizokami

  BACKGROUND: Monitoring of HBV-DNA and HBV-DNA-guided preemptive therapy using nucleos(t)ide analogues (NAs) are recommended for preventing the development of hepatitis due to HBV reactivation after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in recipients with resolved HBV infection. However, little is known about the appropriate duration of NA treatment and the outcomes of NAs cessation on recurrence of HBV reactivation. OBJECTIVE: To clarify the consequences of NAs cessation in recipients with resolved HBV infection who experienced HBV reactivation following allo-HSCT. STUDY DESIGN: We retrospectively reviewed the clinical records of recipients with resolved HBV infection (HBsAg-negative, anti-HBc-positive) before allo-HSCT who had been diagnosed as having HBV reactivation (HBsAg-positive and/or HBV-DNA detectable) after allo-HSCT during the period from January 2010 to December 2020. RESULTS: A total of 72 patients from 16 institutes were registered (median age of the patients, 60 years; age range, 27-73 years; 42 males and 30 females). Initial HBV reactivation was observed on day 10 to day 3034 (median, 513 days) after allo-HSCT. Anti-HBs were lost in more than 80% of the patients at the time of HBV reactivation. All 72 patients received preemptive NAs and no fatal HBV reactivation-related hepatitis was observed. There was continuous detection of HBV-DNA without hepatitis in 5 patients during the follow-up period. Administration of NAs was discontinued in 24 (33%) of 72 patients by each physician's decision. Second HBV reactivation occurred in 11 (46%) of the 24 patients in whom administration of NAs was discontinued. Duration of NA treatment were not significantly different between patients with or without second HBV reactivation. The frequency of further HBV reactivation tended to be lower in patients with anti-HBs titer of more than 10 mIU/mL at the time of NA cessation. CONCLUSION: Multiple reactivation of HBV after NA discontinuation was common in patients with HBV reactivation who received allo-HSCT despite the long duration of NA. Careful monitoring of HBV-DNA is important even after the discontinuation of NA in the case with HBV reactivation after allo-HSCT because multiple reactivations could occur. Active immunization by HB vaccine might be effective for suppressing further HBV reactivation after cessation of NAs.

  Jan. 2024, Transplantation and cellular therapy, English, International magazine

  Scientific journal


• Development of an umbilical cord blood transplantation-specific non-relapse mortality risk assessment score.

  Yosuke Okada, Yoshiaki Usui, Hiromi Hayashi, Masashi Nishikubo, Tomomi Toubai, Naoyuki Uchida, Masatsugu Tanaka, Makoto Onizuka, Satoshi Takahashi, Noriko Doki, Yasufumi Uehara, Yumiko Maruyama, Kazuya Ishiwata, Toshiro Kawakita, Masashi Sawa, Tetsuya Eto, Fumihiko Ishimaru, Koji Kato, Takahiro Fukuda, Yoshiko Atsuta, Junya Kanda, Kimikazu Yakushijin, Hideki Nakasone

  Higher rate of non-relapse mortality (NRM) remains yet to be resolved in umbilical cord blood transplantation (UCBT). Considering that UCBT has some unique features compared with allogeneic hematopoietic cell transplantation from other graft sources, a UCBT-specific NRM risk assessment system is required. Thus, in this study, we sought to develop a UCBT-specific NRM Risk Assessment (CoBRA) score. Using a nationwide registry database, we retrospectively analyzed 4437 recipients who had received their first single-unit UCBT. Using the backward elimination method, we constructed the CoBRA score in a training cohort (n = 2687), which consisted of recipients age ≥ 55 (score 2), hematopoietic cell transplantation-specific comorbidity index (HCT-CI) ≥ 3 (score 2), male recipient, graft-versus-host disease (GVHD) prophylaxis other than tacrolimus in combination with methotrexate, performance status (PS) 2-4, HLA allele mismatch ≥ 2, refined disease risk index (DRI) high-risk, myeloablative conditioning (MAC), and CD34+ cell doses < 0.82 x 105/kg (score 1 in each). The recipients were categorized into three groups: Low (0-4 points), Intermediate (5-7 points), and High (8-11 points) groups according to the CoBRA score. In the validation cohort (n = 1750), the cumulative incidence of NRM at 2 years was 14.9%, 25.5%, and 47.1% (P < 0.001), and 2-year overall survival (OS) was 74.2%, 52.7%, and 26.3% (P < 0.001) in the Low, Intermediate, and High groups, respectively. In summary, the CoBRA score could predict the NRM risk as well as OS after UCBT. Further external validation will be needed to confirm the significance of the CoBRA score.

  Jan. 2024, Blood advances, English, International magazine

  Scientific journal


• Analysis of B-cell receptor repertoire to evaluate the immunogenicity of SARS-CoV-2 RBD mRNA vaccine: MAFB-7256a (DS-5670d).

  Goh Ohji, Yohei Funakoshi, Kimikazu Yakushijin, Takaji Matsutani, Tomoki Sasaki, Takahiro Kusakabe, Sakuya Matsumoto, Taiji Koyama, Yoshiaki Nagatani, Keiji Kurata, Shiro Kimbara, Naomi Kiyota, Hironobu Minami

  A monovalent Omicron XBB.1.5 mRNA RBD analogue vaccine, MAFB-7256a (DS-5670d), was newly developed and approved in Japan in the Spring of 2024 for the prevention of COVID-19. However, clinical efficacy data for this vaccine are currently lacking. We previously established the Quantification of Antigen-specific Antibody Sequence (QASAS) method to assess the response to SARS-CoV-2 vaccination at the mRNA level using B-cell receptor (BCR) repertoire assays and the Coronavirus Antibody Database (CoV-AbDab). Here, we used this method to evaluate the immunogenicity of MAFB-7256a. We analyzed repeated blood samples using the QASAS method from three healthy volunteers before and after MAFB-7256a vaccination. BCR response increased rapidly one week post-vaccination and then decreased, as with conventional vaccine. Notably, the matched sequences after MAFB-7256a vaccination specifically bound to the receptor-binding domain (RBD), with no sequences binding to other epitopes. These results validate that MAFB-7256a is an effective vaccine that exclusively induces antibodies specific for the RBD, demonstrating its targeted immunogenic effect.

  2024, Frontiers in immunology, 15, 1468760 - 1468760, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Preclinical evaluation of the efficacy of an antibody to human SIRPα for cancer immunotherapy in humanized mouse models

  Yasuyuki Saito, Rie Iida-Norita, Tania Afroj, Alaa Refaat, Daisuke Hazama, Satomi Komori, Shinya Ohata, Tomoko Takai, Okechi S. Oduori, Takenori Kotani, Yohei Funakoshi, Yu-Ichiro Koma, Yoji Murata, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami, Hiroshi Yokozaki, Markus G. Manz, Takashi Matozaki

  Tumor-associated macrophages (TAMs) are abundant in the tumor microenvironment and are considered potential targets for cancer immunotherapy. To examine the antitumor effects of agents targeting human TAMs in vivo, we here established preclinical tumor xenograft models based on immunodeficient mice that express multiple human cytokines and have been reconstituted with a human immune system by transplantation of human CD34⁺ hematopoietic stem and progenitor cells (HIS-MITRG mice). HIS-MITRG mice supported the growth of both human cell line (Raji)– and patient-derived B cell lymphoma as well as the infiltration of human macrophages into their tumors. We examined the potential antitumor action of an antibody to human SIRPα (SE12C3) that inhibits the interaction of CD47 on tumor cells with SIRPα on human macrophages and thereby promotes Fcγ receptor–mediated phagocytosis of the former cells by the latter. Treatment with the combination of rituximab (antibody to human CD20) and SE12C3 inhibited Raji tumor growth in HIS-MITRG mice to a markedly greater extent than did rituximab monotherapy. This enhanced antitumor effect was dependent on human macrophages and attributable to enhanced rituximab-dependent phagocytosis of lymphoma cells by human macrophages. Treatment with rituximab and SE12C3 also induced reprogramming of human TAMs toward a proinflammatory phenotype. Furthermore, the combination treatment essentially prevented the growth of patient-derived diffuse large B cell lymphoma in HIS-MITRG mice. Our findings thus support the study of HIS-MITRG mice as a model for the preclinical evaluation in vivo of potential therapeutics, such as antibodies to human SIRPα, that target human TAMs.

  Frontiers Media SA, Dec. 2023, Frontiers in Immunology, 14, English, International magazine, Co-authored internationally

  [Refereed]

  Scientific journal


• Low- versus standard-dose post-transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation.

  Shigeo Fuji, Junichi Sugita, Yuho Najima, Tatsuya Konishi, Takashi Tanaka, Hiroyuki Ohigashi, Tetsuya Eto, Koji Nagafuji, Nobuhiro Hiramoto, Ken-Ichi Matsuoka, Yumiko Maruyama, Shuichi Ota, Jun Ishikawa, Toshiro Kawakita, Takashi Akasaka, Tomohiko Kamimura, Masayuki Hino, Takahiro Fukuda, Yoshiko Atsuta, Kimikazu Yakushijin

  Haploidentical haematopoietic cell transplantation (haplo-HCT) using post-transplant cyclophosphamide (PTCY) as graft-versus-host disease (GVHD) prophylaxis is the standard of care for various haematological malignancies. The original PTCY dose after haplo-HCT was 100 mg/kg, but no dose-finding studies have been performed to identify the optimal dose. We performed a retrospective analysis to compare standard-dose PTCY (100 mg/kg) with reduced-dose PTCY (80 mg/kg): 969 in the standard-dose group and 538 in the reduced-dose group. As there was a significant difference between the two groups regarding patient and transplant characteristics, we performed propensity score (PS) matching. After PS matching, 425 patients in each group were included. The probabilities of 2-year OS were 55.9% in the standard-dose group and 47.0% in the reduced-dose group (p = 0.36). The cumulative incidences of 2-year non-relapse mortality were 21.3% in the standard-dose group and 20.5% in the reduced-dose group (p = 0.55). There was no significant difference in the incidence of acute (grade II-IV 29.2% [95% CI, 24.9-33.6] vs. 25.3% [95% CI, 21.3-29.6]; grade III-IV 7.3% [95% CI, 5.1-10.0] vs. 6.6% [95% CI, 4.5-9.3]) or chronic GVHD. In conclusion, reduced- and standard-dose PTCY were comparable in terms of major clinical outcomes.

  Nov. 2023, British journal of haematology, 204(3) (3), 959 - 966, English, International magazine

  Scientific journal


• Amyloid deposition through endocytosis in vascular endothelial cells.

  Seiji Nishikage, Akira Fujisawa, Hiromi Endoh, Hirotaka Sakamoto, Tomohide Suzuki, Maki Kanzawa, Shinichi Ishii, Mitsumasa Okano, Eriko Nitta, Kimikazu Yakushijin, Hidesaku Asakura, Kandai Nozu, Ryo Nitta, Yoshio Katayama, Kazuhiko Sakaguchi

  No mechanistic lead is known for establishing AL amyloid deposits in organs. We here report an electron microscopic (EM) analysis in a case of intestinal AL amyloidosis before initiating treatment for amyloidosis. The dense deposits of amyloid fibrils are concentrated around the small blood vessels in the submucosal area of intestinal tissue. Surprisingly, we observed endothelial cells (ECs) of blood vessels containing plenty of endocytotic (pinocytotic) and transcytotic vesicles at the luminal side and above the basement membrane, indicating the one-way active trafficking of either the immunoglobulin (Ig) light chain or preassembled amyloid fibrils from the luminal side of ECs to the extraluminal area of ECs. Immunoelectron microscopy displayed that the immuno-gold signals were observed in the vascular cavity and the subendothelial area of amyloid deposits. However, there is no sign of an Ig light chain in pinocytotic vesicles. Therefore, the intestinal ECs may actively pump out mainly the preassembled amyloid fibrils (not light chains) from the blood stream into the subendothelial area as a physiologic function.

  Nov. 2023, Experimental hematology, English, International magazine

  [Refereed]

  Scientific journal


• Efficacy and Safety of Synbiotics in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Randomized, Double-blinded, Placebo-controlled Pilot Study

  Yu Mizutani, Shinichiro Kawamoto, Michiko Takahashi, Hisayo Doi, Kumiko Wakida, Satoko Tabuchi, Masaaki Tanda, Akihiro Soga, Ruri Chijiki, Hidetomo Takakura, Koji Kawaguchi, Ako Higashime, Marika Watanabe, Hiroya Ichikawa, Sakuya Matsumoto, Rina Sakai, Hideaki Goto, Keiji Kurata, Seiji Kakiuchi, Yoshiharu Miyata, Kiyoaki Uryu, Yumiko Inui, Akihito Kitao, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami

  Japanese Society of Internal Medicine, Oct. 2023, Internal Medicine, 62(20) (20), 2949 - 2958

  Scientific journal


• Phase III clinical trial of autologous CD34 + cell transplantation to accelerate fracture nonunion repair.

  Ryosuke Kuroda, Takahiro Niikura, Tomoyuki Matsumoto, Tomoaki Fukui, Keisuke Oe, Yutaka Mifune, Hironobu Minami, Hiroshi Matsuoka, Kimikazu Yakushijin, Yoshiharu Miyata, Shinichiro Kawamoto, Tatsuo Kagimura, Yasuyuki Fujita, Atsuhiko Kawamoto

  BACKGROUND: We previously demonstrated that CD34 + cell transplantation in animals healed intractable fractures via osteogenesis and vasculogenesis; we also demonstrated the safety and efficacy of this cell therapy in an earlier phase I/II clinical trial conducted on seven patients with fracture nonunion. Herein, we present the results of a phase III clinical trial conducted to confirm the results of the previous phase studies using a larger cohort of patients. METHODS: CD34 + cells were mobilized via administration of granulocyte colony-stimulating factor, harvested using leukapheresis, and isolated using magnetic cell sorting. Autologous CD34 + cells were transplanted in 15 patients with tibia nonunion and 10 patients with femur nonunion, who were followed up for 52 weeks post transplantation. The main outcome was a reduction in time to heal the tibia in nonunion patients compared with that in historical control patients. We calculated the required number of patients as 15 based on the results of the phase I/II study. An independent data monitoring committee performed the radiographic assessments. Adverse events and medical device failures were recorded. RESULTS: All fractures healed during the study period. The time to radiological fracture healing was 2.8 times shorter in patients with CD34 + cell transplantation than in the historical control group (hazard ratio: 2.81 and 95% confidence interval 1.16-6.85); moreover, no safety concerns were observed. CONCLUSIONS: Our findings strongly suggest that autologous CD34 + cell transplantation is a novel treatment option for fracture nonunion. TRIAL REGISTRATION: UMIN-CTR, UMIN000022814. Registered on 22 June 2016.

  Oct. 2023, BMC medicine, 21(1) (1), 386 - 386, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 血小板輸血不応の項を含む新診断基準による、類洞閉塞症候群(SOS)の早期診断

  市川 大哉, 藥師神 公和, 宮田 吉晴, 兼平 博史, ジョイス 美紀, 平川 結梨, 松本 咲耶, 長尾 茂輝, 坂井 里奈, 倉田 啓史, 北尾 章人, 齊藤 泰之, 川本 晋一郎, 山本 克也, 伊藤 光宏, 村山 徹, 松岡 広, 南 博信

  (一社)日本血液学会, Oct. 2023, 日本血液学会学術集会, 85回, 683 - 683, English


• Response to mRNA SARS-CoV-2 vaccination evaluated by B-cell receptor repertoire after tixagevimab/cilgavimab administration.

  Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Takaji Matsutani, Wataru Hojo, Hironori Sakai, Sakuya Matsumoto, Marika Watanabe, Akihito Kitao, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Taiji Koyama, Yoshiaki Nagatani, Shiro Kimbara, Yoshinori Imamura, Naomi Kiyota, Mitsuhiro Ito, Hironobu Minami

  The use of anti-SARS-CoV-2 antibody products like tixagevimab/cilgavimab represents an important strategy to protect immunocompromised patients with haematological malignancies from COVID-19. Although patients who receive these agents should still be vaccinated, the use of tixagevimab/cilgavimab can mask the production of anti-spike antibody after vaccination, making it hard to assess vaccine response. We have newly established a quantification method to assess the response to SARS-CoV-2 vaccination at the mRNA level using B-cell receptor (BCR) repertoire assay and the Coronavirus Antibody Database (CoV-AbDab). Repeated blood samples before and after vaccination were analysed for the BCR repertoire, and BCR sequences were searched in the database. We analysed the number and percentage frequency of matched sequences. We found that the number of matched sequences increased 2 weeks after the first vaccination and quickly decreased. Meanwhile, the number of matched sequences more rapidly increased after the second vaccination. These results show that the postvaccine immune response can be assessed at the mRNA level by analysing the fluctuation in matching sequences. Finally, BCR repertoire analysis with CoV-AbDab clearly demonstrated the response to mRNA SARS-CoV-2 vaccination even after tixagevimab/cilgavimab administration in haematological malignancy patients who underwent allogeneic haematopoietic stem cell transplantation.

  Jun. 2023, British journal of haematology, English, International magazine

  Scientific journal


• Unrelated female-to-male bone marrow transplantation would be preferred over cord blood transplantation in male patients.

  Masaharu Tamaki, Yu Akahoshi, Yosuke Okada, Naoyuki Uchida, Masatsugu Tanaka, Noriko Doki, Masashi Sawa, Yumiko Maruyama, Yasunori Ueda, Shigesaburo Miyakoshi, Yuta Katayama, Toshiro Kawakita, Takafumi Kimura, Makoto Onizuka, Takahiro Fukuda, Yoshiko Atsuta, Ryu Yanagisawa, Kimikazu Yakushijin, Junya Kanda, Hideki Nakasone

  BACKGROUND AIMS: Allogeneic hematopoietic stem cell transplantation from female donors to male recipients (female-to-male allo-HCT) is a well-established risk factor for a greater incidence of non-relapse mortality (NRM) and chronic graft-versus-host disease (GVHD). In contrast, unrelated cord blood transplantation (UCBT) is associated with a lower incidence of chronic GVHD. In this study, survival outcomes were compared between the UCBT and unrelated female-to-male bone marrow transplantation (UFMBMT) groups. METHODS: We evaluated male allo-HCT recipients who underwent UCBT or UFMBMT between 2012 and 2020 in Japan. There were 2517 cases in the UCBT group, 456 cases in the HLA-matched UFMBMT group and 457 cases in the HLA-mismatched UFMBMT group. RESULTS: HLA-mismatched UFMBMT was significantly associated with a decreased risk of relapse (hazard ratio [HR] 0.74; 95% confidence interval [CI] 0.57-0.98], P = 0.033) and HLA-matched UFMBMT had the tendency of a decreased risk of relapse (HR 0.78; 95% CI 0.61-1.01, P = 0.059). HLA-matched UFMBMT was also associated with favorable OS (HR 0.82; 95% CI 0.69-0.97, P = 0.021). The relationship between the donor sources and relapse was similarly observed in the lymphoid malignancy cohort. CONCLUSIONS: The difference of graft-versus leukemia effect by H-Y immunity according to donor sources might contribute to the difference in clinical impact. It might be desirable for patients who could sufficiently wait for donor coordination to select BMT rather than UCBT, even if only unrelated female donors are available for male recipients.

  Jun. 2023, Cytotherapy, English, International magazine

  Scientific journal


• Early diagnosis of sinusoidal obstruction syndrome after hematopoietic stem cell transplantation, with modified diagnostic criteria including refractory thrombocytopenia

  Hiroya Ichikawa, Kimikazu Yakushijin, Yoshiharu Miyata, Hirofumi Kanehira, Miki Joyce, Yuri Hirakawa, Sakuya Matsumoto, Shigeki Nagao, Rina Sakai, Keiji Kurata, Akihito Kitao, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Tohru Murayama, Hiroshi Matsuoka, Hironobu Minami

  Abstract Sinusoidal obstruction syndrome (SOS) is a fatal complication of hematopoietic stem cell transplantation (HSCT). Early diagnosis for SOS can improve clinical outcomes significantly. Here, we performed a retrospective study to investigate the Cairo diagnostic criteria, in which SOS was defined as the development of two or more in seven events, including transfusion‐refractory thrombocytopenia. Among 154 cases of allogeneic HSCT, 10 cases of SOS using the European Society for Blood and Marrow Transplantation criteria (EBMT16) as the reference standard were identified. The original Cairo criteria could diagnose SOS 5 days earlier than any other established criteria, with some false‐positive results (sensitivity = 100.0%; specificity = 72.2%). When the cutoff was set to three events for the Cairo criteria, the diagnosis of SOS could be made 3 days earlier than that using the EBMT16 criteria, with comparable precision (specificity = 86.1%). The accuracy of the Cairo criteria improved further when the cutoff point was set to four (specificity = 93.8%). The fulfillment of the Cairo criteria was associated with high mortality. Based on our results, the Cairo criteria were also considered clinically useful, especially at three or four cutoff points. Further studies are required to validate and refine the criteria.

  Wiley, Jun. 2023, eJHaem

  Scientific journal


• Safety and Accuracy of Professional Continuous Glucose Monitoring in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

  Shigeki Nagao, Kimikazu Yakushijin, Ako Higashime, Koji Kawaguchi, Marika Watanabe, Rina Sakai, Hiroya Ichikawa, Yu Mizutani, Hideaki Goto, Seiji Kakiuchi, Keiji Kurata, Akihito Kitao, Yoshiharu Miyata, Yoshinori Imamura, Yushi Hirota, Michiko Takahashi, Shinichiro Kawamoto, Katsuya Yamamoto, Hiroshi Matsuoka, Hironobu Minami

  Hyperglycemia in the early days following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a well-known risk factor for acute graft-versus-host disease (GVHD) and non-relapse mortality. The FreeStyle Libre Pro, a factory calibrated continuous glucose monitoring (CGM) device, has been used for the retrospective analysis of glucose testing in patients with diabetes. We assessed the safety and accuracy of the device in patients undergoing allo-HSCT. We recruited eight patients who underwent allo-HSCT between August 2017 and March 2020. They wore the FreeStyle Libre Pro on the day before or on the day of transplantation until 28 days after transplantation. Adverse events, especially bleeding and infection, were monitored to assess safety, and blood glucose levels were measured and compared with the device values. None of the eight participants experienced bleeding that was difficult to stop from the sensor site or local infection that required antimicrobial administration. The device value was well correlated with blood glucose (correlation coefficient r=0.795, P<0.01); however, the overall mean absolute relative difference was 32.1%±16.0%. Our study demonstrated the safety of FreeStyle Libre Pro in allo-HSCT patients. However, the sensor results tended to be lower than the blood glucose levels.

  May 2023, Blood cell therapy, 6(2) (2), 54 - 60, English, Domestic magazine

  Scientific journal


• Impact of anti-thymocyte globulin on survival outcomes in female-to-male allogeneic hematopoietic stem cell transplantation.

  Masaharu Tamaki, Yu Akahoshi, Masahiro Ashizawa, Yukiko Misaki, Satoshi Koi, Sung-Won Kim, Yukiyasu Ozawa, Shin-Ichiro Fujiwara, Shinichi Kako, Ken-Ichi Matsuoka, Masashi Sawa, Yuta Katayama, Makoto Onizuka, Yoshinobu Kanda, Takahiro Fukuda, Yoshiko Atsuta, Kimikazu Yakushijin, Hideki Nakasone

  Allogeneic hematopoietic cell transplantation between female donors and male recipients (female-to-male allo-HCT) is a well-established risk factor for inferior survival outcomes due to a higher incidence of graft-versus-host disease (GVHD). However, a clinical significance of anti-thymocyte globulin (ATG) in the female-to-male allo-HCT has not been elucidated. In this study, we retrospectively evaluated male patients who underwent allo-HCT between 2012 and 2019 in Japan. In the female-to-male allo-HCT cohort (n = 828), the use of ATG was not associated with a decreased risk of GVHD (HR of acute GVHD 0.691 [95% CI: 0.461-1.04], P = 0.074; HR of chronic GVHD 1.06 [95% CI: 0.738-1.52], P = 0.76), but was associated with favorable overall survival (OS) and a decreased risk of non-relapse mortality (NRM) (HR of OS 0.603 [95% CI: 0.400-0.909], P = 0.016; HR of NRM 0.506 [95% CI: 0.300-0.856], P = 0.011). The use of ATG in female-to-male allo-HCT resulted in survival outcomes that were almost equivalent to those in the male-to-male allo-HCT group. Therefore, GVHD prophylaxis with ATG might overcome the inferiority of survival outcomes in female-to-male allo-HCT.

  May 2023, Scientific reports, 13(1) (1), 7166 - 7166, English, International magazine

  Scientific journal


• Comparable efficacy and safety of COVID-19 vaccines for patients receiving tegafur-uracil as postoperative adjuvant chemotherapy.

  Megumi Nishikubo, Yugo Tanaka, Suguru Mitsui, Takefumi Doi, Daisuke Hokka, Wataru Hojo, Hironori Sakai, Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Hironobu Minami, Yoshimasa Maniwa

  PURPOSE: Many effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed, but a weaker response in individuals undergoing anticancer treatment has been reported. This study evaluates the immunogenic status and safety of SARS-CoV-2 vaccines for patients with non-small-cell lung cancer (NSCLC), receiving tegafur-uracil (UFT) as postoperative adjuvant chemotherapy. METHODS: The subjects of this prospective study were 40 patients who underwent surgery for NSCLC and received SARS-CoV-2 vaccines postoperatively. We compared the antibody titers of SARS-CoV-2 vaccines and the adverse events between patients who received adjuvant UFT and patients who did not. RESULTS: The mean anti-S1 IgG titers were not significantly different between the UFT and without-UFT groups (mean optimal density, 0.194 vs. 0.205; P = 0.76). Multivariate analysis identified the period after the second vaccination as an independent predictor of anti-S1 IgG titer (P = 0.049), but not the UFT status (with or without-UFT treatment; P = 0.47). The prevalence of adverse events did not differ significantly between the groups, and no severe adverse events occurred. CONCLUSIONS: The efficacy and safety of the SARS-CoV-2 vaccines for NSCLC patients who received postoperative adjuvant UFT chemotherapy were comparable to those for NSCLC patients who did not receive postoperative adjuvant UFT chemotherapy. CLINICAL TRIAL REGISTRATION: This study was registered with the University Hospital Medical Information Network (UMIN) in Japan (UMIN000047380).

  Feb. 2023, Surgery today, 1 - 7, English, Domestic magazine

  Scientific journal


• GSK3 inhibitor enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells by overcoming multiple mechanisms of resistance.

  Aki Inase, Yimamu Maimaitili, Shiro Kimbara, Yu Mizutani, Yoshiharu Miyata, Shinya Ohata, Hisayuki Matsumoto, Akihito Kitao, Rina Sakai, Koji Kawaguchi, Ako Higashime, Shigeki Nagao, Keiji Kurata, Hideaki Goto, Shinichiro Kawamoto, Kimikazu Yakushijin, Hironobu Minami, Hiroshi Matsuoka

  In acute myeloid leukemia (AML), the heterogeneity of genetic and epigenetic characteristics makes treatment difficult. The prognosis for AML is therefore poor, and there is an urgent need for new treatments for this condition. Gemtuzumab ozogamicin (GO), the first antibody-drug conjugate (ADC), targets the CD33 antigen expressed in over 90% of AML cases. GO therefore has the potential to counter the heterogeneity of AML patients. However, a major clinical problem is that drug resistance to GO diminishes its effect over time. Here, we report that the inhibition of glycogen synthase kinase 3 (GSK3) alone overcomes several forms of GO resistance at concentrations without antileukemic effects. The GSK3 inhibitors tested significantly enhanced the cytotoxic effect of GO in AML cell lines. We elucidated four mechanisms of enhancement: (1) increased expression of CD33, the target antigen of GO; (2) activation of a lysosomal function essential for hydrolysis of the GO linker; (3) reduced expression of MDR1 that eliminates calicheamicin, the payload of GO; and (4) reduced expression of the anti-apoptotic factor Bcl-2. A similar combination effect was observed against patient-derived primary AML cells. Combining GO with GSK3 inhibitors may be efficacious in treating heterogeneous AML.

  Feb. 2023, EJHaem, 4(1) (1), 153 - 164, English, International magazine

  Scientific journal


• Biclonal Diffuse Large B-cell Lymphoma Commonly Characterized by Partial Trisomy 18q Involving <i>MALT1</i> and <i>BCL2</i>

  Katsuya Yamamoto, Shinichiro Kawamoto, Ruri Chijiki, Marika Watanabe, Sakuya Matsumoto, Akihito Kitao, Yu Mizutani, Kazuyoshi Kajimoto, Yoshitake Hayashi, Kimikazu Yakushijin, Hironobu Minami

  Japanese Society of Internal Medicine, Jan. 2023, Internal Medicine, 62(2) (2), 285 - 292

  Scientific journal


• <i>RUNX1</i> rearrangement in mature B-cell acute lymphoblastic leukemia with non-L3 morphology

  Katsuya Yamamoto, Akihito Kitao, Marika Watanabe, Hiroshi Kanehira, Miki Joyce, Yuri Hirakawa, Sakuya Matsumoto, Kimikazu Yakushijin, Hironobu Minami

  Japanese Society for Lymphoreticular Tissue Research, 2023, Journal of Clinical and Experimental Hematopathology, 63(4) (4), 240 - 245

  Scientific journal


• Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial.

  Satoshi Okumura, Mikiya Ishihara, Naomi Kiyota, Kimikazu Yakushijin, Kohichi Takada, Shinichiro Kobayashi, Hiroaki Ikeda, Makoto Endo, Koji Kato, Shigehisa Kitano, Akihiko Matsumine, Yasuhiro Nagata, Shinichi Kageyama, Taizo Shiraishi, Tomomi Yamada, Keizo Horibe, Kazuto Takesako, Hiroshi Miwa, Takashi Watanabe, Yoshihiro Miyahara, Hiroshi Shiku

  INTRODUCTION: Adoptive cell transfer of genetically engineered T cells is a promising treatment for malignancies; however, there are few ideal cancer antigens expressed on the cell surface, and the development of chimeric antigen receptor T cells (CAR-T cells) for solid tumour treatment has been slow. CAR-T cells, which recognise major histocompatibility complex and peptide complexes presented on the cell surface, can be used to target not only cell surface antigens but also intracellular antigens. We have developed a CAR-T-cell product that recognises the complex of HLA-A*02:01 and an epitope of the MAGE-A4 antigen equipped with a novel signalling domain of human GITR (investigational product code: MU-MA402C) based on preclinical studies. METHODS AND ANALYSIS: This is a dose-escalation, multi-institutional, phase 1 study to evaluate the tolerability and safety of MU-MA402C for patients with MAGE A4-positive and HLA-A*02:01-positive unresectable advanced or recurrent solid cancer. Two dose cohorts are planned: cohort 1, MU-MA402C 2×108/person; cohort 2, MU-MA402C 2×109/person. Prior to CAR-T-cell infusion, cyclophosphamide (CPA) and fludarabine (FLU) will be administered as preconditioning chemotherapy. Three evaluable subjects per cohort, for a total of 6 subjects (maximum of 12 subjects), will be recruited for this clinical trial. The primary endpoints are safety and tolerability. The severity of each adverse event will be evaluated in accordance with Common Terminology Criteria for Adverse Events V.5.0. The secondary endpoint is efficacy. Antitumour response will be evaluated according to Response Evaluation Criteria in Solid Tumours V.1.1. ETHICS AND DISSEMINATION: This clinical trial will be conducted in accordance with the current version of Good Clinical Practice. The protocol was approved by the Clinical Research Ethics Review Committee of Mie University Hospital (approval number F-2021-017). The trial results will be published in peer-reviewed journals and/or disseminated through international conferences. TRIAL REGISTRATION NUMBER: jRCT2043210077.

  Nov. 2022, BMJ open, 12(11) (11), e065109, English, International magazine

  Scientific journal


• Global longitudinal strain is superior to ejection fraction for long‐term follow‐up after allogeneic hematopoietic stem cell transplantation

  Marika Watanabe, Kimikazu Yakushijin, Hidekazu Tanaka, Ruri Chijiki, Miki Saeki, Yuri Hirakawa, Hidetomo Takakura, Yutaro Usui, Hiroya Ichikawa, Rina Sakai, Sakuya Matsumoto, Shigeki Nagao, Yu Mizutani, Keiji Kurata, Akihito Kitao, Yoshiharu Miyata, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Hiroshi Matsuoka, Hironobu Minami

  Abstract Global longitudinal strain (GLS), a new cardiac parameter measured by the speckle‐tracking method, is reportedly more sensitive than ejection fraction (EF) in detecting slight cardiac dysfunction in heart failure patients. We validated the utility of GLS in allogeneic hematopoietic stem cell transplantation (HSCT) patients during a long‐term follow‐up. Medical records of patients who underwent allogeneic HSCT between 2013 and 2020 were reviewed retrospectively. We evaluated the last echocardiography performed before transplantation and those performed annually during the 5 years after transplantation. We also investigated newly diagnosed cardiac events, which developed after HSCT. Among 85 patients, 22 used cardioprotective drugs. The median follow‐up duration in surviving patients was 54.1 months (range, 2.9–92.6 months). GLS significantly decreased year by year, and patients taking cardioprotective agents tended to have a better GLS at 5 years than at 3 years, while EF did not change. Fifteen patients developed newly diagnosed cardiac events. Multivariate analysis revealed that low GLS and high serum ferritin levels at baseline were independently associated with the development of cardiac events. Therefore, we need a continuous follow‐up of cardiac function by GLS and prescription of cardioprotective drugs might be considered for HSCT patients with low GLS. Further research is warranted.

  Wiley, Nov. 2022, eJHaem, 4(1) (1), 192 - 198

  Scientific journal


• A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients.

  Marika Watanabe, Kimikazu Yakushijin, Yohei Funakoshi, Goh Ohji, Hiroya Ichikawa, Hironori Sakai, Wataru Hojo, Miki Saeki, Yuri Hirakawa, Sakuya Matsumoto, Rina Sakai, Shigeki Nagao, Akihito Kitao, Yoshiharu Miyata, Taiji Koyama, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Tohru Murayama, Hiroshi Matsuoka, Hironobu Minami

  We previously reported that a second dose of BNT162b2 was safe and effective for allogeneic hematopoietic stem cell transplantation (HSCT) patients. Here, we investigated the safety and efficacy of a third dose of COVID-19 mRNA vaccine in allogeneic HSCT patients. Antibody titers against the S1 spike protein were measured using the QuaResearch COVID-19 Human IgM IgG ELISA kit. The previous study included 25 allogeneic HSCT patients who received two doses of BNT162b2. Following the exclusion of three patients because of the development of COVID-19 (n = 2) and loss to follow-up (n = 1), the study evaluated 22 allogeneic HSCT patients who received a third dose of COVID-19 mRNA vaccine (BNT162b2 [n = 15] and mRNA-1273 [n = 7]). Median age at the time of the first vaccination was 56 (range, 23-71) years. Five patients were receiving immunosuppressants at the third vaccination, namely calcineurin inhibitors (CI) alone (n = 1), steroids alone (n = 2), or CI combined with steroids (n = 2). Twenty-one patients (95%) seroconverted after the third dose. None of our patients had serious adverse events, new-onset graft-versus-host disease (GVHD), or GVHD exacerbation after vaccination. A third dose of the BNT162b2 and mRNA-1273 COVID-19 vaccines was safe and effective for allogeneic HSCT patients.

  Oct. 2022, Vaccines, 10(11) (11), English, International magazine

  Scientific journal


• A Pathogenic NRAS c.38 G>A (p.G13D) Mutation in RARA Translocation-negative Acute Promyelocytic-like Leukemia with Concomitant Myelodysplastic Syndrome.

  Hideaki Goto, Kimikazu Yakushijin, Yoko Adachi, Hisayuki Matsumoto, Katsuya Yamamoto, Sakuya Matsumoto, Tomoe Yamashita, Ako Higashime, Koji Kawaguchi, Keiji Kurata, Hiroshi Matsuoka, Hironobu Minami

  An acute promyelocytic leukemia (APL) patient not demonstrating the retinoic acid receptor α (RARA) translocation is rare. A 76-year-old man was diagnosed with myelodysplastic syndrome (MDS). After a year, abnormal promyelocytes were detected with pancytopenia and disseminated intravascular coagulopathy. Morphologically, the patient was diagnosed with APL; however, a genetic examination failed to detect RARA translocation. Thereafter, whole-genome sequencing revealed an NRAS missense mutation [c.38 G>A (p.G13D)]. This mutation was not detected in posttreatment bone marrow aspirate, despite residual MDS. Few reports are available on similar cases. Furthermore, the NRAS c.38 G>A mutation may be a novel pathogenic variant exacerbating RARA translocation-negative acute promyelocytic-like leukemia.

  Sep. 2022, Internal medicine (Tokyo, Japan), English, Domestic magazine

  Scientific journal


• Inhaled corticosteroids do not affect the antibody titer against the SARS-CoV-2 spike protein in BNT162b2 mRNA vaccinated patients.

  Takeo Nakajima, Tatsuya Nagano, Yoshiharu Miyata, Shoko Murakami, Satoshi Mitsuyuki, Yohei Funakoshi, Kimikazu Yakushijin, Hitoshi Horimoto, Yoshihiro Nishimura, Kazuyuki Kobayashi

  OBJECTIVES: Oral corticosteroids reduce the antibody titer of the BNT162b2 mRNA vaccine against SARS-CoV-2. To date, the effect of inhaled corticosteroids on antibody titers is unknown. STUDY DESIGN: The design of this study is retrospective study. METHODS: We analyzed the relationship between the clinical features and total antibody titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in 320 subjects who had never been infected with Coronavirus disease 2019 (COVID-19) and were vaccinated the second time with the BNT162b2 mRNA vaccine between October 1 to December 28, 2021. RESULTS: Of the 320 subjects, 205 were treated with inhaled corticosteroids. The median antibody titer of patients treated with inhaled corticosteroids was 572 U/mL, which was significantly higher than that of patients treated without inhaled corticosteroids (454U/mL, P = 0.00258). The median antibody titers of smokers, men, and patients aged 65 years and over, were 315.5 U/mL, 385 U/mL, and 425.5 U/mL, respectively. These results are significantly lower than those of patients who never smoked, women, and patients aged less than 64 years (582 U/mL [P < 0.0001], 682.5 U/mL [P < 0.0001], and 717 U/mL [P < 0.0001], respectively). The multivariate analysis revealed that females and age were independent antibody titer-reducing factors (P = 0.0001 and P < 0.0001, respectively). CONCLUSIONS: The use of inhaled corticosteroids did not reduce the antibody titer against SARS-CoV-2 spike protein. Clinicians should continue treatment with inhaled corticosteroids if indicated.

  Aug. 2022, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 18(1) (1), 78 - 78, English, International magazine

  Scientific journal


• Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination.

  Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Wataru Hojo, Hironori Sakai, Marika Watanabe, Akihito Kitao, Yoshiharu Miyata, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Taiji Koyama, Yoshinori Imamura, Naomi Kiyota, Hiroshi Matsuoka, Yasuko Mori, Hironobu Minami

  Anti-CD20 antibodies react with CD20 expressed not only on malignant B cells, but also on normal B cells. It has been reported that patients treated with anti-CD20 antibodies had an insufficient response to two-dose mRNA SARS-CoV-2 vaccination. To investigate the efficacy of a third dose in these patients, we investigated serum IgG antibody titers for the S1 protein after a third vaccination in 22 patients treated with the anti-CD20 antibody who failed two-dose vaccination. Results showed that overall, 50% of patients seroconverted. Although no patient who received the third dose within 1 year of the last anti-CD20 antibody administration showed an increase in S1 antibody titer, 69% of patients who received the third dose more than 1 year after the last anti-CD20 antibody administration seroconverted. Our data show that a third dose of vaccination is effective in improving the seroconversion rate in patients treated with the anti-CD20 antibody who failed standard two-dose vaccination.

  Jun. 2022, Vaccines, 10(6) (6), English, International magazine

  Scientific journal


• Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trial.

  Yoshinori Imamura, Kazunori Otsui, Kenta Mori, Koichi Kitagawa, Hideaki Okada, Akito Hata, Hidetoshi Hayashi, Taku Nose, Shinya Ohata, Yoshiharu Miyata, Yohei Funakoshi, Masanori Toyoda, Kimikazu Yakushijin, Naomi Kiyota, Hiroshi Matsuoka, Hironobu Minami

  BACKGROUND: Recent pivotal phase III trials involving direct oral anticoagulant (DOAC) versus low molecular weight heparin have demonstrated the utility of DOACs in Western patients with cancer-associated venous thromboembolism (VTE). However, these trials did not include Japanese patients. This phase II trial evaluated the safety and efficacy of apixaban in Japanese patients with cancer-associated VTE (UMIN000028447). METHOD AND RESULTS: Apixaban was initiated at 10 mg twice daily for 7 days, followed by 5 mg twice daily for 23 weeks. The primary endpoint was the incidence of major or clinically relevant non-major (CRNM) bleeding events during the treatment period. The study was terminated due to safety concerns after enrolling 27 patients. Median age was 71 years; median body weight was 51.3 kg; and major primary tumor sites were the gastrointestinal tract (26%) and lung (19%). During the median follow-up period of 5.4 months, major or CRNM bleeding occurred in in 26% of patients (major, n = 5; CRNM, n = 2; 95% confidence interval, 11-46%). No recurrent VTE or VTE-related death occurred. Estimated overall survival at 6 months was 68%. CONCLUSION: This study demonstrated the excessive bleeding risk of apixaban at the standard dose in Japanese patients with cancer-associated VTE.

  Apr. 2022, International journal of hematology, 115(4) (4), 499 - 507, English, Domestic magazine

  Scientific journal


• Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer.

  Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Wataru Hojo, Hironori Sakai, Ryo Takai, Taku Nose, Shinya Ohata, Yoshiaki Nagatani, Taiji Koyama, Akihito Kitao, Meiko Nishimura, Yoshinori Imamura, Naomi Kiyota, Kenichi Harada, Yugo Tanaka, Yasuko Mori, Hironobu Minami

  BACKGROUND: Although COVID-19 severity in cancer patients is high, the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients undergoing chemotherapy for solid cancers in Japan have not been reported. METHODS: We investigated the safety and immunogenicity of BNT162b2 in 41 patients undergoing chemotherapy for solid cancers and in healthy volunteers who received 2 doses of BNT162b2. We evaluated serum IgG antibody titers for S1 protein by ELISA at pre-vaccination, prior to the second dose and 14 days after the second vaccination in 24 cancer patients undergoing cytotoxic chemotherapy (CC group), 17 cancer patients undergoing immune checkpoint inhibitor therapy (ICI group) and 12 age-matched healthy volunteers (HV group). Additionally, inflammatory cytokine levels were compared between the HV and ICI groups at pre and the next day of each vaccination. RESULTS: Anti-S1 antibody levels were significantly lower in the ICI and CC groups than in the HV group after the second dose (median optimal density: 0.241 [0.063-1.205] and 0.161 [0.07-0.857] vs 0.644 [0.259-1.498], p = 0.0024 and p < 0.0001, respectively). Adverse effect profile did not differ among the three groups, and no serious adverse event occurred. There were no differences in vaccine-induced inflammatory cytokines between the HV and ICI groups. CONCLUSION: Although there were no significant differences in adverse events in three groups, antibody titers were significantly lower in the ICI and CC groups than in the HV group. Further protection strategies should be considered in cancer patients undergoing CC or ICI.

  Apr. 2022, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 28(4) (4), 516 - 520, English, International magazine

  Scientific journal


• Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors.

  Masaharu Tamaki, Kazuaki Kameda, Shun-Ichi Kimura, Naonori Harada, Naoyuki Uchida, Noriko Doki, Masatsugu Tanaka, Kazuhiro Ikegame, Masashi Sawa, Yuta Katayama, Shigesaburo Miyakoshi, Takahide Ara, Junya Kanda, Makoto Onizuka, Takahiro Fukuda, Yoshiko Atsuta, Yoshinobu Kanda, Kimikazu Yakushijin, Hideki Nakasone

  The graft-versus-leukemia (GVL) effect is one of the curative mechanisms of allogeneic hematopoietic stem cell transplantation (allo-HCT). H-Y antigens, which are encoded by Y chromosome, are important targets of the GVL effect. Thus, deletion of the Y chromosome (del[Y]) might cause the GVL effect to deteriorate in a transplantation involving a female donor and male recipient, although the clinical significance of the del(Y) group remains to be elucidated. In this study, we evaluated adult male patients who underwent allo-HCT between 2010 and 2019 in Japan. There were 155 cases in the del(Y) group and 4149 cases without del(Y) who underwent female-to-male allo-HCT. Del(Y) was significantly associated with inferior overall survival (hazard ratio [HR], 1.24; 95% confidence interval [CI], 1.00-1.53; P = .049) and an increased risk of relapse (HR, 1.40; 95% CI, 1.08-1.80; P = .0098) in multivariate analyses. There was no significant difference in nonrelapse mortality between recipients with and without del(Y) (HR, 1.08; 95% CI, 0.769-1.51; P = .67). In contrast, del(Y) was not significantly associated with any clinical outcomes in the cohort of male-to-male allo-HCT. A higher incidence of relapse might have been caused by attenuation of the GVL effect resulting from a lack of H-Y antigens. Because a GVL effect resulting from sex mismatch may not be expected in men with del(Y) who undergo allo-HCT with a female donor, additional post-allo-HCT strategies might be required to prevent disease relapse.

  Mar. 2022, Blood advances, 6(6) (6), 1895 - 1903, English, International magazine

  Scientific journal


• The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation.

  Marika Watanabe, Kimikazu Yakushijin, Yohei Funakoshi, Goh Ohji, Wataru Hojo, Hironori Sakai, Miki Saeki, Yuri Hirakawa, Sakuya Matsumoto, Rina Sakai, Shigeki Nagao, Akihito Kitao, Yoshiharu Miyata, Taiji Koyama, Yasuyuki Saito, Shinichiro Kawamoto, Mitsuhiro Ito, Tohru Murayama, Hiroshi Matsuoka, Hironobu Minami

  Patients who have undergone hematopoietic stem cell transplantation (HSCT) for hematological disease experience high mortality when infected by coronavirus disease 2019 (COVID-19). However, the safety and efficacy of the COVID-19 vaccine in HSCT patients remain to be investigated. We prospectively evaluated the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine (Pfizer BioNTech) in 25 Japanese allogeneic HSCT patients in comparison with 19 healthy volunteers. While anti-S1 antibody titers in almost all healthy volunteers after the second dose were higher than the cut-off value reported previously, levels in HSCT patients after the second dose were diverse. Nineteen patients (76%) had seroconversion of anti-S1 IgG. The median optical density of antibody levels in HSCT patients with low IgG levels (<600 mg/dL), steroid treatment, or low lymphocytes (<1000/μL) was significantly lower than that in the other HSCT patients. There were no serious adverse events (>Grade 3) and no new development or exacerbation of graft-versus-host disease after vaccination. We concluded that the BNT162b2 mRNA vaccine is safe and effective in Japanese allogeneic HSCT patients.

  Jan. 2022, Vaccines, 10(2) (2), English, International magazine

  Scientific journal


• Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody.

  Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Wataru Hojo, Hironori Sakai, Marika Watanabe, Miki Saeki, Yuri Hirakawa, Rina Sakai, Sakuya Matsumoto, Yu Mizutani, Akihito Kitao, Yoshiharu Miyata, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Meiko Nishimura, Yoshinori Imamura, Naomi Kiyota, Hiroshi Matsuoka, Yasuko Mori, Hironobu Minami

  We investigated the efficacy of BNT162b2 mRNA COVID-19 vaccine in patients with B-cell malignancies treated with anti-CD20 antibody. Although T-cell-mediated immune responses were detected even in patients receiving R-CHOP treatment, the S1 antibody titer following BNT162b2 vaccination remained only marginally increased for more than 3 years after the final dose of anti-CD20 antibody. We found no relationship between the percent of B-cells and S1 antibody titer. The duration of this suppression was much longer than we anticipated. Further protection and treatment strategies against COVID-19 for these patients are warranted.

  Jan. 2022, International journal of hematology, 115(1) (1), 7 - 10, English, Domestic magazine

  Scientific journal


• 5年の経過で再発・寛解を繰り返しCLIPPERSが先行してT細胞リンパ腫と診断した一例

  荒木 健, 末廣 大知, 立花 久嗣, 田中 伴典, 坂井 里奈, 水谷 優, 齊藤 泰之, 藥師神 公和, 千原 典夫, 上田 健博, 関口 兼司, 松本 理器

  (一社)日本神経学会, Dec. 2021, 臨床神経学, 61(12) (12), 885 - 885, Japanese


• Serum Cytokine Profiles of Rapid Recovery Patients with COVID-19: Series of 6 Cases.

  Goh Ohji, Yohei Funakoshi, Kei Ebisawa, Kimikazu Yakushijin, Yu Arakawa, Jun Saegusa, Shinichiro Kawamoto, Takamitsu Imanishi, Yasuko Mori, Kentaro Iwata, Hironobu Minami

  COVID-19 patients reveal various clinical manifestations; however, the specific mechanisms and factors contributing to rapid recovery remain unclear. We performed serum cytokine profiling using a bead-based immunoassay in six COVID-19 patients with mild symptoms who experienced rapid recovery. All patients had fever that resolved within 4 days. During the study, the interferon gamma-related protein 10 (IP-10) level rapidly increased initially, and then rapidly decreased in all six patients. Similarly, the interferon (IFN)-λ 2/3 levels rapidly increased initially, and then decreased in five of the six patients. IP-10 and IFN-λ2/3 may play a key role in the rapid recovery of mild COVID-19.

  Oct. 2021, The Kobe journal of medical sciences, 67(2) (2), E55-E60, English, Domestic magazine

  [Refereed]

  Scientific journal


• Cryptic insertion of CBFB into MYH11 leading to a type D fusion in acute myeloid leukemia with normal karyotype.

  Katsuya Yamamoto, Keiji Kurata, Akihito Kitao, Rina Sakai, Sakuya Matsumoto, Hisayuki Matsumoto, Jun Saegusa, Kimikazu Yakushijin, Hironobu Minami

  Sep. 2021, International journal of laboratory hematology, English, International magazine


• NRAS c.38G>A変異により発症したRARAの相互転座を伴わない急性前骨髄球性白血病(Novel NRAS c.38G>A mutation causes RARA translocation negative acute promyelocytic-like leukemia)

  後藤 秀彰, 藥師神 公和, 足立 陽子, 松本 久幸, 山本 克也, 松本 咲耶, 東目 亜湖, 川口 晃司, 倉田 啓史, 松岡 広, 南 博信

  (一社)日本血液学会, Sep. 2021, 日本血液学会学術集会, 83回, PS - 7, English


• 新たなKMT2A/EPS15融合遺伝子発現とt(1;11)(p32;q23)転座を認めたFLT3変異陽性B細胞性急性リンパ性白血病(Expression of a novel KMT2A/EPS15 fusion gene in FLT3 mutation-positive B-ALL with t(1;11)(p32;q23))

  山本 克也, 藥師神 公和, 水谷 優, 渡部 まりか, 後藤 秀彰, 東目 亜湖, 宮田 吉晴, 北尾 章人, 松本 久幸, 三枝 淳, 松岡 広, 南 博信

  (一社)日本血液学会, Sep. 2021, 日本血液学会学術集会, 83回, PS - 2, English


• 慢性GVHDに対する肝移植後の一過性末梢血マクロキメリズム(Transient macrochimerism following a liver transplant for hepatic GVHD after an allo-PBSCT)

  渡部 まりか, 藥師神 公和, 蔵満 薫, 福本 巧, 林 宏樹, 安冨 栄一郎, 千々木 瑠里, 高倉 嗣丈, 坂井 里奈, 松本 咲耶, 長尾 茂輝, 水谷 優, 宮田 吉晴, 北尾 章人, 川本 晋一郎, 山本 克也, 松岡 広, 南 博信

  (一社)日本血液学会, Sep. 2021, 日本血液学会学術集会, 83回, PS - 6, English


• 自家造血幹細胞移植患者におけるsynbiotics投与の有効性についての臨床試験(Efficacy of synbiotics in auto-PBSCT patients: a prospective, double-blind, placebo-controlled trial)

  水谷 優, 川本 晋一郎, 丹田 雅明, 曽我 昭宏, 脇田 久美子, 田渕 聡子, 高橋 路子, 土井 久容, 千々木 瑠里, 高倉 嗣丈, 川口 晃司, 東目 亜湖, 渡部 まりか, 市川 大哉, 松本 咲耶, 坂井 里奈, 後藤 秀彰, 倉田 啓史, 垣内 誠司, 宮田 吉晴, 瓜生 恭章, 乾 由美子, 北尾 章人, 藥師神 公和, 松岡 広, 南 博信

  (一社)日本血液学会, Sep. 2021, 日本血液学会学術集会, 83回, OS2 - 4, English


• 同種移植におけるflash sensor-based glucose monitoringの安全性の検討(Safety and accuracy of flash sensor-based glucose monitoring devise in patients after Allo-HSCT)

  長尾 茂輝, 藥師神 公和, 東目 亜湖, 川口 晃司, 渡部 まりか, 坂井 里奈, 水谷 優, 垣内 誠司, 倉田 啓史, 北尾 章人, 宮田 吉晴, 今村 善宣, 廣田 勇士, 高橋 路子, 川本 晋一郎, 山本 克也, 松岡 広, 南 博信

  (一社)日本血液学会, Sep. 2021, 日本血液学会学術集会, 83回, OS3 - 5, English


• Prognostic factors in salvage transplantation for graft failure following allogeneic hematopoietic stem cell transplantation.

  Kaito Harada, Shun-Ichi Kimura, Shigeo Fuji, Yuho Najima, Kimikazu Yakushijin, Naoyuki Uchida, Makoto Onizuka, Kazuhiro Ikegame, Shingo Yano, Naoki Shingai, Ken-Ichi Matsuoka, Yasushi Onishi, Masashi Sawa, Satoru Takada, Toshiro Kawakita, Takahiro Fukuda, Junya Kanda, Yoshiko Atsuta, Hideaki Nakasone

  Although graft failure (GF) is a fatal complication after allogeneic stem cell transplantation (SCT), no mortality risk assessments after salvage SCT have been reported. We developed a comprehensive prognostic scoring system consisting of patient and comorbidity factors with 470 patients as a training cohort out of 940; these patients underwent salvage SCT for GF. The multivariate analysis demonstrated that older age, poorer performance status, a continuation of antimicrobial treatment, and severe organ dysfunction were independently associated with worse overall survival (OS) and non-relapse mortality (NRM). Based on each factor's hazard ratio, weighted scores of 1-3 were assigned to these factors. Using the summed scores (0-8), a prognostic scoring system successfully stratified outcomes after salvage SCT in the cohort. For patients in the low (0-2, n = 122), intermediate (3-4, n = 209), and high score (5-8, n = 110) groups, the 1-year OS was 62.8%, 40.8%, and 14.2%, respectively (P < 0.001), whereas the 1-year NRM was 24.1%, 43.9%, and 72.7%, respectively (P < 0.001). The prognostic value of the scoring system was confirmed in the validation cohort (n = 470). Our scoring system is useful for predicting survival after salvage SCT.

  Sep. 2021, Bone marrow transplantation, 56(9) (9), 2183 - 2193, English, International magazine

  Scientific journal


• Massive surge of mRNA expression of clonal B-cell receptor in patients with COVID-19.

  Yohei Funakoshi, Goh Ohji, Kimikazu Yakushijin, Kei Ebisawa, Yu Arakawa, Jun Saegusa, Hisayuki Matsumoto, Takamitsu Imanishi, Eriko Fukuda, Takaji Matsutani, Yasuko Mori, Kentaro Iwata, Hironobu Minami

  Background: Antibody production is one of the primary mechanisms for recovery from coronavirus disease 2019 (COVID-19). It is speculated that massive clonal expansion of B cells, which can produce clinically meaningful neutralizing antibodies, occurs in patients who recover on the timing of acquiring adaptive immunity. Methods: To evaluate fluctuations in clonal B cells and the size of the clones, we chronologically assessed the B-cell receptor (BCR) repertoire in three patients with COVID-19 who recovered around 10 days after symptom onset. Results: We focused on the three dominant clonotypes (top 3) in each individual. The percentage frequencies of the top 3 clonotypes increased rapidly and accounted for 27.8 % on day 9 in patient 1, 10.4 % on day 12 in patient 2, and 10.8 % on day 11 in patient 3, respectively. The frequencies of these top 3 clonotypes rapidly decreased as the patients' clinical symptoms improved. Furthermore, BCR network analysis revealed that accumulation of clusters composed of similar complementarity-determining region 3 (CDR3) sequences were rapidly formed, grew, and reached their maximum size around 10 days after symptom onset. Conclusions: BCR repertoire analysis revealed that a massive surge of some unique BCRs occurs during the acquisition of adaptive immunity and recovery. The peaks were more prominent than expected. These results provide insight into the important role of BCRs in the recovery from COVID-19 and raise the possibility of developing neutralizing antibodies as COVID-19 immunotherapy.

  Aug. 2021, Heliyon, 7(8) (8), e07748, English, International magazine

  Scientific journal


• Expression of a novel type of KMT2A/EPS15 fusion transcript in FLT3 mutation-positive B-lymphoblastic leukemia with t(1;11)(p32;q23)

  Katsuya Yamamoto, Kimikazu Yakushijin, Yu Mizutani, Marika Okuni-Watanabe, Hideaki Goto, Ako Higashime, Yoshiharu Miyata, Akihito Kitao, Hisayuki Matsumoto, Jun Saegusa, Hiroshi Matsuoka, Hironobu Minami

  Elsevier BV, Jun. 2021, Cancer Genetics, 254-255, 92 - 97

  Scientific journal


• Non-inverted Duplication of 11q, dup(11)(q11q24), in a Diffuse Large B Cell Lymphoma Without MYC Rearrangement: Case Report

  Katsuya Yamamoto, Keiji Kurata, Ako Higashime, Satoshi Sai, Kimikazu Yakushijin, Shinichiro Kawamoto, Kazuyoshi Kajimoto, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu Minami

  Springer Science and Business Media LLC, Mar. 2021, SN Comprehensive Clinical Medicine, 3(6) (6), 1455 - 1462

  Scientific journal


• Regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report.

  Shiro Kimbara, Yoshinori Imamura, Kimikazu Yakushijin, Ako Higashime, Taiji Koyama, Yoshimi Fujishima, Yohei Funakoshi, Masanori Toyoda, Naomi Kiyota, Hiroshi Matsuoka, Hironobu Minami

  Regorafenib is an oral multi-kinase inhibitor which targets tumor angiogenesis, the tumor microenvironment and oncogenesis. Based on this mode of action, regorafenib has a broad spectrum of toxicities. However, at present, few reports have focused on autoimmune adverse events. We report a first case of regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission during treatment for the patients with heavily treated advanced colorectal cancer. This case report highlights the need for caution with regard to regorafenib treatment in patients with cancer with concomitant immune thrombocytopenic purpura.

  Feb. 2021, Molecular and clinical oncology, 14(2) (2), 30 - 30, English, International magazine

  Scientific journal


• Serum Soluble Interleukin-2 Receptor as a Potential Biomarker for Immune-related Adverse Events.

  Ryo Takai, Yohei Funakoshi, Hirotaka Suto, Yoshiaki Nagatani, Yoshinori Imamura, Masanori Toyoda, Kimikazu Yakushijin, Naomi Kiyota, Ken-Ichi Harada, Kimihiro Yamashita, Yoshihiro Kakeji, Hironobu Minami

  BACKGROUND/AIM: Biomarkers for immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) are required. We encountered a patient whose skin irAE fluctuated in parallel with serum soluble interleukin-2 receptor (sIL-2R). PATIENTS AND METHODS: We examined 15 patients with cancer who received ICIs. Serum sIL-2R levels before and during ICI treatment were measured. The sIL-2R levels of preserved serum samples from another five patients who developed grade 3 irAEs were measured. RESULTS: Twelve patients showed no significant changes in sIL-2R levels during ICI treatment. Baseline serum sIL-2R levels in three patients increased beyond the normal range before the second cycle. These three patients had grade ≥2 irAEs at the second cycle treatment visit, supporting our hypothesis. Furthermore, at diagnosis of irAEs, the sIL-2R levels of all preserved samples from patients with grade 3 irAEs were significantly elevated. CONCLUSION: Serum sIL-2R is a promising biomarker for the diagnosis of irAEs.

  Feb. 2021, Anticancer research, 41(2) (2), 1021 - 1026, English, International magazine

  Scientific journal


• Lymphoplasmacytic lymphoma in a patient with Birt–Hogg–Dubé syndrome

  Keiji Kurata, Hisayuki Matsumoto, Naoe Jimbo, Kimikazu Yakushijin, Katsuya Yamamoto, Mitsuhiro Ito, Yuji Nakamachi, Hiroshi Matsuoka, Jun Saegusa, Kuniaki Seyama, Tomoo Itoh, Hironobu Minami

  Springer Science and Business Media LLC, Dec. 2020, International Journal of Hematology, 112(6) (6), 864 - 870

  Scientific journal


• Disseminated cryptococcosis resembling miliary tuberculosis in a patient with acute myeloid leukemia

  Keiji Kurata, Sho Nishimura, Ako Higashime, Koji Kawaguchi, Shigeki Nagao, Yoko Kozuki, Satoshi Sai, Kimikazu Yakushijin, Katsuya Yamamoto, Mitsuhiro Ito, Hiroshi Matsuoka, Hironobu Minami

  Elsevier BV, Nov. 2020, Journal of Infection and Chemotherapy, 26(11) (11), 1216 - 1219

  Scientific journal


• Bleeding Events Associated with Anticoagulant Therapy; Apixaban in Japanese Patients with Cancer-associated Venous Thromboembolism: A Multicenter Phase II Trial(J-CAV)(和訳中)

  Mori Kenta, Otsui Kazunori, Imamura Yoshinori, Kitagawa Koichi, Okada Hideaki, Hata Akito, Hayashi Hidetoshi, Nose Taku, Ohata Shinya, Miyata Yoshiharu, Funakoshi Yohei, Toyoda Masanori, Kiyota Naomi, Yakushijin Kimikazu, Matsuoka Hiroshi, Minami Hironobu

  (一社)日本循環器学会, Jul. 2020, 日本循環器学会学術集会抄録集, 84回, PE52 - 6, English


• 初期研修医の患者把握能力向上を目的としたTime-dependent Problem Listの有用性の更なる検討

  後藤 秀彰, 木村 真希, 坂井 里奈, 金原 史朗, 小山 泰司, 今村 善宣, 豊田 昌徳, 藥師神 公和, 河野 誠司, 南 博信

  (一社)日本医学教育学会, Jul. 2020, 医学教育, 51(Suppl.) (Suppl.), 105 - 105, Japanese


• MYC amplification on double minute chromosomes in plasma cell leukemia with double IGH/CCND1 fusion genes

  Katsuya Yamamoto, Kimikazu Yakushijin, Mitsuhiro Ito, Hideaki Goto, Ako Higashime, Kazuyoshi Kajimoto, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu Minami

  Elsevier BV, Apr. 2020, Cancer Genetics, 242, 35 - 40

  Scientific journal


• Detection of a novel CBFB-MYH11 fusion transcript in acute myeloid leukemia M1 with inv(16)(p13q22).

  Keiji Kurata, Katsuya Yamamoto, Yoko Okazaki, Yoriko Noguchi, Keiji Matsui, Hisayuki Matsumoto, Yumiko Inui, Kimikazu Yakushijin, Mitsuhiro Ito, Yuji Nakamachi, Hiroshi Matsuoka, Jun Saegusa, Hironobu Minami

  Acute myeloid leukemia (AML) with an inv(16)(p13q22) or t(16;16)(p13;q22) chromosomal abnormality represents one of the most common subtypes of de novo cases. These chromosomal rearrangements result in multiple CBFB-MYH11 fusion transcripts, with type-A being the most frequent. We here describe a unique case of de novo AML-M1, with inv(16)(p13q22), leading to an unusual CBFB-MYH11 fusion transcript, and der(7)t(7;11)(q31;q21). The fusion transcript involves a CBFB exon 5 with a breakpoint at nucleotide 754, an insertion of a 13-bp sequence of CBFB intron 5 at the fusion point, and the MYH11 exon 27 with a breakpoint at nucleotide 3464. To our knowledge, this CBFB-MYH11 fusion transcript has never been reported previously. The clinical characteristics of the present case are in line with previous reports suggesting that rare CBFB-MYH11 fusion transcripts lead to aberrant characteristics such as an atypical cytomorphology and additional cytogenetic abnormalities.

  Feb. 2020, Cancer genetics, 241, 72 - 76, English, International magazine

  [Refereed]


• Comparison between quantitative and subjective assessments of chemotherapy-induced peripheral neuropathy in cancer patients: A prospective cohort study.

  Takashi Saito, Daisuke Makiura, Junichiro Inoue, Hisayo Doi, Kimikazu Yakushijin, Atsuo Okamura, Hiroshi Matsuoka, Toru Mukohara, Ryuichi Saura, Yoshitada Sakai, Rei Ono

  OBJECTIVE: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event experienced by cancer patients. In general, CIPN is evaluated subjectively based on patient self-assessment or clinician-reported scales; evidence supporting the utility and validity of quantitative sensory tests (QST) is lacking in this patient population. The aim of this study was to objectively assess CIPN of lower extremities by QSTs, and to evaluate the concordance between QSTs and subjective assessments. METHODS: In this prospective cohort study, outpatients with cancer receiving chemotherapy were recruited at a single university hospital. We assessed CIPN at the lower extremities at baseline and three months after baseline. The QSTs were performed by applying a monofilament and a tuning fork to determine touch and vibration thresholds, respectively, at the affected site. Subjective assessments were performed based on the visual analog scale (VAS) and the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) toxicity grade. Kappa coefficients were calculated to evaluate the concordance between QSTs and subjective assessments. RESULTS: After exclusion and drop-outs during follow-up, nineteen patients were included in the analysis. The prevalence of patients with abnormal sensation was 37% based on QSTs, 32% based on the VAS, and 14% based on CTCAE grading, respectively. Kappa coefficients were 0.32 between QSTs and VAS, and 0.28 between QSTs and CTCAE. CONCLUSIONS: The concordance rates between quantitative and subjective assessments were low. CIPN should be assessed using both quantitative and subjective assessments.

  2020, Physical therapy research, 23(2) (2), 166 - 171, English, Domestic magazine

  [Refereed]

  Scientific journal


• Tetrasomy 8 and isochromosome 7q in CD5-positive hepatosplenic T-cell lymphoma with leukemic presentation

  Katsuya Yamamoto, Kimikazu Yakushijin, Marika Okuni-Watanabe, Akiko Hashimoto, Hiroshi Matsuoka, Hironobu Minami

  Springer Science and Business Media LLC, Nov. 2019, International Journal of Hematology, 110(5) (5), 521 - 523

  Scientific journal


• An mTORC1/2 dual inhibitor, AZD2014, acts as a lysosomal function activator and enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells.

  Mizutani Y, Inase A, Maimaitili Y, Miyata Y, Kitao A, Matsumoto H, Kawaguchi K, Higashime A, Goto H, Kurata K, Yakushijin K, Minami H, Matsuoka H

  Oct. 2019, International journal of hematology, 110(4) (4), 490 - 499

  [Refereed]


• Double-hit pancreatic B-lymphoblastic lymphoma with a variant translocation t(2;18)(p11;q21)

  Katsuya Yamamoto, Shinichiro Kawamoto, Akihito Kitao, Yu Mizutani, Yumiko Inui, Kimikazu Yakushijin, Kazuyoshi Kajimoto, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu Minami

  Springer Science and Business Media LLC, Jul. 2019, International Journal of Hematology, 110(1) (1), 107 - 114

  Scientific journal


• BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient.

  Hideki Nakasone, Koji Kawamura, Kimikazu Yakushijin, Akihito Shinohara, Masatsugu Tanaka, Kazuteru Ohashi, Shuichi Ota, Naoyuki Uchida, Takahiro Fukuda, Hirohisa Nakamae, Ken-Ichi Matsuoka, Junya Kanda, Tatsuo Ichinohe, Yoshiko Atsuta, Yoshihiro Inamoto, Sachiko Seo, Fumihiko Kimura, Masao Ogata

  The use of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells (PBSCs) and sex-mismatched hematopoietic cell transplantation (HCT), especially with female donors and male recipients (FtoM), is known to be associated with an increased risk of chronic graft-versus-host disease (GVHD) compared with transplantation with bone marrow (BM). This raises the question of whether the use of PBSCs in FtoM HCT might affect allogeneic responses, resulting in fatal complications. Using a Japanese transplantation registry database, we analyzed 1132 patients (FtoM, n = 315; MtoF, n = 260; sex-matched, n = 557) with standard-risk diseases who underwent HCT with an HLA-matched related donor without in vivo T-cell depletion between 2013 and 2016. The impact of PBSC vs BM on transplantation outcomes was separately assessed in FtoM, MtoF, and sex-matched HCT. Overall survival (OS) and nonrelapse mortality (NRM) at 2 years post-HCT were significantly worse in patients with PBSCs vs those with BM in FtoM HCT (2-year OS, 76% vs 62%; P = .0084; 2-year NRM, 10% vs 21%; P = .0078); no differences were observed for MtoF or sex-matched HCT. Multivariate analyses confirmed the adverse impact of PBSCs in FtoM HCT (hazard ratio [HR] for OS, 1.91; P = .025; HR for NRM, 3.70; P = .0065). In FtoM HCT, patients with PBSCs frequently experienced fatal GVHD and organ failure. In conclusion, the use of PBSCs in FtoM HCT was associated with an increased risk of NRM in the early phase, resulting in inferior survival. This suggests that, when we use female-related donors for male patients in HCT, BM may result in better outcomes than PBSCs.

  Jun. 2019, Blood advances, 3(11) (11), 1750 - 1760, English, International magazine

  [Refereed]

  Scientific journal


• Clinical effects of recombinant thrombomodulin and defibrotide on sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation.

  Kimikazu Yakushijin, Takayuki Ikezoe, Chikako Ohwada, Kazuko Kudo, Hiroshi Okamura, Hiroaki Goto, Hiromasa Yabe, Atsushi Yasumoto, Hideyuki Kuwabara, Shiro Fujii, Kumiko Kagawa, Masao Ogata, Yasushi Onishi, Akio Kohno, Koichi Watamoto, Nobuhiko Uoshima, Daisuke Nakamura, Shuichi Ota, Yasunori Ueda, Tatsuo Oyake, Kazutoshi Koike, Ishikazu Mizuno, Hiroatsu Iida, Yoshio Katayama, Hiroatsu Ago, Koji Kato, Atsuo Okamura, Atsushi Kikuta, Takahiro Fukuda

  Sinusoidal obstruction syndrome (SOS) is a lethal complication after hematopoietic stem cell transplantation (HSCT). Defibrotide (DF) is the only drug internationally recommended for SOS treatment in Western countries. Recombinant human soluble thrombomodulin (rhTM), which is promising for the treatment of patients with disseminated intravascular coagulation, is also reported to be potentially effective for SOS. To clarify the safety and efficacy of DF and rhTM, we conducted a retrospective survey of these agents in Japan. Data from 65 patients who underwent allogeneic HSCT and received DF (n  =  24) or rhTM (n  =  41) for SOS treatment were collected. The complete response rates for SOS on day 100 were 50% and 54% in the DF and rhTM groups, respectively. The 100-day overall survival rates were 50% in the DF group, and 48% in the rhTM group. Several severe hemorrhagic adverse events were observed in one patient in the DF group and five patients in the rhTM group. The main causes of death were SOS-related death, and no patient died of direct adverse events of DF or rhTM. Our results suggest that rhTM, as well as DF, can be effective as a novel treatment option for SOS.

  May 2019, Bone marrow transplantation, 54(5) (5), 674 - 680, English, International magazine

  [Refereed]

  Scientific journal


• Anemia Is a Novel Predictive Factor for the Onset of Severe Chemotherapy-Induced Peripheral Neuropathy in Lymphoma Patients Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone Therapy.

  Takashi Saito, Atsuo Okamura, Junichiro Inoue, Daisuke Makiura, Hisayo Doi, Kimikazu Yakushijin, Hiroshi Matsuoka, Yoshitada Sakai, Rei Ono

  Chemotherapy-induced peripheral neuropathy (CIPN) frequently occurs in lymphoma patients receiving R-CHOP, a drug combination therapy. Although severe CIPN may lead to reduction and/or discontinuation of the medication, predictive factors of CIPN have not been investigated sufficiently to date. We performed a retrospective exploratory research to determine associations between prevalence of severe CIPN and sociodemographic data, health characteristics, and medical conditions such as anemia at initial diagnosis. Forty patients (indolent lymphoma, n = 9; diffuse large B-cell lymphoma; n = 31) received R-CHOP therapy from September 2009 to July 2014. The median age of patients was 58 years (range = 27-76 years). Statistical analyses were applied to the patients, who were divided into two groups: mild CIPN (no symptoms or grade 1 according to the CTCAE version 3.0 program) and severe CIPN patients (grade 2 or higher). Forward stepwise logistic regression analyses were performed using the following variables: sex, BMI, BSA, hyperglycemia, malnutrition, and anemia. Severe CIPN occurred in seven patients (17.5%). Gender and anemia remained following the stepwise procedure, and anemia predicted severe CIPN significantly (OR = 19.45, 95% confidence interval = 1.52-171.12). Our study suggests that anemia at initial diagnosis could be a predictive factor of R-CHOP-induced CIPN.

  Mar. 2019, Oncology research, 27(4) (4), 469 - 474, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Successful Bridging Chemotherapy with Gemcitabine, Carboplatin, and Dexamethasone before Unrelated Stem Cell Transplantation for Hepatosplenic T-cell Lymphoma.

  Okuni M, Yakushijin Kimikazu, Uehara Keiichiro, Ichikawa H, Suto H, Hashimoto A, Tanaka Y, Shinzato I, Sakai R, Mizutani Y, Nagao S, Kurata K, Kakiuchi S, Miyata Y, Inui Y, Saito Y, Kawamoto Shinichiro, Yamamoto K, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu

  A 45-year-old woman was diagnosed with hepatosplenic T-cell lymphoma (HSTCL), a rare subtype of peripheral T-cell lymphoma. She received different types of chemotherapy, but disease progression was observed. To reduce the tumor burden before an unrelated bone marrow transplantation, combination chemotherapy consisting of the gemcitabine, carboplatin, and dexamethasone (GCD) was administered as bridging therapy, resulting in a reduction in the number of lymphoma cells. We were then able to perform bone marrow transplantation. Although she experienced some adverse events, she successfully achieved long-term remission. We herein report a successful case of HSTCL treated with unrelated stem cell transplantation following the GCD regimen as bridging chemotherapy.

  Mar. 2019, Intern Med., 58(5) (5), 707 - 712, English, Domestic magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Human herpesvirus 6 encephalitis in patients administered mycophenolate mofetil as prophylaxis for graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

  Inui Y, Yakushijin Kimikazu, Okamura A, Tanaka Y, Shinzato I, Nomura T, Ichikawa H, Mizutani Y, Kitao A, Kurata K, Kakiuchi S, Miyata Y, Sanada Y, Kitagawa K, Uryu K, Kawamoto Shinichiro, Yamamoto K, Matsuoka Hiroshi, Murayama T, Ito Mitsuhiro, Minami Hironobu

  BACKGROUND: Human herpesvirus 6 (HHV-6) encephalitis is a known life-threatening complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, few studies have focused on the occurrence of HHV-6 encephalitis in patients receiving mycophenolate mofetil (MMF) combined with a calcineurin inhibitor as prophylaxis for graft-versus-host disease (GVHD). This study aimed to investigate the impact of MMF administered for GVHD prophylaxis in the occurrence of HHV-6 encephalitis after allo-HSCT and the characteristics of this condition. METHODS AND RESULTS: We retrospectively analyzed 73 patients who underwent allo-HSCT (83 transplants) at our hospital between April 2010 and December 2015. MMF (2-3 g/d) was administered along with a calcineurin inhibitor. Seven patients (8.0%) developed encephalitis due to HHV-6. The median period from allo-HSCT to the onset of HHV-6 encephalitis was 23 days (range, 17-98 days). The cumulative incidence of HHV-6 encephalitis on day 100 after treatment was 12% and 6% in patients who underwent cord blood transplantation (CBT) and non-CBT (ie, bone marrow transplantation and peripheral blood stem cell transplantation), respectively (P = 0.344). Neurological symptoms of encephalitis were more severe in non-CBT cases than those in CBT cases. All patients diagnosed with HHV-6 encephalitis were treated with ganciclovir or foscarnet. None of the enrolled patients died from HHV-6 encephalitis. CONCLUSIONS: Mycophenolate mofetil may have the potential to increase the frequency of severe HHV-6 encephalitis in patients undergoing CBT and non-CBT. Thus, MMF should be administered with caution, and patients should be monitored closely for HHV-6 encephalitis even those who did not undergo CBT.

  Feb. 2019, Transpl Infect Dis., 21(1) (1), e13024, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• PET/MRI陰性だが頭部造影MRIにて中枢神経浸潤が明らかとなった精巣原発DLBCLの1例

  後藤 秀彰, 東目 亜湖, 坂井 里奈, 川口 晃司, 石川 瑶子, 倉田 啓史, 藥師神 公和, 松岡 広, 南 博信

  (一社)日本血液学会-東京事務局, Jan. 2019, 臨床血液, 60(1) (1), 59 - 59, Japanese


• Invasive Scopulariopsis alboflavescens infection in patient with acute myeloid leukemia.

  Kurata K, Nishimura S, Ichikawa H, Sakai R, Mizutani Y, Takenaka K, Kakiuchi S, Miyata Y, Kitao A, Yakushijin Kimikazu, Kawamoto Shinichiro, Yamamoto K, Ito Mitsuhiro, Matsuoka Hiroshi, Tokimatsu I, Kamei K, Minami Hironobu

  Scopulariopsis alboflavescens is a soil saprophyte that is widely distributed in nature. Recently, there have been increasing number of reports of invasive infections with Scopulariopsis species in immunocompromised patients. In this report, we described an adult woman with acute myeloid leukemia and who developed S. alboflavescens pneumonia. Liposomal amphotericin B and voriconazole combination therapy was unsuccessful and the patient died because of pneumonia. Scopulariopsis is highly resistant to available antifungal agents and almost invariably fatal. This case report should alert clinicians to the importance of listing Scopulariopsis as a pathogenic fungus in immunocompromised patients.

  Dec. 2018, Int J Hematol., 108(6) (6), 658 - 664, English, Domestic magazine

  [Refereed]

  Scientific journal


• Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive acute myeloid leukemia

  Kakiuchi S, Yakushijin Kimikazu, Sakai R, Kawaguchi K, Higashime A, Kurata K, Ichikawa H, Nagao S, Rikitake J, Kiyota Naomi, Matsuoka Hiroshi, Minami Hironobu

  A 69-year-old woman who had been diagnosed with unresectable papillary thyroid cancer was referred to our hospital. We initially treated her with sorafenib, but she subsequently developed erythema multiforme, which was suspected to be a drug rush due to sorafenib; therefore, sorafenib was discontinued. At the time of discontinuation, immature blast cells were detected in her peripheral blood. Approximately two weeks later, her skin rash improved substantially, but the proportion of blasts in the peripheral blood increased. We performed a bone marrow examination, and she was diagnosed with FLT3-ITD-positive acute myeloid leukemia. FLT3-ITD expression is found in 20-25% of AML and is a known independent poor prognostic factor. To overcome the poor prognosis associated with FLT3-ITD, molecular drugs targeting FLT3-ITD are attracting much attention. Sorafenib, a multi-kinase inhibitor, also has an effect on FLT3-ITD. Although primary disease flares after tyrosine kinase inhibitor discontinuation have been reported, this is the first report to describe discontinuation of sorafenib treatment as a potential trigger of FLT3-ITD-positive acute myeloid leukemia in papillary thyroid cancer.

  Dec. 2018, J Oncol Pharm Pract, 25(8) (8), 2010 - 2015, English, International magazine

  [Refereed]

  Scientific journal


• Delayed Socket Healing After Dental Extraction in Patients Undergoing Myelosuppressive Chemotherapy for Hematological Malignancy: Incidence and Risk Factors

  Akashi Masaya, Kishimoto M, Kusumoto J, Yakushijin Kimikazu, Matsuoka Hiroshi, Komori Takahide

  PURPOSE: The purpose of this study was to measure the frequency and identify factors associated with delayed socket healing after dental extraction in patients undergoing myelosuppressive chemotherapy for hematologic malignancy. MATERIALS AND METHODS: This prospective cohort study focused on delayed healing after extraction in patients with hematologic malignancy. Sockets with delayed healing were defined as those with intense pain and bone exposure 1 week postoperatively. Patients with and without delayed socket healing were compared using the Fisher exact test and Mann-Whitney U test with some variables. Receiver operating characteristics curve analysis was conducted to define cutoff values for delayed healing. RESULTS: One hundred ninety-four dental extractions in 93 patients (median age, 64 yr; range, 20 to 85 yr) were analyzed. The incidence of delayed socket healing was 7.5% (7 of 93 patients). There was no postoperative bleeding. Older age, type of hematologic malignancy (acute leukemia), shorter time from dental extraction to initiation of chemotherapy, low platelet count or hemoglobin level, requirement for red blood cell concentrate or platelet transfusion, and use of an absorbable hemostatic agent were statistically associated with the occurrence of delayed socket healing. Platelet and hemoglobin cutoffs were 4.6 × 104/μL and 7.7 g/dL, respectively. CONCLUSIONS: Although dental extraction can be safely performed in patients undergoing myelosuppressive chemotherapy for hematologic malignancy, oral surgeons should understand the potential risk for delayed socket healing. When considering dental extraction, patients with hematologic malignancy and low hemoglobin or platelet levels should be informed about the possibility of delayed socket healing.

  Oct. 2018, J Oral Maxillofac Surg, 76(10) (10), 2057 - 2065, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• sorafenib投薬を中断することで顕在化したFLT3-ITD陽性急性骨髄性白血病の一例(Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive acute myeloid leukemia)

  垣内 誠司, 坂井 里奈, 川口 晃司, 東目 亜湖, 倉田 啓史, 市川 大哉, 長尾 茂輝, 力武 隼平, 清田 尚臣, 藥師神 公和, 松岡 広, 南 博信

  (一社)日本血液学会-東京事務局, Sep. 2018, 臨床血液, 59(9) (9), 1641 - 1641, English


• 多発性筋炎様症状を呈したNK/T細胞リンパ腫(Extranodal NK/T-cell lymphoma mimicking polymyositis)

  長尾 茂輝, 倉田 啓史, 東目 亜湖, 川口 晃司, 市川 大哉, 坂井 里奈, 後藤 秀彰, 水谷 優, 垣内 誠司, 宮田 吉晴, 北尾 章人, 藥師神 公和, 山本 克也, 松岡 広, 南 博信

  (一社)日本血液学会-東京事務局, Sep. 2018, 臨床血液, 59(9) (9), 1733 - 1733, English


• TLR9の一塩基多型により無症候性CMV感染症を呈した再生不良性貧血の一例(Aplastic anemia that developed asymptomatic CMV infection due to SNPs of TLR9)

  北尾 章人, 川本 晋一郎, 水谷 優, 坂井 里奈, 市川 大哉, 須藤 洋崇, 藥師神 公和, 松岡 広, 南 博信

  (一社)日本血液学会-東京事務局, Sep. 2018, 臨床血液, 59(9) (9), 1756 - 1756, English


• シクロスポリン療法後の骨髄移植にて重症肝類洞閉塞症候群をきたした一例(Severe sinusoidal obstruction syndrome after cyclosporine treatment followed by transplantation)

  川口 晃司, 坂井 里奈, 垣内 誠司, 東目 亜湖, 倉田 啓史, 長尾 茂樹, 藥師神 公和, 足立 陽子, 松岡 広, 南 博信

  (一社)日本血液学会-東京事務局, Sep. 2018, 臨床血液, 59(9) (9), 1815 - 1815, English


• 新たなZMYND11/MBTD1融合遺伝子の発現とt(10;17)(p15;q21)転座を認めたCD7+CD56+急性骨髄性白血病(Expression of a novel ZMYND11/MBTD1 fusion transcript in CD7+CD56+ AML with t(10;17)(p15;q21))

  山本 克也, 藥師神 公和, 市川 大哉, 垣内 誠司, 川本 晋一郎, 松本 久幸, 中町 祐司, 三枝 淳, 松岡 広, 南 博信

  (一社)日本血液学会-東京事務局, Sep. 2018, 臨床血液, 59(9) (9), 1640 - 1640, English

  [Refereed]


• Early lymphocyte recovery predicts clinical outcome after HSCT with mycophenolate mofetil prophylaxis in the Japanese population

  Keiji Kurata, Kimikazu Yakushijin, Ishikazu Mizuno, Hiroshi Gomyo, Atsuo Okamura, Hiroya Ichikawa, Rina Sakai, Yu Mizutani, Seiji Kakiuchi, Yoshiharu Miyata, Akihito Kitao, Yukinari Sanada, Yumiko Inui, Kiyoaki Uryu, Shinichiro Kawamoto, Takeshi Sugimoto, Katsuya Yamamoto, Mitsuhiro Ito, Hiroshi Matsuoka, Tohru Murayama, Hironobu Minami

  Springer Science and Business Media LLC, Jul. 2018, International Journal of Hematology, 108(1) (1), 58 - 65

  Scientific journal


• Human CD134 (OX40) expressed on T cells plays a key role for human herpesvirus 6B replication after allogeneic hematopoietic stem cell transplantation.

  Satoshi Nagamata, Miwako Nagasaka, Akiko Kawabata, Kenji Kishimoto, Daiichiro Hasegawa, Yoshiyuki Kosaka, Takeshi Mori, Ichiro Morioka, Noriyuki Nishimura, Kazumoto Iijima, Hideto Yamada, Shinichiro Kawamoto, Kimikazu Yakushijin, Hiroshi Matsuoka, Yasuko Mori

  BACKGROUND: CD134 (OX40), which is a cellular receptor for human herpesvirus-6B (HHV-6B) and expresses on activated T cells, may play a key role for HHV-6B replication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). OBJECTIVES: Therefore, we examined the CD134 expression on T cells and HHV-6B replication after allo-HSCT, and analyzed the correlation between them. STUDY DESIGN: Twenty-three patients after allo-HSCT were enrolled. The percentages of CD134-positive cells within the CD4+ and CD8+ cell populations were measured by flow cytometry, and the viral copy number of HHV-6B was simultaneously quantified by real-time PCR. The correlation between CD134 and HHV-6B viral load was then statistically analyzed. RESULTS: HHV-6B reactivation occurred in 11 of 23 patients (47.8%). CD134 expression was seen on T cells and was coincident with the time of peak viral load. The percentage of CD134-positive cells decreased significantly when HHV-6B DNA disappeared (p = .005 in CD4+ T cells, p = .02 in CD8+ T cells). In the 4 patients who underwent umbilical cord blood transplantation (UCBT), the viral load varied with the percentage of CD134-positive cells. In the comparison between the HHV-6B reactivation group and non-reactivation group, maximum percentages of CD134-positive cells among CD4+ T cells in reactivation group were significantly higher than those in non-reactivation group (p = .04). CONCLUSIONS: This is the first study to show that a correlation of CD134 expression on T cells with HHV-6B replication after allo-HSCT, especially in UCBT. The results possibly indicate that CD134 on T cells plays a key role for HHV-6B replication after allo-HSCT.

  May 2018, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 102, 50 - 55, English, International magazine

  [Refereed]

  Scientific journal


• Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients

  KurataK, Yakushijin Kimikazu, OkamuraA, YamamoriM, IchikawaH, SakaiR, MizutaniY, KakiuchiS, MiyataY, KitaoA, KawamotoS, Matsuoka Hiroshi, MurayamaT, MinamiH

  PURPOSE: Mycophenolate mofetil (MMF) is increasingly used among Japanese patients undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT). Because pharmacokinetic data for MMF in the Asian population are limited, we conducted this investigation. METHODS: Intravenous MMF (1000 mg/dose) was administered to 10 patients along with cyclosporine or tacrolimus for 10 days after allo-SCT; it was administered every 8 h in peripheral blood stem cell- and bone marrow-transplanted patients, and every 12 h in cord blood-transplanted patients. MMF was administered orally at the same dose from day 11. Plasma concentrations of mycophenolic acid (MPA) were measured by high-performance liquid chromatography. RESULTS: The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively. The AUC0 - tau and Cmax were significantly higher after intravenous MMF dosing than after oral MMF dosing. All patients exhibited successful neutrophil engraftments in a median time of 18 days. Grade II acute graft-versus-host disease (GvHD) of the skin was observed in two patients, and one patient developed limited chronic GvHD. Individual cases of transient and curable grade III oral mucositis and diarrhea were observed; however, MMF was not discontinued. No other severe complications or infections were observed. CONCLUSIONS: Intravenously administered MMF was safe and possibly effective in achieving higher MPA plasma concentrations for GvHD prophylaxis after allo-SCT in Japanese patients.

  Mar. 2018, Cancer Chemother Pharmacol, 81(5) (5), 839 - 846, English, International magazine

  [Refereed]

  Scientific journal


• A Case of Classical Hodgkin Lymphoma with Total Lymph Node Infarction.

  Okuni M, Yakushijin Kimikazu, Sakai Y, Suto H, Ichikawa H, Sakai R, Kakiuchi S, Kurata K, Mizutani Y, Kitao A, Miyata Y, Saito Y, Kawamoto S, Yamamoto K, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu

  Lymph node infarction is very rare, and is frequently associated with neoplasms, such as malignant lymphoma and non-neoplastic disease, or interventions such as fine-needle aspiration (FNA). A 76-year-old-man presented with cervical lymph node swelling. Although FNA was performed, the findings were insufficient for a definitive diagnosis. Consequently, surgical biopsy of the cervical lymph node was performed, which revealed total infarction; a diagnosis of classical Hodgkin lymphoma was made later. Both lymphoma itself and FNA may cause total lymph node infarction, which makes diagnosis confusing. Therefore, it is important to repeat the biopsy rather than repeat FNA to correctly diagnose malignant lymphoma, including Hodgkin lymphoma.

  Mar. 2018, J Clin Exp Hematop., 58(1) (1), 24 - 26, English, Domestic magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• MYC Amplification in the Form of Ring Chromosomes 8 in Acute Myeloid Leukemia with t(11;16)(q13;p11.2)

  Katsuya Yamamoto, Shinichiro Kawamoto, Keiji Kurata, Akihito Kitao, Yu Mizutani, Hiroya Ichikawa, Kimikazu Yakushijin, Kazuyoshi Kajimoto, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu Minami

  S. Karger AG, Feb. 2018, Cytogenetic and Genome Research, 153(3) (3), 131 - 137, English

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia

  Yukio Kobayashi, Wataru Munakata, Michinori Ogura, Toshiki Uchida, Masafumi Taniwaki, Tsutomu Kobayashi, Fumika Shimada, Masataka Yonemura, Fumiko Matsuoka, Takeshi Tajima, Kimikazu Yakushijin, Hironobu Minami

  Springer Tokyo, Jan. 2018, International Journal of Hematology, 107(1) (1), 83 - 91, English

  [Refereed]

  Scientific journal


• Megakaryoblastic transformation of therapy-related myeloid neoplasms with concomitant MYC amplification on double minute chromosomes

  Katsuya Yamamoto, Kimikazu Yakushijin, Yumiko Inui, Shinichiro Kawamoto, Kazuyoshi Kajimoto, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu Minami

  Dec. 2017, INTERNATIONAL JOURNAL OF HEMATOLOGY, 106(6) (6), 729 - 731, English

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 慢性C型肝炎治療後に発症したB細胞性前リンパ球性白血病の1例

  毛利 華奈子, 坂井 里奈, 須藤 洋崇, 川本 晋一郎, 藥師神 公和, 松岡 広, 南 博信

  (一社)日本血液学会-東京事務局, Nov. 2017, 臨床血液, 58(11) (11), 2289 - 2289, Japanese


• A multi-center prospective study randomizing the use of fat emulsion in intensive glucose control after allogeneic hematopoietic stem cell transplantation using a myeloablative conditioning regimen

  FujiS, KimSW, KamiyaS, NakaneT, MatsumotoK, OnishiY, Yakushijin Kimikazu, YamazakiE, HinoM, KurosawaS, YoshimuraKI, FukudaT

  Nov. 2017, Clin Nutr, English

  [Refereed]

  Scientific journal


• 悪性リンパ腫患者におけるコリンエステラーゼ値層別化による腫瘍崩壊症候群発症リスクの後方視的解析

  小嶋 真理子, 坂井 里奈, 川本 晋一郎, 市川 大哉, 水谷 優, 倉田 啓史, 垣内 誠司, 宮田 吉晴, 北尾 章人, 藥師神 公和, 山本 克也, 松岡 広, 南 博信

  (一社)日本血液学会-東京事務局, Sep. 2017, 臨床血液, 58(9) (9), 1763 - 1763, Japanese


• Intensity and duration of neutropenia relates to the development of oral mucositis but not odontogenic infection during chemotherapy for hematological malignancy

  Megumi Kishimoto, Masaya Akashi, Kazuyuki Tsuji, Junya Kusumoto, Shungo Furudoi, Yasuyuki Shibuya, Yumiko Inui, Kimikazu Yakushijin, Shinichiro Kawamoto, Atsuo Okamura, Hiroshi Matsuoka, Takahide Komori

  Jul. 2017, PLOS ONE, 12(7) (7), e0182021, English

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem-cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials

  Takahiko Nakane, Hirohisa Nakamae, Takuhiro Yamaguchi, Saiko Kurosawa, Atsuo Okamura, Michihiro Hidaka, Shigeo Fuji, Akio Kohno, Takeshi Saito, Yasutaka Aoyama, Kazuo Hatanaka, Yoshio Katayama, Kimikazu Yakushijin, Toshimitsu Matsui, Motohiro Yamamori, Akiyoshi Takami, Masayuki Hino, Takahiro Fukuda

  Apr. 2017, INTERNATIONAL JOURNAL OF HEMATOLOGY, 105(4) (4), 485 - 496, English

  [Refereed]

  Scientific journal


• NANOG expression as a responsive biomarker during treatment with hedgehog signal inhibitor in acute myeloid leukemia

  Seiji Kakiuchi, Yosuke Minami, Yoshiharu Miyata, Yu Mizutani, Hideaki Goto, Shinichiro Kawamoto, Kimikazu Yakushijin, Keiji Kurata, Hiroshi Matsuoka, Hironobu Minami

  MDPI AG, Mar. 2017, International Journal of Molecular Sciences, 18(3) (3), English

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Impact of total body irradiation on successful neutrophil engraftment in unrelated bone marrow or cord blood transplantation

  Hideki Nakasone, Shigeo Fuji, Kimikazu Yakushijin, Makoto Onizuka, Akihito Shinohara, Kazuteru Ohashi, Koichi Miyamura, Naoyuki Uchida, Minoko Takanashi, Tatsuo Ichinohe, Yoshiko Atsuta, Takahiro Fukuda, Masao Ogata

  Feb. 2017, AMERICAN JOURNAL OF HEMATOLOGY, 92(2) (2), 171 - 178, English

  [Refereed]

  Scientific journal


• Constitutional t(8;22)(q24;q11.2) that mimics the variant Burkitt-type translocation in Philadelphia chromosome-positive chronic myeloid leukemia

  Shinichiro Kawamoto, Katsuya Yamamoto, Masanori Toyoda, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami

  Feb. 2017, INTERNATIONAL JOURNAL OF HEMATOLOGY, 105(2) (2), 226 - 229, English

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Loss of CD45 expression at relapse of acute myeloid leukemia

  YAMAMOTO Katsuya, YAKUSHIJIN Kimikazu, KURATA Keiji, MIZUTANI Yu, INUI Yumiko, URYU Kiyoaki, KAWAMOTO Shinichiro, SUGIMOTO Takeshi, MATSUOKA Hiroshi, MINAMI Hironobu

  A 49-year-old female was initially diagnosed with acute myeloid leukemia (AML) M4 with a CD45＋CD13＋CD33＋CD34−HLA-DR＋ immunophenotype. She underwent allogeneic bone marrow transplantation, but the disease recurred. The bone marrow was infiltrated with 87.0% blasts negative for myeloperoxidase (MPO) staining. Immunophenotyping by flow cytometry identified the presence of a CD45-negative blast population. These blasts exhibited a CD13＋CD33＋CD19−CD10−CD34−HLA-DR− immunophenotype. The lack of CD45 expression is often observed in B-cell acute lymphoblastic leukemia, whereas CD45-negative AML is extremely rare; only one older male with AML-M0 has been reported. In the present case, the CD45-negative blasts had an MPO−CD13＋CD33＋ phenotype, which is similar to AML-M0.

  The Japanese Society of Hematology, 2017, Rinsho Ketsueki, 58(8) (8), 938 - 941, Japanese


• A prospective study of the antiemetic effect of palonosetron in malignant lymphoma patients treated with the CHOP regimen

  Yoshiharu Miyata, Kimikazu Yakushijin, Yumiko Inui, Yoshinori Imamura, Hideaki Goto, Yu Mizutani, Keiji Kurata, Seiji Kakiuchi, Yukinari Sanada, Yosuke Minami, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Ryo Tominaga, Hiroshi Gomyo, Ishikazu Mizuno, Tetsuhiko Nomura, Koichi Kitagawa, Takeshi Sugimoto, Tohru Murayama, Hiroshi Matsuoka, Hironobu Minami

  Dec. 2016, INTERNATIONAL JOURNAL OF HEMATOLOGY, 104(6) (6), 682 - 691, English

  [Refereed]

  Scientific journal


• Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes

  K. Yakushijin, Y. Atsuta, N. Doki, A. Yokota, H. Kanamori, T. Miyamoto, C. Ohwada, K. Miyamura, Y. Nawa, M. Kurokawa, I. Mizuno, T. Mori, M. Onizuka, J. Taguchi, T. Ichinohe, H. Yabe, Y. Morishima, K. Kato, R. Suzuki, T. Fukuda

  This retrospective study was conducted in Japan to determine the incidence, risk factors and outcomes of sinusoidal obstruction syndrome (SOS) after allogeneic hematopoietic stem cell transplantation (HSCT). Among 4290 patients undergoing allogeneic HSCT between 1999 and 2010, 462 were diagnosed with SOS according to the Seattle criteria (cumulative incidence, 10.8%). The cumulative incidence of SOS diagnosed by the modified Seattle criteria was 9.3%. Of 462 patients, 107 met the Baltimore criteria and 168 had severe SOS with renal and/or respiratory failure. The median onset for SOS was 12 days after HSCT (range, -2-30). Overall survival at day 100 was 32% for SOS and 15% for severe SOS. Multivariate analyses showed that significant independent risk factors for SOS were the number of HSCTs, age, performance status, hepatitis C virus-seropositivity, advanced disease status and myeloablative regimen. SOS was highly associated with overall mortality (hazard ratio, 2.09; P<0.001). Our retrospective survey showed that the cumulative incidence of SOS in Japan was 10.8%, similar to that previously reported in Western countries, and that the overall survival of patients who developed SOS

  Mar. 2016, Bone Marrow Transplant, 51(3) (3), 403 - 9, English


• Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes

  K. Yakushijin, Y. Atsuta, N. Doki, A. Yokota, H. Kanamori, T. Miyamoto, C. Ohwada, K. Miyamura, Y. Nawa, M. Kurokawa, I. Mizuno, T. Mori, M. Onizuka, J. Taguchi, T. Ichinohe, H. Yabe, Y. Morishima, K. Kato, R. Suzuki, T. Fukuda

  Mar. 2016, BONE MARROW TRANSPLANTATION, 51(3) (3), 403 - 409, English

  [Refereed]

  Scientific journal


• Coexpression of NUP98/TOP1 and TOP1/NUP98 in de novo Acute Myeloid Leukemia with t(11;20)(p15;q12) and t(2;5)(q33;q31)

  Katsuya Yamamoto, Yosuke Minami, Kimikazu Yakushijin, Yu Mizutani, Yumiko Inui, Shinichiro Kawamoto, Keiji Matsui, Yuji Nakamachi, Seiji Kawano, Hiroshi Matsuoka, Hironobu Minami

  2016, Cytogenetic and Genome Research, 150(3-4) (3-4), 287 - 292

  Scientific journal


• Coexpression of NUP98/TOP1 and TOP1/NUP98 in de novo Acute Myeloid Leukemia with t(11;20)(p15;q12) and t(2;5)(q33;q31)

  Katsuya Yamamoto, Yosuke Minami, Kimikazu Yakushijin, Yu Mizutani, Yumiko Inui, Shinichiro Kawamoto, Keiji Matsui, Yuji Nakamachi, Seiji Kawano, Hiroshi Matsuoka, Hironobu Minami

  2016, CYTOGENETIC AND GENOME RESEARCH, 150(3-4) (3-4), 287 - 292, English

  [Refereed]

  Scientific journal


• Absolute Lymphocyte Count Recovery Predicts Clinical Outcome after Allogeneic Hematopoietic Stem Cell Transplantation in a Japanese Population

  Kurata K, Yakushijin K, Mizuno I, Inui Y, Gomyo H, Okamura A, Ichikawa H, Mizutani Y, Kakiuchi S, Miyata Y, Tominaga R, Kitao A, Sanada Y, Saito Y, Minami Y, Kawamoto S, Maeda A, Yamamoto K, Murayama T, Ito M, Matsuoka H, Minami H

  2016, Bone Marrow Transplantation, 51, S411

  [Refereed]


• Mixed Phenotype Acute Leukemia with t(12;17)(p13;q21)/TAF15-ZNF384 and Other Chromosome Abnormalities

  Katsuya Yamamoto, Shinichiro Kawamoto, Yu Mizutani, Kinnikazu Yakushijin, Tonnoe Yamashita, Yuji Nakannachi, Seiji Kawano, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu Minami

  2016, CYTOGENETIC AND GENOME RESEARCH, 149(3) (3), 165 - 170, English

  [Refereed]

  Scientific journal


• A prospective study on the efficacy of two-dose influenza vaccinations in cancer patients receiving chemotherapy

  Yukinari Sanada, Kimikazu Yakushijin, Tetsuhiko Nomura, Naoko Chayahara, Masanori Toyoda, Yosuke Minami, Naomi Kiyota, Toru Mukohara, Shinichiro Kawamoto, Mitsuhiro Ito, Hiroshi Matsuoka, Hironobu Minami

  Oxford University Press, 2016, Japanese Journal of Clinical Oncology, 46(5) (5), 448 - 452, English

  [Refereed]

  Scientific journal


• A new transcriptional variant and small azurophilic granules in an acute promyelocytic leukemia case with NPM1/RARA fusion gene

  Tomoe Kikuma, Yuji Nakamachi, Yoriko Noguchi, Yoko Okazaki, Daisuke Shimomura, Kimikazu Yakushijin, Katsuya Yamamoto, Hiroshi Matsuoka, Hironobu Minami, Tomoo Itoh, Seiji Kawano

  Dec. 2015, INTERNATIONAL JOURNAL OF HEMATOLOGY, 102(6) (6), 713 - 718, English

  [Refereed]

  Scientific journal


• Methotrexate-associated lymphoproliferative disorders: Management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal

  Yumiko Inui, Hiroshi Matsuoka, Kimikazu Yakushijin, Atsuo Okamura, Takaki Shimada, Shingo Yano, Mai Takeuchi, Mitsuhiro Ito, Tohru Murayama, Katsuya Yamamoto, Tomoo Itoh, Keisuke Aiba, Hironobu Minami

  Taylor and Francis Ltd, Nov. 2015, Leukemia and Lymphoma, 56(11) (11), 3045 - 3051, English

  [Refereed]

  Scientific journal


• Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal

  Yumiko Inui, Hiroshi Matsuoka, Kimikazu Yakushijin, Atsuo Okamura, Takaki Shimada, Shingo Yano, Mai Takeuchi, Mitsuhiro Ito, Tohru Murayama, Katsuya Yamamoto, Tomoo Itoh, Keisuke Aiba, Hironobu Minami

  Nov. 2015, LEUKEMIA & LYMPHOMA, 56(11) (11), 3045 - 3051, English

  [Refereed]

  Scientific journal


• O1-11-3A phase I b study of panobinostat and 5-azacitidine in Japanese patients with MDS, CMML, or AML

  Kimikazu Yakushijin, Hironobu Minami, Toshiki Uchida, Michinori Ogura, Masafumi Taniwaki, Tsutomu Kobayashi, Asuka Mori, Masataka Yonemura, Wataru Munakata, Yukio Kobayashi

  Oxford University Press ({OUP}), Oct. 2015, Ann Oncol, 26(suppl 7) (suppl 7), vii85.1

  [Refereed]


• A case of intravascular lymphoma diagnosed in an explanted liver after liver transplantation

  Kuramitsu K, Fukumoto T, Yano Yoshihiko, Hirano H, Misumi T, Katayama Y, Kawano H, Yakushijin K, Zen Y, Itoh T, Ku Yonson

  May 2015, Transpl Int, English

  [Refereed]

  Scientific journal


• Disappearance of double minute chromosomes with MYC amplification in relapsed acute myeloid leukemia after stem cell transplantation

  Katsuya Yamamoto, Kimikazu Yakushijin, Keiji Kurata, Yukinari Sanada, Shinichiro Kawamoto, Hiroshi Matsuoka, Hironobu Minami

  Springer-Verlag Tokyo, May 2015, International Journal of Hematology, 101(5) (5), 423 - 425, English

  Research society


• Prospective Study of Dental Intervention for Hematopoietic Malignancy

  K. Tsuji, Y. Shibuya, M. Akashi, S. Furudoi, K. Yakushijin, S. Kawamoto, A. Okamura, H. Matsuoka, T. Komori

  Feb. 2015, JOURNAL OF DENTAL RESEARCH, 94(2) (2), 289 - 296, English

  [Refereed]

  Scientific journal


• Coexistent t(8;21)(q22;q22) Translocation and 5q Deletion in Acute Myeloid Leukemia

  YamamotoK, YakushijinK, SanadaY, Kawamoto Shinichiro, Matsuoka Hiroshi, MinamiH

  2015, J Clin Exp Hematop, 55(3) (3), 181 - 5, English

  [Refereed]

  Scientific journal


• Translocation t(11;19)(q23;q13.1) without MLL Rearrangement in Acute Myeloid Leukemia: Heterogeneity of the 11q23 Breakpoints

  Katsuya Yamamoto, Shinichiro Kawamoto, Seiji Kakiuchi, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami

  2015, ACTA HAEMATOLOGICA, 134(2) (2), 76 - 79, English

  [Refereed]

  Scientific journal


• Severe weight loss in 3 months after allogeneic hematopoietic SCT was associated with an increased risk of subsequent non-relapse mortality

  S. Fuji, T. Mori, N. Khattry, J. Cheng, Y. R. Do, K. Yakushijin, S. Kohashi, T. Fukuda, S-W Kim

  Jan. 2015, BONE MARROW TRANSPLANTATION, 50(1) (1), 100 - 105, English

  [Refereed]

  Scientific journal


• Conversion from nuclear bilobation to indentation in BCR/ABL1-positive acute myeloid leukemia lacking CD34 and HLA-DR expression

  Katsuya Yamamoto, Kimikazu Yakushijin, Yukinari Sanada, Shinichiro Kawamoto, Yuji Nakamachi, Seiji Kawano, Hiroshi Matsuoka, Hironobu Minami

  Jan. 2015, ANNALS OF HEMATOLOGY, 94(1) (1), 177 - 179, English

  [Refereed]

  Scientific journal


• Extramedullary T-lymphoid blast crisis of an ETV6/ABL1-positive myeloproliferative neoplasm with t(9;12)(q34;p13) and t(7;14)(p13;q11.2)

  Katsuya Yamamoto, Kimikazu Yakushijin, Yuji Nakamachi, Yoshiharu Miyata, Yukinari Sanada, Yasuhiro Tanaka, Atsuo Okamura, Seiji Kawano, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu Minami

  Aug. 2014, ANNALS OF HEMATOLOGY, 93(8) (8), 1435 - 1438, English

  [Refereed]

  Scientific journal


• A mimicking "multiple liver metastasis" of breast cancer by recurrent B lymphoblastic leukemia

  Meiko Nishimura, Atsuo Okamura, Yumiko Inui, Yoshinori Imamura, Kimikazu Yakushijin, Hiroshi Matsuoka, Katsuya Yamamoto, Hironobu Minami

  Mar. 2014, ANNALS OF HEMATOLOGY, 93(3) (3), 499 - 500, English

  [Refereed]

  Scientific journal


• Tandem triplication of the BCL2 gene in CD5-positive intravascular large B cell lymphoma with bone marrow involvement

  Yamamoto K, Okamura A, Yakushijin Kimikazu, Hayashi Yoshitake, Matsuoka Hiroshi, Minami Hironobu

  Feb. 2014, Ann Hematol, 93(10) (10), 1791 - 3, English, International magazine

  [Refereed]

  Scientific journal


• Unbalanced Translocation der(7)t(7q;11q): A New Recurrent Aberration Leading to Partial Monosomy 7q and Trisomy 11q in Acute Myeloid Leukemia

  Katsuya Yamamoto, Kimikazu Yakushijin, Yoshiharu Miyata, Hiroshi Matsuoka, Hironobu Minami

  2014, ACTA HAEMATOLOGICA, 132(2) (2), 244 - 246, English

  [Refereed]

  Scientific journal


• A new complex translocation t(8;11;21)(q22;q24;q22) in acute myeloid leukemia with RUNX1/RUNX1T1

  Yamamoto K, Yakushijin Kimikazu, Funakoshi Y, Sanada Y, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu

  2014, J Clin Exp Hematop, 54(2) (2), 167 - 70, English, Domestic magazine

  [Refereed]

  Scientific journal


• Marked thrombocytosis and dysmegakaryopoiesis in acute myeloid leukemia with t(2;3)(p22;q26.2) and EVI1 rearrangement

  Katsuya Yamamoto, Atsuo Okamura, Yukinari Sanada, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami

  Dec. 2013, Annals of Hematology, 92(12) (12), 1713 - 1715, English

  [Refereed]

  Scientific journal


• Reduced-intensity conditioning regimen with low-dose ATG-F for unrelated bone marrow transplant is associated with lower non-relapse mortality than a regimen with low-dose TBI: A single-center retrospective analysis of 103 cases

  Shigeo Fuji, Niina Ueno, Nobuhiro Hiramoto, Yoshitaka Asakura, Kimikazu Yakushijin, Yutaro Kamiyama, Saiko Kurosawa, Sung-Won Kim, Yuji Heike, Takuya Yamashita, Takahiro Fukuda

  Nov. 2013, International Journal of Hematology, 98(5) (5), 608 - 614, English

  [Refereed]

  Scientific journal


• Enlargement of bilateral kidneys by infiltration of leukemic cells in acute lymphoblastic leukemia at relapse after allogeneic hematopoietic stem cell transplantation

  Yasuhiro Tanaka, Kimikazu Yakushijin, Toshiro Takafuta

  Nov. 2013, International Journal of Hematology, 98(5) (5), 513 - 514, English

  [Refereed]

  Scientific journal


• がんリハビリテーション治療の最前線 多職種チームでのがんリハビリテーションの取り組み 食道癌・造血幹細胞移植を中心に

  井上 順一朗, 小野 玲, 牧浦 大祐, 柏 美由紀, 岡村 篤夫, 薬師神 公和, 中村 哲, 今西 達也, 掛地 吉弘, 土井 久容, 石橋 有希, 三浦 靖史, 酒井 良忠, 佐浦 隆一

  (一社)日本癌治療学会, Sep. 2013, 日本癌治療学会誌, 48(3) (3), 809 - 809, Japanese

  [Refereed]


• Hyperdiploidy and duplication of der(11)ins(10;11)(p12;q23q14) in acute myeloid leukemia with MLL/MLLT10 fusion gene

  Katsuya Yamamoto, Kimikazu Yakushijin, Atsuo Okamura, Shinnosuke Ueda, Yuji Nakamachi, Seiji Kawano, Hiroshi Matsuoka, Hironobu Minami

  Sep. 2013, Leukemia and Lymphoma, 54(9) (9), 2055 - 2058, English

  [Refereed]

  Scientific journal


• Recent decrease in non-relapse mortality due to GVHD and infection after allogeneic hematopoietic cell transplantation in non-remission acute leukemia

  S. Kurosawa, K. Yakushijin, T. Yamaguchi, Y. Atsuta, T. Nagamura-Inoue, H. Akiyama, S. Taniguchi, K. Miyamura, S. Takahashi, T. Eto, H. Ogawa, M. Kurokawa, J. Tanaka, K. Kawa, K. Kato, R. Suzuki, Y. Morishima, H. Sakamaki, T. Fukuda

  Sep. 2013, Bone Marrow Transplantation, 48(9) (9), 1198 - 1204, English

  [Refereed]

  Scientific journal


• Myelosuppression grading of chemotherapies for hematologic malignancies to facilitate communication between medical and dental staff: Lessons from two cases experienced odontogenic septicemia

  Masaya Akashi, Yasuyuki Shibuya, Junya Kusumoto, Shungo Furudoi, Yumiko Inui, Kimikazu Yakushijin, Atsuo Okamura, Hiroshi Matsuoka, Takahide Komori

  Aug. 2013, BMC Oral Health, 13(1) (1), 41, English

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Micronuclei-associated MYC amplification in the form of double minute chromosomes in acute myeloid leukemia

  Katsuya Yamamoto, Atsuo Okamura, Yukinari Sanada, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami

  Aug. 2013, American Journal of Hematology, 88(8) (8), 717 - 718, English

  [Refereed]

  Scientific journal


• L-Asparaginase-induced fulminating liver dysfunction

  Atsuo Okamura, Meiko Nishimura, Yukinari Sanada, Kimikazu Yakushijin, Hiroshi Matsuoka, Katsuya Yamamoto, Hironobu Minami

  Jul. 2013, INTERNATIONAL JOURNAL OF HEMATOLOGY, 98(1) (1), 6 - 7, English

  [Refereed]

  Scientific journal


• Impact of hepatitis C virus infection on clinical outcome in recipients after allogeneic hematopoietic cell transplantation.

  Hideki Nakasone, Saiko Kurosawa, Kimikazu Yakushijin, Shuichi Taniguchi, Makoto Murata, Kazuhiro Ikegame, Takeshi Kobayashi, Tetsuya Eto, Koichi Miyamura, Hisashi Sakamaki, Yasuo Morishima, Tokiko Nagamura, Ritsuro Suzuki, Takahiro Fukuda

  The impact of hepatitis C virus (HCV) infection on outcomes following allogeneic hematopoietic cell transplantation (HCT) remains a matter of debate. We have retrospectively examined the significance of HCV infection among recipients who received allogeneic HCT, using a Japan transplant outcome registry database between 2006 and 2009. Among 7,831 recipients, 136 were HCV-positive. The rate of hematopoietic recovery was lower in the HCV-positive group (neutrophil recovery of 500 × 10(6) /L or higher: 79% vs. 87% at Day 30, P = 0.087; platelet recovery of 50 × 10(9) /L or higher: 57% vs. 65% at Day 60, P = 0.012). The HCV-positive group had a significantly higher incidence of nonrelapse mortality 38% vs. 25% at 2 years, P < 0.01) and inferior overall survival (41% vs. 51% at 2 years, P < 0.01). A multivariate analysis revealed that HCV seropositivity was associated with an independent risk for higher nonrelapse mortality (hazard ratio: 1.65, P < 0.01) and inferior overall survival (hazard ratio: 1.39, P < 0.01). The incidences of death due to hepatic problems (8% vs. 2%, P < 0.01), bacterial infection (10% vs. 4%, P < 0.01), or graft failure (5% vs. 2%, P = 0.084) tended to be higher in the HCV-positive group. HCV infection had an adverse impact on the clinical outcome following HCT, especially in the setting of unrelated transplantation. Careful evaluation before embarking on HCT and intensive assessment against complications are warranted in HCV-infected recipients.

  Jun. 2013, American journal of hematology, 88(6) (6), 477 - 84, English, International magazine

  [Refereed]

  Scientific journal


• 骨髄原発B細胞リンパ腫において新規に見つかったMYCとBCL6の改変を伴った5ヶ所の転座 t(3;9;13;8;14)(q27;p13;q32;q24;q32)(A novel five-way translocation, t (3:9:13:8:14) (q27:p13:q32:q24:q32), with concurrent MYC and BCL6 rearrangements in primary bone marrow B-cell lymphoma)(英語)

  山本 克也, 松岡 広, Yakushijin Kimikazu, 船越 洋平, 岡村 篤夫, Hayashi Yoshitake, 南 博信

  (一社)日本リンパ網内系学会, Apr. 2013, 日本リンパ網内系学会会誌, 53, 109 - 109, Japanese

  Research society


• Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia/myelodysplastic syndrome: an analysis of the Japan Transplant Outcome Registry

  S. Kurosawa, K. Yakushijin, T. Yamaguchi, Y. Atsuta, T. Nagamura-Inoue, H. Akiyama, S. Taniguchi, K. Miyamura, S. Takahashi, T. Eto, H. Ogawa, M. Kurokawa, J. Tanaka, K. Kawa, K. Kato, R. Suzuki, Y. Morishima, H. Sakamaki, T. Fukuda

  Apr. 2013, BONE MARROW TRANSPLANTATION, 48(4) (4), 529 - 536, English

  [Refereed]

  Scientific journal


• Pericentric chromosome 8 inversion, inv(8)(p11.2q22), associated with RUNX1/RUNX1T1 rearrangement in acute myeloid leukemia

  Katsuya Yamamoto, Atsuo Okamura, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami

  Mar. 2013, ANNALS OF HEMATOLOGY, 92(3) (3), 403 - 405, English

  [Refereed]

  Scientific journal


• 鼻腔原発NK/T細胞リンパ腫に対する放射線治療経験

  原田 文, Miyawaki Daisuke, 西村 英輝, 吉田 賢史, Yakushijin Kimikazu, 松岡 広, 土井 清司, 大月 直樹, 丹生 健一, Sasaki Ryohei

  (公社)日本医学放射線学会, Feb. 2013, 日本医学放射線学会学術集会抄録集, 72回(72回) (72回), S402 - S402, Japanese

  [Refereed]

  Research society


• Tolvaptan as an alternative treatment for refractory fluid retention associated with sinusoidal obstruction syndrome after allogeneic stem cell transplantation

  Kimikazu Yakushijin, Katsuya Yamamoto, Keiji Kurata, Yoshiharu Miyata, Seiji Kakiuchi, Hideo Tomioka, Yuriko Kawamori-Iwamoto, Yumiko Inui, Yukinari Sanada, Atsuo Okamura, Tohru Murayama, Hiroshi Matsuoka, Hironobu Minami

  Feb. 2013, INTERNATIONAL JOURNAL OF HEMATOLOGY, 97(2) (2), 284 - 286, English

  [Refereed]

  Scientific journal


• Gain of 11q by an additional ring chromosome 11 and trisomy 18 in CD5-positive intravascular large B-cell lymphoma

  Yamamoto K, Yakushijin Kimikazu, Okamura A, Hayashi Yoshitake, Matsuoka Hiroshi, Minami Hironobu

  Chromosomal abnormalities of intravascular large B-cell lymphoma (IVLBCL), a rare form of extranodal diffuse large B-cell lymphoma, have been described in only a small number of cases. A 59-year-old female presented with pancytopenia and splenomegaly. Bone marrow was normocellular with 30.4% abnormal large lymphoid cells that were positive for CD5, CD19, CD20, HLA-DR and λ chain. Bone marrow biopsy showed intrasinusoidal infiltration of large lymphoid cells. G-banding and spectral karyotyping of the bone marrow cells demonstrated a complex karyotype as follows : 48,XX,-8,+r(11),+12,del(12)(p?) ×2,+18,der(19)(19?::p13 → qter),der(21)t(8;21)(q11.2;p11.2). Fluorescence in situ hybridization on interphase nuclei revealed three signals of CCND1 at 11q13, but two signals of BIRC3 at 11q22 and MLL at 11q23, indicating that r(11) contained CCND1. Together with other reported cases, our results indicate that the gain of 11q as well as trisomy 18 may be among the recurrent chromosomal aberrations in IVLBCL. Furthermore, an additional ring chromosome 11 could be a novel mechanism leading to the gain of 11q.

  2013, J Clin Exp Hematop, 53(2) (2), 161 - 5, English, Domestic magazine

  [Refereed]

  Scientific journal


• A novel TRB@/NOTCH1 fusion gene in T-cell lymphoblastic lymphoma with t(7;9)(q34;q34)

  Katsuya Yamamoto, Yuji Nakamachi, Kimikazu Yakushijin, Yoshiharu Miyata, Atsuo Okamura, Seiji Kawano, Hiroshi Matsuoka, Hironobu Minami

  Jan. 2013, EUROPEAN JOURNAL OF HAEMATOLOGY, 90(1) (1), 68 - 75, English

  [Refereed]

  Scientific journal


• IGH@/BCL6 rearrangement on the der(3)t(3;14)(q27;q32) in primary mediastinal large B-cell lymphoma

  Katsuya Yamamoto, Atsuo Okamura, Yumiko Inui, Kimikazu Yakushijin, Fumi Kawakami, Tomoo Itoh, Hiroshi Matsuoka, Hironobu Minami

  Dec. 2012, LEUKEMIA RESEARCH, 36(12) (12), E218 - E221, English

  [Refereed]

  Scientific journal


• 多彩な神経症状を呈し、再燃時に皮疹を認めたジアフェニルスルホンによるDIHSの1例

  Yamada Yozo, Shimizu Hideki, Yakushijin Kimikazu, Arai Takashi, Hiraoka Eiji, Nishigori Chikako

  日本皮膚アレルギー・接触皮膚炎学会, Oct. 2012, Journal of Environmental Dermatology and Cutaneous Allergology, 6(5号) (5号), 433 - 438, Japanese

  [Refereed]

  Scientific journal


• Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma

  Kohei Tada, Sung-Won Kim, Yoshitaka Asakura, Nobuhiro Hiramoto, Kimikazu Yakushijin, Saiko Kurosawa, Kinuko Tajima, Shin-ichiro Mori, Yuji Heike, Ryuji Tanosaki, Akiko Miyagi Maeshima, Hirokazu Taniguchi, Koh Furuta, Yoshikazu Kagami, Yoshihiro Matsuno, Kensei Tobinai, Yoichi Takaue, Takahiro Fukuda

  Aug. 2012, AMERICAN JOURNAL OF HEMATOLOGY, 87(8) (8), 770 - 775, English

  [Refereed]

  Scientific journal


• Reed-Sternberg-like cells of ALK-positive anaplastic large cell lymphoma with near-tetraploidy

  Katsuya Yamamoto, Kimikazu Yakushijin, Yumiko Inui, Atsuo Okamura, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu Minami

  Jun. 2012, EUROPEAN JOURNAL OF HAEMATOLOGY, 88(6) (6), 553 - 554, English

  Scientific journal


• A novel recurrent translocation t(7;17)(q22;p13) and a late-appearing t(2;3)(p13;q26.2) with dysmegakaryopoiesis in acute myeloid leukemia

  Katsuya Yamamoto, Atsuo Okamura, Yumiko Inui, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami

  Apr. 2012, LEUKEMIA RESEARCH, 36(4) (4), E84 - E86, English

  Scientific journal


• Expression of the novel NUP98/PSIP1 fusion transcripts in myelodysplastic syndrome with t(9;11)(p22;p15)

  Katsuya Yamamoto, Yuji Nakamachi, Kimikazu Yakushijin, Yohei Funakoshi, Atsuo Okamura, Seiji Kawano, Hiroshi Matsuoka, Hironobu Minami

  Mar. 2012, EUROPEAN JOURNAL OF HAEMATOLOGY, 88(3) (3), 244 - 248, English

  Scientific journal


• SMILE療法及び同種骨髄移植によって良好な経過が得られた再発・難治性NK/T細胞リンパ腫の1例

  Yakushijin Kimikazu

  (一社)日本血液学会-東京事務局, Jan. 2012, 臨床血液, 53巻, 1号, pp. 118-119(1) (1), 118 - 119, Japanese

  International conference proceedings


• Biallelic ETV6 rearrangements by recurrent translocations t(7;12)(p15;p13) and t(3;12)(q26.2;p13) in acute myeloid leukemia

  Katsuya Yamamoto, Kimikazu Yakushijin, Yohei Funakoshi, Yumiko Inui, Atsuo Okamura, Hiroshi Matsuoka, Hironobu Minami

  Nov. 2011, LEUKEMIA RESEARCH, 35(11) (11), E212 - E214, English

  Scientific journal


• A novel five-way translocation, t(3;9;13;8;14)(q27;p13;q32;q24;q32), with concurrent MYC and BCL6 rearrangements in a primary bone marrow B-cell lymphoma

  Katsuya Yamamoto, Hiroshi Matsuoka, Kimikazu Yakushijin, Yohei Funakoshi, Atsuo Okamura, Yoshitake Hayashi, Hironobu Minami

  Sep. 2011, CANCER GENETICS, 204(9) (9), 501 - 506, English

  [Refereed]

  Scientific journal


• A novel dicentric chromosome, dic(9;9)(p12;q34), leading to trisomy 9 in follicular lymphoma without t(14;18)

  Katsuya Yamamoto, Hiroshi Matsuoka, Yohei Funakoshi, Kimikazu Yakushijin, Atsuo Okamura, Tomoo Itoh, Hironobu Minami

  Jul. 2011, LEUKEMIA RESEARCH, 35(7) (7), E100 - E103, English

  [Refereed]

  Scientific journal


• 皮疹を欠くもののHHV-6の再活性化と多彩な臓器症状を呈したレクチゾールによるDrug hypersensitivityの1例

  Yakushijin Kimikazu

  Jul. 2011, Journal of Environmental Dermatology and Cutaneous Allergology, 5巻, 3号, pp. 263-263, Japanese

  International conference proceedings


• Successful neutrophil engraftment by reduced use of granulocyte colony-stimulating factor after allogeneic hematopoietic stem cell transplantation with mycophenolate mofetil for graft-versus-host disease prophylaxis

  Atsuo Okamura, Kimikazu Yakushijin, Yumiko Inui, Yohei Funakoshi, Yuriko Kawamori, Takanobu Shimada, Masanori Toyoda, Naoko Chayahara, Naomi Kiyota, Yutaka Fujiwara, Toru Mukohara, Hiroshi Matsuoka, Katsuya Yamamoto, Hironobu Minami

  Jun. 2011, INTERNATIONAL JOURNAL OF HEMATOLOGY, 93(6) (6), 765 - 770, English

  [Refereed]

  Scientific journal


• NPM/RARαキメラ遺伝子を認めた急性前骨髄性白血病の一例

  Kawano Seiji, Yakushijin Kimikazu, Minami Hironobu

  Jun. 2011, 日本検査血液学会雑誌, 12巻, 学術集会, pp. S79-S79, Japanese

  International conference proceedings


• Feasibility of Reduced-Intensity Cord Blood Transplantation as Salvage Therapy for Graft Failure: Results of a Nationwide Survey of Adult Patients

  Fusako Waki, Kazuhiro Masuoka, Takahiro Fukuda, Yoshinobu Kanda, Mika Nakamae, Kimikazu Yakushijin, Katsuhiro Togami, Kaichi Nishiwaki, Yasunori Ueda, Fumio Kawano, Masaharu Kasai, Koji Nagafuji, Maki Hagihara, Kazuo Hatanaka, Masafumi Taniwaki, Yoshinobu Maeda, Naoki Shirafuji, Takehiko Mori, Atae Utsunomiya, Tetsuya Eto, Hitoshi Nakagawa, Makoto Murata, Toshiki Uchida, Hiroatsu Iida, Kazuaki Yakushiji, Takuya Yamashita, Atsushi Wake, Satoshi Takahashi, Yoichi Takaue, Shuichi Taniguchi

  Jun. 2011, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(6) (6), 841 - 851, English

  Scientific journal


• Impact of Reduction in GVHD-Related Mortality for Recent Improvement of Non-Relapse Mortality After Allogeneic Hematopoietic Cell Transplantation

  Hisashi Sakamaki, K Miyamura, Tetsuya Eto, Tokiko Nagamura-Inoue, H Akiyama, Yoshiko Atsuta, Takuhiro Yamaguchi, Yasuo Morishima, Takahiro Fukuda, Satoru Takahashi, Shuhei Kurosawa, Kimikazu Yakushijin, S. Taniguchi

  Elsevier BV, Feb. 2011, Biology of Blood and Marrow Transplantation, 17, S288 - S289


• Day +11 Methotrexate (MTX) Might Reduce the Risk of Engraftment Syndrome (ES) and Acute Graft-Versus-Host Disease (GvHD) After Unrelated Bone Marrow Transplantation (U-BMT) With Reduced-Intensity Conditioning Regimens

  T. Maeda, Kensei Tobinai, Nobuhiro Hiramoto, Sung Won Kim, R. Tanosaki, Yuji Heike, Yoichi Takaue, Takahiro Fukuda, Shuhei Kurosawa, Shin Ichiro Mori, Yoshitaka Asakura, Kimikazu Yakushijin

  Elsevier BV, Feb. 2011, Biology of Blood and Marrow Transplantation, 17, S296


• Therapy-Related Pure Erythroid Leukemia with Hepatic Infiltration and Hemophagocytic Syndrome

  Yohei Funakoshi, Hiroshi Matsuoka, Katsuya Yamamoto, Kimikazu Yakushijin, Yumiko Inui, Atsuo Okamura, Mai Takeuchi, Hiroshi Yokozaki, Hironobu Minami

  2011, INTERNAL MEDICINE, 50(24) (24), 3031 - 3035, English

  [Refereed]

  Scientific journal


• Fungal Endophthalmitis Successfully Treated with Intravitreal Voriconazole Injection

  Yohei Funakoshi, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami

  2011, INTERNAL MEDICINE, 50(8) (8), 941 - 941, English

  [Refereed]

  Scientific journal


• Allogeneic Hematopoietic Stem Cell Transplantation With A Reduced-Intensity Conditioning Regimen (RIST) For The Treatment Of Solid Tumors: A Single-Institute Experience

  Yoshitaka Asakura, Ako Hosono, R. Tanosaki, Shuhei Kurosawa, Shin Ichiro Mori, Y. Kamiyama, N. Ueno, Nobuhiro Hiramoto, Sung Won Kim, Atsushi Makimoto, Yuji Heike, Kimikazu Yakushijin, Suguru Fukuhara, Yoichi Takaue, Takahiro Fukuda

  Elsevier BV, Feb. 2010, Biology of Blood and Marrow Transplantation, 16, S254


• Cytoreductive Regimen Containing Ranimustine (MCNU), Carboplatin, Etoposide and Cyclophosphamide (MCEC) Before Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) for Relapsed or Refractory Lymphoma

  Y. Asakura, R. Tanosaki, S.-W. Kim, T. Azuma, S. Kurosawa, K. Yakushijin, D. Maruyama, S.-i. Mori, T. Fukuda, T. Watanabe, Y. Kobayashi, K. Tobinai, Y. Takaue

  Elsevier {BV}, Feb. 2009, Biology of Blood and Marrow Transplantation, 15(2) (2), 41

  [Refereed]


• Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation

  Okamura Atsuo, Yamamori M, Shimoyama Manabu, Kawano Y, Kawano H, Kawamori Y, Nishikawa S, Minagawa K, Yakushijin K, Katayama Yoshio, Hirai Midori, Matsui Toshimitsu

  Jul. 2008, International journal of hematology, 88(1) (1), 104 - 10, English

  [Refereed]

  Scientific journal


• Imatinib resistance in a novel translocation der(17)t(1;17)(q25;p13) with loss of TP53 but without BCR/ABL kinase domain mutation in chronic myelogenous leukemia

  Yamamoto K, Yakushijin K, Nishikawa S, Minagawa K, Katayama Yoshio, Shimoyama Manabu, Matsui Toshimitsu

  May 2008, Cancer genetics and cytogenetics, 183(1) (1), 77 - 81, English

  [Refereed]

  Scientific journal


• Deregulation of a possible tumour suppressor gene, ZC3H12D, by translocation of IGK@ in transformed follicular lymphoma with t(2;6)(p12;q25)

  Minagawa K, Yamamoto K, Nishikawa S, Ito Mitsuhiro, Sada A, Yakushijin K, Okamura, Shimoyama Manabu, Katayama Yoshio, Matsui Toshimitsu

  Oct. 2007, British Journal Of Haematology, 139(1) (1), 161 - 3, English

  Scientific journal


• Translocation (7;9)(q22;q34) in therapy-related myelodysplastic syndrome after allogeneic bone marrow transplantation for acute myeloblastic leukemia

  Yamamoto K, Yakushijin K, Kawamori Y, Minagawa K, Katayama Yoshio, Matsui Toshimitsu

  Jul. 2007, Cancer Genetics And Cytogenetics, 176(1) (1), 61 - 6, English

  Scientific journal


• Successful Engraftment in Reduced-Intensity Cord Blood Transplantation (CBT) as a Salvage Therapy for Graft Failure After Primary CBT in Adults

  Kawamori Y, Yakushijin K, Okamura A, Nishikawa S, Minagawa K, Shimoyama M, Yamamoto K, KATAYAMA YOSHIO, MATSUI TOSHIMITSU

  May 2007, Transplantation, 83(9) (9), 1281 - 2, English

  [Refereed]

  Scientific journal


• The role of transcriptional coactivator TRAP220 in myelomonocytic differentiation.

  Urahama N, Ito M, Sada A, Yakushijin K, Yamamoto K, Okamura A, Minagawa K, Hato A, Chihara K, Roeder RG, Matsui T

  Dec. 2005, Genes to cells : devoted to molecular & cellular mechanisms, 10(12) (12), 1127 - 1137

  [Refereed]


• Cyclosporin neurotoxicity with Epstein-Barr virus-associated hemophagocytic syndrome.

  Yakushijin K, Mizuno I, Sada A, Imoto S, Koizumi T, Imashuku S, Murayama T

  Mar. 2005, Haematologica, 90(3) (3), ECR11

  [Refereed]


• An extra X chromosome as a sole abnormality in relapse of an adult acute lymphoblastic leukemia

  K Yamamoto, A Hato, K Minagawa, K Yakushijin, N Urahama, A Sada, A Okamura, M Ito, T Matsui

  Dec. 2004, CANCER GENETICS AND CYTOGENETICS, 155(2) (2), 154 - 155, English

  [Refereed]


• Unbalanced translocation der(11)t(11;12)(q23;q13): a new recurrent cytogenetic aberration in myelodysplastic syndrome with a complex karyotype

  K Yamamoto, A Hato, K Minagawa, K Yakushijin, N Urahama, H Gomyo, A Sada, A Okamura, M Ito, T Matsui

  Nov. 2004, CANCER GENETICS AND CYTOGENETICS, 155(1) (1), 67 - 73, English

  [Refereed]

  Scientific journal


• Involvement of casein kinase Iε in cytokine-induced granulocytic differentiation

  Atsuo Okamura, Nobuko Iwata, Aki Nagata, Akira Tamekane, Manabu Shimoyama, Hiroshi Gomyo, Kimikazu Yakushijin, Norinaga Urahama, Miyuki Hamaguchi, Chie Fukui, Kazuo Chihara, Mitsuhiro Ito, Toshimitsu Matsui

  American Society of Hematology, Apr. 2004, Blood, 103(8) (8), 2997 - 3004, English

  Scientific journal


• Morphologic, flow cytometric and cytogenetic evaluation of bone marrow involvement in B-cell lymphoma

  H Gomyo, M Shimoyama, K Minagawa, K Yakushijin, N Urahama, A Okamura, K Yamamoto, M Ito, K Chihara, Y Hayashi, T Matsui

  Dec. 2003, HAEMATOLOGICA, 88(12) (12), 1358 - 1365, English

  [Refereed]

  Scientific journal


• Impact of stem cell source and conditioning regimen on erythrocyte recovery kinetics after allogeneic haematopoietic stem cell transplantation from an ABO-incompatible donor.

  Kanda Y, Tanosaki R, Nakai K, Saito T, Ohnishi M, Niiya H, Chizuka A, Yakushijin K, Urahama N, Ueda K, Iijima K, Ando T, Matsubara H, Kami M, Makimoto A, Kobayashi Y, Tobinai K, Mineishi S, Takaue Y

  Wiley Blackwell (Blackwell Publishing), Jul. 2002, British journal of haematology, 118(1) (1), 128 - 131

  [Refereed]


• Chronic eosinophilic leukemia with unique chromosomal abnormality, t(5;12) (q33;q22).

  Yakushijin K, Murayama T, Mizuno I, Sada A, Koizumi T, Imoto S

  Dec. 2001, Am J Hematol., 68(4) (4), 301 - 302, English

  [Refereed]

  Scientific journal


• T-cell receptor gammadelta T-cell leukemia with the morphology of T-cell prolymphocytic leukemia and a postthymic immunophenotype.

  Sugimoto T, Imoto S, Matsuo Y, Kojima K, Yasukawa M, Murayama T, Kohfuku J, Mizuno I, Yakushijin K, Sada A, Nishimura R, Koizumi T

  Dec. 2001, Ann Hematol., 80(12) (12), 749 - 751, English

  [Refereed]

  Scientific journal

• Performance status is a useful predictor of SOS/VOD progression

  市川大哉, 藥師神公和, 飯田幸太郎, 福井さくら, 梁間敢, 岡副結梨, 高橋瑠里, 松本咲耶, 坂井里奈, 倉田啓史, 北尾章人, 北尾章人, 宮田吉晴, 齊藤泰之, 川本晋一郎, 山本克也, 伊藤光宏, 村山徹, 村山徹, 松岡広, 南博信

  2025, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 47th


• Efficacy of the refined EBMT diagnostic criteria 2023 for sinusoidal obstruction syndrome

  市川大哉, 藥師神公和, 辻高寛, 武本奈緒子, ジョイス美紀, 岡副結梨, 高橋瑠里, 松本咲耶, 坂井里奈, 倉田啓史, 北尾章人, 宮田吉晴, 齊藤泰之, 川本晋一郎, 山本克也, 伊藤光宏, 村山徹, 松岡広, 南博信, 北尾章人, 宮田吉晴, 齊藤泰之, 川本晋一郎, 伊藤光宏, 村山徹, 松岡広

  2024, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 46th


• The Comparison between BM and PBSC for the Patients with Pre-Transplant Pulmonary Dysfunction in HLA-Matched Allo-HCT: Subgroup Analysis Exploring the Impact Based on HCT Factors

  Shunto Kawamura, Masaharu Tamaki, Takaaki Konuma, Makoto Onizuka, Emiko Sakaida, Hiromi Hayashi, Noriko Doki, Tetsuya Nishida, Masashi Sawa, Hiroyuki Ohigashi, Takahiro Fukuda, Jun Ishikawa, Ken-Ichi Matsuoka, Toshiro Kawakita, Masatsugu Tanaka, Fumihiko Ishimaru, Tatsuo Ichinohe, Yoshiko Atsuta, Yoshinobu Kanda, Kimikazu Yakushijin, Junya Kanda, Hideki Nakasone

  02 Nov. 2023, BLOOD, 142, English

  Summary international conference


• がん関連静脈血栓塞栓症に対するアピキサバン療法の出血リスク予測:多施設共同第2相臨床試験副次的解析

  今村善宣, 能勢拓, 宮田吉晴, 小山泰司, 長谷善明, 金原史朗, 船越洋平, 清田尚臣, 藥師神公和, 南博信

  2023, 日本内科学会雑誌, 112


• 小児がん経験者の移行期医療の現状およびがん治療歴と心機能に関する解析

  平川結梨, 藥師神公和, 松本咲耶, 坂井里奈, 倉田啓史, 今村善宜, 北尾章人, 船越洋平, 田中秀和, 清田尚臣, 南博信

  2023, 日本腫瘍循環器学会学術集会抄録集(Web), 6th


• SARS-CoV-2PCRが持続陽性となったDLBCLの1症例

  佐伯美紀, 北尾章人, 臼井佑太郎, 高倉嗣丈, 渡部まりか, 松本咲耶, 水谷優, 坂井里奈, 船越洋平, 藥師神公和, 南博信

  2022, 臨床血液, 63(2) (2)


• Safety and Efficacy of SARS-CoV-2 Vaccine (BNT162b2) in Allogeneic HSCT Patients

  渡部まりか, 藥師神公和, 船越洋平, 大路剛, 酒井博則, 北條渉, 佐伯美紀, 平川結梨, 松本咲耶, 坂井里奈, 北尾章人, 宮田吉晴, 伊藤光宏, 松岡広, 南博信

  2022, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 44th


• 5年の経過で再発・寛解を繰り返しCLIPPERSが先行してT細胞リンパ腫と診断した一例

  荒木 健, 末廣 大知, 立花 久嗣, 田中 伴典, 坂井 里奈, 水谷 優, 齊藤 泰之, 藥師神 公和, 千原 典夫, 上田 健博, 関口 兼司, 松本 理器

  (一社)日本神経学会, Dec. 2021, 臨床神経学, 61(12) (12), 885 - 885, Japanese


• リソソーム機能活性化を介した抗体薬物複合体であるゲムツズマブオゾガマイシンの殺細胞効果増強法

  水谷優, 稲瀬安希, マイマイテイリイマム, 宮田吉晴, 北尾章人, 松本久幸, 後藤秀彰, 藥師神公和, 松岡広, 南博信

  2020, 日本内科学会雑誌, 109


• Coexpression of ETV6/MDS1/EVI1 and ETV6/EVI1 fusion transcripts in acute myeloid leukemia with t(3;12)(q26.2;p13) and thrombocytosis.

  Katsuya Yamamoto, Kimikazu Yakushijin, Hiroya Ichikawa, Atsuo Okamura, Shigeki Nagao, Seiji Kakiuchi, Keiji Kurata, Shinichiro Kawamoto, Keiji Matsui, Yuji Nakamachi, Jun Saegusa, Hiroshi Matsuoka, Hironobu Minami

  May 2019, Leukemia & lymphoma, 60(5) (5), 1294 - 1298, English, International magazine

  [Refereed]

  Report scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 【薬物性肝障害:新薬登場で変わる実態】 造血幹細胞移植とSOS/VOD

  Yakushijin Kimikazu

  Mar. 2019, 消化器・肝臓内科, 5(3) (3), 356 - 364, Japanese

  [Invited]

  Introduction commerce magazine


• Expression of a novel ZMYND11/MBTD1 fusion transcript in CD7+CD56+ acute myeloid leukemia with t(10;17)(p15;q21).

  Katsuya Yamamoto, Kimikazu Yakushijin, Hiroya Ichikawa, Seiji Kakiuchi, Shinichiro Kawamoto, Hisayuki Matsumoto, Yuji Nakamachi, Jun Saegusa, Hiroshi Matsuoka, Hironobu Minami

  Nov. 2018, Leukemia & lymphoma, 59(11) (11), 2706 - 2710, English, International magazine

  [Refereed]

  Report scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 自家末梢血幹細胞移植における栄養状態と予後に関する後方視的解析

  水谷優, 藥師神公和, 市川大哉, 坂井里奈, 後藤秀彰, 倉田啓史, 西村明子, 北尾章人, 田渕聡子, 瓜生恭章, 垣内誠司, 宮田吉晴, 乾由美子, 眞田幸尚, 今村善宣, 船越洋平, 高橋路子, 高橋路子, 岡村篤夫, 川本晋一郎, 山本克也, 伊藤光宏, 松岡広, 南博信, 南博信

  2017, 日本造血細胞移植学会総会プログラム・抄録集, 40th


• Impact of Total Body Irradiation on Successful Neutrophil Engraftment in Unrelated Bone Marrow or Cord Blood Transplantation

  Hideki Nakasone, Kimikazu Yakushijin, Shigeo Fuji, Makoto Onizuka, Akihito Shinohara, Kazuteru Ohashi, Koichi Miyamura, Naoyuki Uchida, Minoko Takanashi, Tatsuo Ichinohe, Yoshiko Atsuta, Takahiro Fukuda, Masao Ogata

  Dec. 2016, BLOOD, 128(22) (22), English

  Summary international conference


• Sea-blue histiocytes in acute myeloid leukemia with trisomy 9

  Katsuya Yamamoto, Yosuke Minami, Shinichiro Kawamoto, Kimikazu Yakushijin, Tomoe Kikuma, Jun Saegusa, Hiroshi Matsuoka, Hironobu Minami

  Nov. 2016, INTERNATIONAL JOURNAL OF HEMATOLOGY, 104(5) (5), 531 - 533, English

  [Refereed]

  Others


• 客観的ツールで評価した化学療法誘発性末梢神経障害の経時的変化 その障害様式の調査

  斎藤 貴, 岡村 篤夫, 井上 順一朗, 牧浦 大祐, 土井 久容, 向原 徹, 松岡 広, 薬師神 公和, 澤 龍一, 杉本 大貴, 中村 凌, 村田 峻輔, 小野 玲

  (公社)日本理学療法士協会, Oct. 2016, 理学療法学, 43(Suppl.2) (Suppl.2), O - DM, Japanese


• Clinical practice and evidence on rehabilitation for patients undergoing hematopoietic cell transplantation

  Inoue Junichiro, Makiura Daisuke, Kashiwa Miyuki, Ono Rei, Okamura Atsuo, Yakushijin Kimikazu, Saura Ryuichi, Sakai Yoshitada

  01 Jul. 2016, ANNALS OF ONCOLOGY, 27

  [Refereed]


• Nationwide Survey of Defbrotide and Recombinant Human Soluble Thrombomodulin for Treatment of Sinusoidal Obstruction Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

  K. Yakushijin, T. Ikezoe, C. Ohwada, K. Kudo, H. Okamura, H. Goto, H. Yabe, A. Yasumoto, H. Kuwabara, S. Fujii, K. Kagawa, T. Ikebe, Y. Onishi, Y. Morishita, K. Watamoto, N. Uoshima, D. Nakamura, S. Ota, Y. Ueda, T. Oyake, K. Koike, I. Mizuno, H. Iida, Y. Katayama, A. Hiroatsu, K. Kato, A. Okamura, A. Kikuta, T. Fukuda

  Mar. 2016, BONE MARROW TRANSPLANTATION, 51, S77 - S78, English

  Summary international conference


• 当院におけるゼヴァリンの初期経験

  西川遼, 江島泰生, 吉田賢史, Miyawaki Daisuke, 上薗玄, 石原武明, ノル・シャズリナ, Sasaki Ryohei, Matsuoka Hiroshi, 薬師神公和

  (公社)日本医学放射線学会, Feb. 2016, Japanese Journal of Radiology, 34(Suppl.) (Suppl.), 49 - 49, Japanese

  [Refereed]

  Meeting report


• 造血細胞移植後における肝中心静脈閉塞症 (SOS/VOD) の診断と治療

  菊田敦, Yakushijin Kimikazu

   Sinusoidal obstruction syndrome (SOS), also called veno-occlusive disease (VOD) of the liver, is one of the most relevant complications of hepatic sinusoidal endothelial origin that appears early after haematopoietic cell transplantation (HCT). Despite its relatively low incidence and the fact that most cases of SOS/VOD resolve spontaneously, in the severe SOS/VOD that evolve to multi-organ failure have a mortality rate higher than 80% and represent one of the major clinical problems after HCT. In these patients, the sinusoidal endothelial cells and hepatocytes are damaged by toxic metabolites generated by the conditioning regimen. Several risk factors have been identified for the development of SOS/VOD. Despite defibrotide is recommended for both prevention and treatment, there is no satisfactory therapy for managing severe SOS/VOD. In the present review we report the new definition for late onset SOS/VOD diagnosis and severity grading by the European Society for Blood and Marrow Transplantation, results of nationwide survey in Japan and current treatment.

  The Japan Society for Hematopoietic Stem Cell Transplantation, 2016, 日本造血細胞移植学会雑誌, 5(4) (4), 124 - 137, Japanese

  [Invited]

  Introduction scientific journal


• Dynamic change of glycemic status during the early phase after allogeneic hematopoietic stem cell transplantation

  S. Fuji, K. Yakushijin, S-W Kim, K. Yoshimura, S. Kurosawa, T. Fukuda

  Nov. 2015, BONE MARROW TRANSPLANTATION, 50(11) (11), 1473 - 1475, English

  [Refereed]

  Report scientific journal


• 【ICUで遭遇する血液疾患】(Part 2.)血液内科のクリティカルシンドローム 造血幹細胞移植に伴う重症合併症(感染症を除く) 造血幹細胞移植に伴う類洞閉塞症候群/肝中心静脈閉塞症 深刻な合併症であり,予防法・治療法の確立が求められる

  Yakushijin Kimikazu

  メディカル・サイエンス・インターナショナル, Apr. 2015, Intensivist, 7(2号) (2号), 405 - 411, Japanese

  [Refereed]

  Introduction commerce magazine


• 造血幹細胞移植患者に対する栄養管理への介入とその評価

  生田智子, 丹田雅明, 青木紫織, 曽我昭宏, 山岡慶子, 田淵聡子, 高橋路子, 川本晋一郎, 薬師神公和, 西岡達也, 槇本博雄, 久米学, 平野剛, 宇佐美眞, 平井みどり

  2015, 日本薬学会年会要旨集(CD-ROM), 135th, ROMBUNNO.26PB-AM058, Japanese


• Rhabdomyolysis Caused by Candida parapsilosis in a Patient with Acute Myeloid Leukemia after Bone Marrow Transplantation

  Seiji Kakiuchi, Kimikazu Yakushijin, Katsuya Yamamoto, Hideo Tomioka, Yumiko Inui, Atsuo Okamura, Shinichiro Kawamoto, Yosuke Minami, Tohru Murayama, Mitsuhiro Ito, Hiroshi Matsuoka, Hironobu Minami

  2015, INTERNAL MEDICINE, 54(16) (16), 2057 - 2060, English

  [Refereed]

  Report scientific journal


• Low Hypodiploid Acute Lymphoblastic Leukemia with Burkitt-like Morphology

  Katsuya Yamamoto, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami

  2015, INTERNAL MEDICINE, 54(22) (22), 2955 - 2955, English

  [Refereed]

  Others


• Efficacy of the Two-Dose Influenza Vaccine in Cancer Patients Receiving Chemotherapy: A Prospective Study

  Yukinari Sanada, Kimikazu Yakushijin, Tetsuhiko Nomura, Katsuya Yamamoto, Keiji Kurata, Kei Takenaka, Seiji Kakiuchi, Yoshiharu Miyata, Yoshinori Imamura, Meiko Nishimura, Yohei Funakoshi, Yuriko Iwamoto, Naoko Chayahara, Masanori Toyoda, Yosuke Minami, Naomi Kiyota, Toru Mukohara, Shinichiro Kawamoto, Yohei Shimono, Mitsuhiro Ito, Hiroshi Matsuoka, Hironobu Minami

  Dec. 2014, BLOOD, 124(21) (21), English

  Summary international conference


• 腹部DLBCL病変出現1ヵ月前に発症したNeurolymphomatosisの1例

  井本 寛東, Kawamoto Shinichiro, 垣内 誠司, 宮田 吉晴, 眞田 幸尚, 川森 有里子, Yakushijin Kimikazu, 南 陽介, Matsuoka Hiroshi, Minami Hironobu

  (一社)日本血液学会-東京事務局, Nov. 2014, 臨床血液, 55(11号) (11号), 2339 - 2339, Japanese

  Meeting report


• A PROSPECTIVE STUDY OF THE EFFICACY OF INFLUENZA VACCINATION FOR CANCER PATIENTS RECEIVING CHEMOTHERAPY

  Yukinari Sanada, Kimikazu Yakushijin, Katsuya Yamamoto, Meiko Nishimura, Yohei Funakoshi, Naoko Chayahara, Masanori Toyoda, Naomi Kiyota, Toru Mukohara, Hironobu Minami

  Oct. 2014, ANNALS OF ONCOLOGY, 25, English

  Summary international conference


• POOR PROGNOSIS OF PATIENTS WITH SEVERE SINUSOIDAL OBSTRUCTION SYNDROME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN JAPANESE POPULATION: ON BEHALF OF COMPLICATIONS WORKING GROUP OF JSHCT

  K. Yakushijin, Y. Atsuta, N. Doki, A. Yokota, H. Kanamori, T. Miyamoto, H. Yabe, Y. Morishima, K. Kato, R. Suzuki, T. Fukuda

  Jun. 2014, HAEMATOLOGICA, 99, 169 - 170, English

  Summary international conference


• Senile angiomaに腫瘍細胞の浸潤をみたintravascular large B-cell lymphomaの1例

  西井 径子, 井上 友介, 東田 由香, 池田 哲哉, 菅原 香織, 王 康治, Yakushijin Kimikazu

  Mar. 2014, 皮膚の科学, 12(2) (2), 143, Japanese

  Meeting report


• HLA一致血縁または7‐8/8HLA一致非血縁ドナーからの同種造血細胞移植におけるMMFおよびカルシニューリン阻害剤を用いたGVHD予防の有用性:多施設共同第2相臨床試験

  中根孝彦, 中前博久, 黒澤彩子, 岡村篤夫, 日高道弘, 山下卓也, 河野彰夫, 齋藤健, 青山泰孝, 畑中一生, 片山義雄, 薬師神公和, 松井利充, 高見昭良, 山口拓洋, 日野雅之, 福田隆浩

  14 Feb. 2014, 日本造血細胞移植学会総会プログラム・抄録集, 36th, 238, Japanese


• Nationwide Survey of Sinusoidal Obstruction Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, and Outcome: On Behalf of Complications Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)

  Kimikazu Yakushijin, Yoshiko Atsuta, Doki Noriko, Akira Yokota, Heiwa Kanamori, Toshihiro Miyamoto, Hisashi Sakamaki, Hiromasa Yabe, Yasuo Morishima, Koji Kato, Ritsuro Suzuki, Takahiro Fukuda

  Nov. 2013, BLOOD, 122(21) (21), English

  Summary international conference


• 鼻腔原発NK/T細胞リンパ腫に対する放射線治療経験

  原田 文, Miyawaki Daisuke, 西村 英輝, Ejima Yasuo, 吉田 賢史, Yakushijin Kimikazu, 松岡 広, 土井 清司, 大月 直樹, 丹生 健一, Sasaki Ryohei

  (一社)日本頭頸部癌学会, May 2013, 頭頸部癌, 39(2号) (2号), 264 - 264, Japanese

  Meeting report


• DACARBAZINE MONO-THERAPY FOR UNRESECTABLE NEUROENDOCRINE TUMOR: A RETROSPECTIVE ANALYSIS

  Y. Imamura, Y. Fujiwara, M. Toyoda, N. Chyayahara, M. Nishimura, Y. Funakoshi, H. Tomioka, T. Shimada, K. Yakushijin, A. Okamura, N. Kiyota, T. Mukohara, H. Matsuoka, H. Minami

  Oct. 2012, ANNALS OF ONCOLOGY, 23, 161 - 161, English

  Summary international conference


• Cryptic insertion of BCL2 gene into immunoglobulin heavy locus in follicular lymphoma with t(6;9)(p23;p13)

  Katsuya Yamamoto, Atsuo Okamura, Yumiko Inui, Kimikazu Yakushijin, Tohru Murayama, Hiroshi Matsuoka, Hironobu Minami

  Sep. 2012, LEUKEMIA RESEARCH, 36(9) (9), E202 - E205, English

  [Refereed]

  Report scientific journal


• Hyperglycaemia during the early phase after haematopoietic stem cell transplantation is caused by the elevation of insulin resistance

  K. Yakushijin, S. Fuji, S. Kim, K. Yoshimura, S. Kurosawa, Y. Asakura, N. Hiramoto, M. Mori, S. Fukuhara, Y. Kamiyama, N. Ueno, K. Tada, T. Maeda, D. Nakamura, M. Nishinohara, K. Furuta, S. Mori, R. Tanosaki, Y. Heike, Y. Takaue, K. Tobinai, T. Fukuda

  Apr. 2012, BONE MARROW TRANSPLANTATION, 47, S201 - S202, English

  Summary international conference


• THE IMPACT OF HCV SERO-POSITIVITY OF RECIPIENTS ON CLINICAL OUTCOMES FOLLOWING ALLOGENEIC HSCT IN JAPAN

  H. Nakasone, K. Yakushijin, S. Kurosawa, H. Ogawa, K. Ohashi, T. Eto, H. Sakamaki, Y. Morishima, T. Nagamura, R. Suzuki, M. Murata, S. Taniguchi, T. Fukuda

  Feb. 2012, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18(2) (2), S328 - S329, English

  Summary international conference


• 同種造血幹細胞移植後合併症と長期予後に与えるHCV陽性の影響

  仲宗根秀樹, 薬師神公和, 黒澤彩子, 小川啓恭, 大橋一輝, 衛藤徹也, 坂巻壽, 森島泰雄, 長村登紀子, 鈴木律朗, 村田誠, 谷口修一, 福田隆浩

  01 Feb. 2012, 日本造血細胞移植学会総会プログラム・抄録集, 34th, 228, Japanese


• SMILE療法及び末梢血幹細胞移植によって良好な経過が得られた再発・難治性NK/T細胞リンパ腫の一例

  垣内誠司, 船越洋平, 豊田昌徳, 乾由美子, 川森有里子, 薬師神公和, 岡村篤夫, 山本克也, 松岡広, 南博信

  2012, 日本造血細胞移植学会総会プログラム・抄録集, 34th


• Isolated Isochromosome 17q in Myelodysplastic Syndromes with Pure Red Cell Aplasia and Basophilia

  Yumiko Inui, Katsuya Yamamoto, Atsuo Okamura, Kimikazu Yakushijin, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu Minami

  2012, INTERNAL MEDICINE, 51(12) (12), 1579 - 1584, English

  [Refereed]

  Introduction scientific journal


• 【進化するがん免疫療法(ワクチン療法、細胞療法、抗体療法)】 抗体療法 造血器腫瘍の抗体療法

  Yakushijin Kimikazu, Minami Hironobu

  科学評論社, Nov. 2011, 腫瘍内科, 8巻, 5号, pp. 505-513(5) (5), 409 - 416, Japanese

  Introduction scientific journal


• 【内科診療における論点】 血液 急性リンパ性白血病に対する骨髄非破壊的移植前治療を用いた同種造血幹細胞移植の適応をどう考えるか?

  Yakushijin Kimikazu

  南江堂, Jun. 2011, 内科, 107巻, 6号, pp. 1351-1354(6) (6), 1355 - 1359, Japanese

  Introduction scientific journal


• Changes In Incidence and Causes of Non-Relapse Mortality (NRM) After Allogeneic Hematopoietic Cell Transplantation (allo-HCT): Are Transplants Improving?

  Saiko Kurosawa, Kimikazu Yakushijin, Takuhiro Yamaguchi, Yoshiko Atsuta, Tokiko Nagamura-Inoue, Hideki Akiyama, Shuichi Taniguchi, Koichi Miyamura, Satoshi Takahashi, Tetsuya Eto, Yasuo Morishima, Hisashi Sakamaki, Takahiro Fukuda

  Nov. 2010, BLOOD, 116(21) (21), 397 - 397, English

  Summary international conference


• LONG-TERM FOLLOW UP OF ANTI-HOST A/B ANTIBODY AFTER MINOR ABO-INCOMPATIBLE HEMATOPOIETIC STEM CELL TRANSPLANTATION

  K. Yakushijin, S. Kurosawa, Y. Asakura, A. Ito, R. Otake, T. Kumazawa, R. Kuroda, S. Mori, S. W. Kim, T. Fukuda, R. Tanosaki

  Nov. 2009, VOX SANGUINIS, 97, 46 - 46, English

  Summary international conference


• Renal Complications after Busulfan-Based Reduced-Intensity Stem Cell Transplantation in 286 Patients with Hematological Disorders

  Kimikazu Yakushijin, Takahiro Fukuda, Yoshitaka Asakura, Saiko Kurosawa, Nobuhiro Hiramoto, Daisuke Nakamura, Kohei Tada, Masaaki Nishinohara, Akihito Hagiwara, Niina Ueno, Yutaro Kamiyama, Masakazu Mori, Sung-Won Kim, Shin-ichiro Mori, Ryuji Tanosaki, Yuji Heike, Yoichi Takaue

  Nov. 2009, BLOOD, 114(22) (22), 1301 - 1302, English

  Summary international conference


• ABSOLUTE LYMPHOCYTE COUNT KINETICS MAY PREDICT THE CLINICAL OUTCOME AFTER RELATED ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION WITH A BUSULFAN-BASED REDUCED-INTENSITY CONDITIONING REGIMEN

  K. Yakushijin, T. Fukuda, B. Saito, S. Kurosawa, Y. Asakura, T. Azuma, S. -W Kim, S. -i Mori, R. Tanosaki, Y. Heike, Y. Takaue

  Feb. 2009, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 15(2) (2), 137 - 138, English

  Summary international conference


• Defibrotide therapy for patients with sinusoidal obstruction syndrome after hematopoietic stem cell transplantation

  YAKUSHIJIN Kimikazu, SADA Akiko, SHIMOYAMA Manabu, YAMAMOTO Katsuya, KATAYAMA Yoshio, MATSUI Toshimitsu, OKAMURA Atsuo, ONO Kanako, KAWANO Yuko, KAWANO Hiroki, FUNAKOSHI Yohei, KAWAMORI Yuriko, NISHIKAWA Shinichiro, MINAGAWA Kentaro

  Sinusoidal obstruction syndrome (SOS) is one of the life-threatening complications caused by endothelial damage to the hepatic sinusoids after hematopoietic stem cell transplantation. However, a satisfactory treatment for SOS has not yet been established. Defibrotide has anti-thrombotic, anti-ischemic, anti-inflammatory, and thrombolytic properties without systemic anticoagulant effects. We treated eight post-transplant SOS patients with defibrotide. Three patients responded to the therapy and the initial response was observed within a week. In addition to the improvement of liver function, rapid recovery of response to diuretic drugs followed by the improvement of renal function was observed. All of the five patients with respiratory dysfunction died despite administration of defibrotide, suggesting that early treatment might lead to better outcomes. There were no severe adverse effects directly due to defibrotide administration. Defibrotide seems to be a promising treatment for SOS, and the initiation of a clinical study in Japan would be important.

  The Japanese Society of Hematology, 2009, Rinsho Ketsueki, 50(1) (1), 3 - 8, Japanese


• 悪性リンパ腫に対する当院単施設における自家末梢血幹細胞移植を併用したMCEC療法の検討

  ASAKURA YOSHITAKA, TANOZAKI RYUJI, KIN SHIGEMOTO, AZUMA TERUHISA, KUROSAWA AYAKO, YAKUSHIJIN KIMIKAZU, MORI MASAKAZU, MARUYAMA MASARU, MORI SHIN'ICHIRO, FUKUDA TAKAHIRO, WATANABE TAKASHI, KOBAYASHI YUKIO, TOBINAI KENSEI, TAKAUE YOICHI

  (一社)日本血液学会-東京事務局, 30 Sep. 2008, 臨床血液, 49(9) (9), 1125 - 1225, Japanese


• 成人寛解期急性リンパ芽球性白血病における臍帯血移植の有用性

  西川真一郎, 皆川健太郎, 薬師神公和, 船越洋平, 川森有里子, 川野裕子, 川野宏樹, 山本克也, 岡村篤夫, 片山義雄, 下山学, 松井利充

  2008, 臨床血液, 49(9) (9)


• Feasibility of reduced-intensity cord blood transplantation (RICBT) as a salvage therapy for graft failure (GF): Results of a nationwide survey of 63 patients.

  Fusako Ohara, Kazuhiro Masuoka, Takahiro Fukuda, Yoshinobu Kanda, Mika Nakamae, Katsuhiro Togami, Kimikazu Yakushijin, Kaichi Nishiwaki, Yasunori Ueda, Fumio Kawano, Takuya Yamashita, Masaharu Kasai, Koji Nagafuji, Maki Takabayashi, Kazuo Hatanaka, Masafumi Taniwaki, Yoshinobu Maeda, Naoki Shirafuji, Atae Utsunomiya, Toshiki Uchida, Takehiko Mori, Tetsuya Eto, Kazuaki Yakushiji, Hiroshi Nakagawa, Makto Murata, Kosei Matsue, Yoichi Takaue, Shuichi Taniguchi

  Nov. 2006, BLOOD, 108(11) (11), 888A - 888A, English

  Summary international conference


• A biphenotypic transformation of 8p11 myeloproliferative syndrome with CEP1/FGFR1 fusion gene

  Katsuya Yamamoto, Hiroki Kawano, Shinichiro Nishikawa, Kimikazu Yakushijin, Atsuo Okamura, Toshimitsu Matsui

  Oct. 2006, EUROPEAN JOURNAL OF HAEMATOLOGY, 77(4) (4), 349 - 354, English


• Therapy-related myelodysplastic syndrome with inv(16)(p13q22) and I type CBF beta/MYH11 after autologous transplantation: Undetectable fusion transcript in pretransplant progenitor cells

  K Yamamoto, S Nishikawa, K Minagawa, K Yakushijin, A Okamura, T Matsui

  Mar. 2006, LEUKEMIA RESEARCH, 30(3) (3), 354 - 361, English


• The role of transcriptional coactivator TRAP220/MED1 in nuclear receptor-mediated myelomonocytic differentiation.

  M Ito, N Urahama, A Sada, K Yakushijin, K Yamamoto, A Okamura, K Minagawa, A Hato, K Chihara, RG Roeder, T Matsui

  Nov. 2005, BLOOD, 106(11) (11), 765A - 765A, English

  Summary international conference


• A t(2;3)(q11;q27) involving the BCL6 gene in follicular lymphoma with dup(12q) and t(14;18)

  K Yamamoto, A Okamura, A Hato, S Nishikawa, K Yakushijin, T Matsui

  Jun. 2005, CANCER GENETICS AND CYTOGENETICS, 159(2) (2), 184 - 186, English

  Report scientific journal


• Successful treatment with defibrotide for sinusoidal obstruction syndrome after hematopoietic stem cell transplantation

  Yakushijin Kimikazu, Matsui Toshimitsu, Okamura Atsuo, Yamamoto Katsuya, Ito Mitsuhiro, Chihara Kazuo

  Sinusoidal obstruction syndrome (SOS) (formerly known as hepatic veno-occlusivedisease (VOD)) is a life-threatening complication subsequent to hematopoietic stem celltransplantation. However, no completely satisfactory strategies for the treatment ofSOS have been established yet. Defibrotide is a single-strandedpolydeoxyribonucleotide with anti-thrombotic, anti-ischemic, anti-inflammatory andthrombolytic properties, but without systemic anticoagulant effects, and someencouraging results have been reported in western countries. We treated fourpatients with defibrotide for SOS, since there seemed to be no possibility to cure thepatients with conventionally available treatments in Japan. All patients showedevidence of multiple organ failure at the start of the treatment. Defibrotide wasadministered intravenously in normal saline in four divided doses for 14 to 27 days.Three patients (75%) responded to the therapy, while one died of SOS andcytomegalovirus infection despite intensive therapy. None of the patients sufferedfrom significant adverse effects such as severe hemorrhage. This is the first reportdealing with the treatment with defibrotide of Japanese patients with SOS. Becausedefibrotide is considered to be promising for the treatment of SOS, it is important tostart a phase II study as soon as possible.

  Kobe University, 2005, The Kobe journal of the medical sciences, 51(3) (3), 55 - 65, English


• Casein kinase I epsilon downregulates PI3K/Akt signaling, followed by genotoxic stress-induced apoptosis of hematopoietic cells.

  A Okamura, K Yamamoto, K Yakushijin, N Urahama, K Minagawa, A Sada, A Hato, S Nishikawa, K Yokoyama, M Ito, T Matsui

  Nov. 2004, BLOOD, 104(11) (11), 360A - 360A, English

  Summary international conference


• A novel t(2;6)(p12;q23) appearing during transformation of follicular lymphoma with t(18;22)(q21;q11) to diffuse large cell lymphoma

  K Yamamoto, A Okamura, K Minagawa, K Yakushijin, N Urahama, H Gomyo, M Shimoyama, M Itoh, T Matsui

  Dec. 2003, CANCER GENETICS AND CYTOGENETICS, 147(2) (2), 128 - 133, English


• Stabilization of SOCS3 and beta-catenin by casein kinase I epsilon to regulate hematopoietic cell differentiation.

  A Okamura, M Shimoyama, H Gomyo, K Yakushijin, N Urahama, K Minagawa, A Sada, A Hato, K Yamamoto, M Ito, T Matsui

  Nov. 2003, BLOOD, 102(11) (11), 837A - 837A, English

  Summary international conference


• Morphologic, flow cytometric and cytogenetic evaluation of bone marrow involvement in B-cell lymphoma.

  H Gomyo, M Shimoyama, A Hato, K Minagawa, K Yakushijin, N Urahama, A Sada, A Okamura, K Yamamoto, M Ito, K Chihara, Y Hayashi, T Matsui

  Nov. 2003, BLOOD, 102(11) (11), 263B - 263B, English

  Summary international conference


• A novel RDH5 gene mutation in a patient with fundus albipunctatus presenting with macular atrophy and fading white dots.

  Hiroyuki Yamamoto, Kimikazu Yakushijin, Sentaro Kusuhara, Michael Francis T Escaño, Azusa Nagai, Akira Negi

  PURPOSE: To report a novel homozygous RDH5 gene mutation in a 76-year-old fundus albipunctatus who developed macular atrophy with the disappearance of white dots. DESIGN: Observational case report. METHODS: Direct genomic sequencing for RDH5 mutations was done after complete ophthalmic examination. RESULTS: Fundoscopy revealed only macular atrophy with notable absence of white dots. A homozygous G490T (Val164Phe) missense RDH5 gene mutation was detected. CONCLUSIONS: This is the first reported long-term case of fundus albipunctatus demonstrating macular atrophy with fading of the typical white dots. Gene studies may be the only method for distinguishing fundus albipunctatus from other types of macular atrophy in the elderly.

  Sep. 2003, American journal of ophthalmology, 136(3) (3), 572 - 4, English, International magazine


• Effective anti-viral therapy for hemophagocytic syndrome associated with B-cell lymphoma

  H Gomyo, M Shimoyama, K Minagawa, K Yakushijin, N Urahama, A Okamura, K Yamamoto, M Ito, K Chihara, T Matsui

  Sep. 2003, LEUKEMIA & LYMPHOMA, 44(10) (10), 1807 - 1810, English

• 新臨床腫瘍学 がん薬物療法専門医のために / 電解質異常（高カルシウム血症、低ナトリウム血症）

  Yakushijin Kimikazu

  Others, 南江堂, 2018, Japanese

  Textbook


• 電解質異常（高カルシウム血症、低ナトリウム血症） / 新臨床腫瘍学 がん薬物療法専門医のために

  Yakushijin Kimikazu

  Others, 南江堂, 2015, Japanese

  Textbook


• がん薬物療法の支持療法マニュアル 〜症状の見分け方から治療まで〜 / がん薬物療法の支持療法マニュアル ?症状の見分け方から治療まで?

  Yakushijin Kimikazu

  Others, 南江堂, Mar. 2013, Japanese

  General book


• 新臨床腫瘍学 がん薬物療法専門医のために / 電解質異常（高カルシウム血症、低ナトリウム血症）

  Yakushijin Kimikazu

  Others, 南江堂, Dec. 2012, Japanese

  Textbook


• がん診療レジデントマニュアル 第５版 / 造血幹細胞移植

  Yakushijin Kimikazu

  Joint work, 医学書院, Jun. 2010, Japanese

  Textbook

• 筋炎症状で発症した節外性NK/T細胞リンパ腫

  倉田 啓史, 長尾 茂輝, 東目 亜湖, 川口 晃司, 市川 大哉, 坂井 里奈, 後藤 秀彰, 水谷 優, 垣内 誠司, 北尾 章人, YAKUSHIJIN KIMIKAZU, 山本 克也, MATSUOKA HIROSHI, MINAMI HIRONOBU

  第41回日本造血細胞移植学会総会, Mar. 2019, Japanese, 日本造血細胞移植学会, 大阪, Domestic conference

  Poster presentation


• ポナチニブ投与後に遅発性類洞閉塞症候群を発症した一例

  倉田 啓史, YAKUSHIJIN KIMIKAZU, 市川 大哉, 大國 まりか, 東目 亜湖, 川口 晃司, 長尾 茂輝, 山本 克也, MATSUOKA HIROSHI, MINAMI HIRONOBU

  第41回日本造血細胞移植学会総会, Mar. 2019, Japanese, 日本造血細胞移植学会, 大阪, Domestic conference

  Poster presentation


• ステロイド軟膏の使用中止後に相対的副腎不全をきたした1例

  上杉 早希子, 東目 亜湖, 後藤 秀彰, 川口 晃司, 石川 瑤子, 倉田 啓史, 宮田 吉晴, YAKUSHIJIN KIMIKAZU, MATSUOKA HIROSHI, MINAMI HIRONOBU

  第223回日本内科学会近畿地方会, Mar. 2019, Japanese, 日本内科学会, 京都, Domestic conference

  Oral presentation


• EBV関連 sequential lymphomaの1例

  佐伯 美紀, 倉田 啓史, 川口 晃司, 長尾 茂輝, 石川 瑶子, 崔 諭司, YAKUSHIJIN KIMIKAZU, MATSUOKA HIROSHI, MINAMI HIRONOBU

  第223回日本内科学会近畿地方会, Mar. 2019, Japanese, 日本内科学会, 京都, Domestic conference

  Oral presentation


• Would Bone Marrow be Associated with Superior Outcomes Compared with Peripheral Blood for Male Recipients with Female Donors in HLA-Matched Related Transplantation?

  Hideki Nakasone, Koji Kawamura, Kimikazu Yakushijin, Akihito Shinohara, Heiwa Kanamori, Kazuteru Ohashi, Takahiro Fukuda, Naoyuki Uchida, Hirohisa Nakamae, Junya Kanda, Tatsuo Ichinohe, Yoshiko Atsuta, Yoshihiro Inamoto, Sachiko Seo, Fumihiko Kimura, Masao Ogata

  米国血液学会, Dec. 2018, English, San Diego, International conference

  Poster presentation


• PET/MRI陰性だが頭部造影MRIにて中枢神経浸潤が明らかとなった精巣原発DLBCLの一例

  後藤 秀彰, 東目 亜湖, 坂井 里奈, 川口 晃司, 石川 瑶子, 倉田 啓史, YAKUSHIJIN KIMIKAZU, MATSUOKA HIROSHI, MINAMI HIRONOBU

  第110回近畿血液学地方会, Nov. 2018, Japanese, 日本血液学会, 奈良, Domestic conference

  Oral presentation


• Nutrition and Rehabilitation of Hematopoietic Stem Cell Transplantation Patients

  Hisayo Doi, Aya Okano, Mika Tanaka, Michiko Takahashi, Satoko Tabuchi, Junichiro Inoue, Keiji Kurata, Shinichiro Kawamoto, Hiroshi Matsuoka, Kimikazu Yakushijin

  APBMT, Nov. 2018, English, アジア太平洋骨髄移植学会, Taipei, International conference

  Poster presentation


• 多発性筋炎様症状を呈したNK/T細胞リンパ腫

  長尾 茂輝, 倉田 啓史, 東目 亜湖, 川口 晃司, 市川 大哉, 坂井 里奈, 後藤 秀彰, 水谷 優, 垣内 誠司, 宮田 吉晴, 北尾 章人, YAKUSHIJIN KIMIKAZU, 山本 克也, MATSUOKA HIROSHI, MINAMI HIRONOBU

  第80回日本血液学会学術集会, Oct. 2018, Japanese, 日本血液学会, 大阪, Domestic conference

  Poster presentation


• 新たなZMYND11/MBTD1融合遺伝子の発現とt(10;17)(p15;q21)転座を認めたCD7+CD56+急性骨髄性白血病

  山本 克也, YAKUSHIJIN KIMIKAZU, 市川 大哉, 垣内 誠司, KAWAMOTO SHINICHIRO, 松本 久幸, 中町 祐司, 三枝 淳, MATSUOKA HIROSHI, MINAMI HIRONOBU

  第80回日本血液学会学術集会, Oct. 2018, Japanese, 日本血液学会, 大阪, Domestic conference

  Poster presentation


• シクロスポリン療法後の骨髄移植にて重症肝類洞閉塞症候群をきたした一例

  川口 晃司, 坂井 里奈, 垣内 誠司, 東目 亜湖, 倉田 啓史, 長尾 茂樹, YAKUSHIJIN KIMIKAZU, 足立 陽子, MATSUOKA HIROSHI, MINAMI HIRONOBU

  第80回日本血液学会学術集会, Oct. 2018, Japanese, 日本血液学会, 大阪, Domestic conference

  Poster presentation


• TLR9の一塩基多型により無症候性CMV感染症を呈した再生不良性貧血の一例.

  北尾 章人, KAWAMOTO SHINICHIRO, 水谷 優, 坂井 里奈, 市川 大哉, 須藤 洋崇, YAKUSHIJIN KIMIKAZU, MATSUOKA HIROSHI, MINAMI HIRONOBU

  第80回日本血液学会学術集会, Oct. 2018, Japanese, 日本血液学会, 大阪, Domestic conference

  Poster presentation


• Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive actute myeloid leukemia.

  Kakiuchi S, Sakai R, Kawaguchi K, Higashime A, Kurata K, Ichikawa H, Nagao S, Rikitake J, KIYOTA NAOMI, YAKUSHIJIN KIMIKAZU, MATSUOKA HIROSHI, Minami H

  第80回日本血液学会学術集会, Oct. 2018, English, 日本血液学会, 大阪, Domestic conference

  Poster presentation


• CLLとの鑑別を要したt(18;22)(q21;q11)を伴う白血化で発症した濾胞性リンパ腫

  後藤 秀彰, 水谷 優, 垣内 誠司, YAKUSHIJIN KIMIKAZU, 山本 克也, 山野 剛, 足立 陽子

  第80回日本血液学会学術集会, Oct. 2018, Japanese, 日本血液学会, 大阪, Domestic conference

  Poster presentation


• Aplastic anemia that developed asymptomatic CMV infection due to a single nucleotide polymorphism of TLR9

  Akihito Kitao, Shinichiro Kawamoto, Yu Mizutani, Rina Sakai, Hiroya Ichikawa, Hirotaka Suto, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami

  第80回日本血液学会学術集会, Oct. 2018, English, 日本血液学会, 大阪, Domestic conference

  Poster presentation


• Synchronous esophageal cancer and multiple myeloma: a report of two cases

  東目 亜湖, FUNAKOSHI YOUHEI, 力武 隼平, 兵庫 寧子, 鈴木 千晶, IMAMURA YOSHINORI, TOYODA MASANORI, YAKUSHIJIN KIMIKAZU, KIYOTA NAOMI, MATSUOKA HIROSHI, MINAMI HIRONOBU

  第16回日本臨床腫瘍学会, Jul. 2018, English, 日本臨床腫瘍学会, 神戸, Domestic conference

  Poster presentation


• 類洞閉塞症候群（SOS/VOD）のリスクファクター、検査・早期診断および治療 ー新ガイドラインの解説も含めた最近の潮流ー

  Yakushijin Kimikazu

  第40回日本造血細胞移植学会総会, Feb. 2018, Japanese, 日本造血細胞移植学会, 札幌, Domestic conference

  Public discourse


• 非血縁者間骨髄移植前の病勢コントロールとしてGCD療法が有効であった肝脾原発T細胞性リンパ腫の一例

  大國まりか, 市川大哉, 須藤洋崇, 橋本朗子, 田中康博, 新里偉咲, 長尾茂樹, 坂井里奈, 水谷優, 北尾章人, 倉田啓史, 垣内誠司, 宮田吉晴, 乾由美子, 齊藤 泰之, Yakushijin Kimikazu, Kawamoto Shinichiro, Ito Mitsuhiro, 山本克也, Matsuoka Hiroshi, Minami Hironobu

  第40回日本造血細胞移植学会総会, Feb. 2018, Japanese, 日本造血細胞移植学会, 札幌, Domestic conference

  Poster presentation


• Investigation of patients who required intensive care during the course of allo-HSCT

  北尾章人, Yakushijin Kimikazu, Misumi Takuyo, 東目亜湖, 川口晃司, 坂井里奈, 市川大哉, 水谷優, 倉田啓史, 長尾茂輝, 垣内誠司, 宮田吉晴, Kawamoto Shinichiro, 岡村篤夫, Matsuoka Hiroshi, Minami Hironobu

  第40回日本造血細胞移植学会総会, Feb. 2018, Japanese, 日本造血細胞移植学会, 札幌, Domestic conference

  Oral presentation


• A retrospective analysis of Pharmaceutical Inquiries in the Transplantation Unit

  丸上奈穂, 奥野護, 丹田雅明, 宮田吉晴, Yakushijin Kimikazu, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu

  第40回日本造血細胞移植学会総会, Feb. 2018, Japanese, 日本造血細胞移植学会, 札幌, Domestic conference

  Oral presentation


• 自家末梢血幹細胞移植における栄養状態と予後に関する方視的解析

  水谷 優, Yakushijin Kimikazu, 市川 大哉, 坂井 里奈, 後藤 秀彰, 倉田 啓史, 西村 明子, 北尾 章人, 田渕 聡子, 瓜生 恭章, 垣内 誠司, 宮田 吉晴, 乾 由美子, 眞田 幸尚, Takahashi Michiko, 岡村 篤夫, Kawamoto Shinichiro, 山本 克也, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu

  第40回日本造血細胞移植学会総会, Feb. 2018, Japanese, 日本造血細胞移植学会, 札幌, Domestic conference

  Poster presentation


• 血縁ドナーにおける血液成分分離装置Spectra OptiaとCOBE Spectraの採取データの比較検討

  宮田 吉晴, Kawamoto Shinichiro, 市川大哉, 坂井里奈, 水谷優, 倉田啓史, 垣内誠司, 北尾章人, 真田幸尚, 乾由美子, Yakushijin Kimikazu, 岡村篤夫, Matsuoka Hiroshi, Minami Hironobu

  第40回日本造血細胞移植学会総会, Feb. 2018, Japanese, 日本造血細胞移植学会, 札幌, Domestic conference

  Poster presentation


• Pharmacokinetics of intravenous mycophenolate mofetil after hematopoietic stem cell transplantation in Japanese population

  Keiji Kurata, Atsuo Okamura, Motohiro Yamamori, Yakushijin Kimikazu, Koji Kawaguchi, Ako Higashime, Hiroya Ichikawa, Rina Sakai, Yu Mizutani, Seiji Kakiuchi, Yoshiharu Miyata, Akihito Kitao, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu

  ASBMT/CIBMTR tandem meetings 2018, Feb. 2018, English, ASBMT/CIBMTR, Salt Lake City, USA, International conference

  Poster presentation


• Pharmacokinetics of intravenous mycophenolate mofetil after cord blood transplantation in Japanese

  Keiji Kurata, Atsuo Okamura, Hiroya Ichikawa, Rina Sakai, Yu Mizutani, Akihito Kitao, Yakushijin Kimikazu, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu

  第40回日本造血細胞移植学会総会, Feb. 2018, Japanese, 日本造血細胞移植学会, 札幌, Domestic conference

  Oral presentation


• Retrospective analysis of TLS risk in lymphoma patients stratified by cholinesterase level

  Mariko Kojima, Risa Sakai, Kawamoto Shinichiro, Hiroya Ichikawa, Yu Mizutani, Keiji Kurata, Seiji Kakiuchi, Yoshiharu Miyata, Akihito Kitao, Yakushijin Kimikazu, Katsuya Yamamoto, Matsuoka Hiroshi, Minami Hironobu

  第79回日本血液学会学術集会, Oct. 2017, Japanese, 日本血液学会, 東京, Domestic conference

  Poster presentation


• Retrospective analysis of the ESHAP regimen for malignant lymphoma in Kobe University Hospital.

  Miyata Y, Yakushijin Kimikazu, Ichikawa H, Sakai R, Goto H, Mizutani Y, Kurata K, Kakiuchi S, Kitao A, Kawamoto Shinichiro, Yamamoto K, Ito M, Matsuoka Hiroshi, Minami Hironobu

  第79回日本血液学会学術集会, Oct. 2017, English, 日本血液学会, 東京, Domestic conference

  Poster presentation


• MYC amplification in the form of ring chromosomes 8 in acute myeloid leukemia with t(11;16)(q13;p11)

  Katsuya Yamamoto, Kawamoto Shinichiro, Keiji Kurata, Akihito Kitao, Yu Mizutani, Hiroya Ichikawa, Yakushijin Kimikazu, Matsuoka Hiroshi, Minami Hironobu

  The 79th annual meeting of the Japanese Society of Hematology, Oct. 2017, Japanese, Japanese Society of Hematology, 東京, Domestic conference

  Poster presentation


• Establishment and Gene Expression Analysis of a Double-Hit Lymphoma Cell Line

  Keiji Kurata, Kawamoto Shinichiro, Hiroya Ichikawa, Rina Sakai, Yu Mizutani, Akihito Kitao, Yakushijin Kimikazu, Matsuoka Hiroshi, Minami Hironobu

  第15回日本臨床腫瘍学会学術集会, Jul. 2017, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference

  Poster presentation


• 慢性C型肝炎治療後に発症したB細胞性前リンパ球性白血病の一例

  毛利華奈子, 坂井里奈, 須藤洋崇, Kawamoto Shinichiro, Yakushijin Kimikazu, Matsuoka Hiroshi, Minami Hironobu, 毛利華奈子

  第107回近畿血液学地方会, Jun. 2017, Japanese, 日本血液学会, 京都, Domestic conference

  Oral presentation


• 造血幹細胞移植後のT細胞におけるCD134(OX40）の発現が、移植後HHV-6B再活性化および増殖の誘因となる

  長坂 美和子, Kawabata Akiko, 岸本 健治, 長谷川 大一郎, 小阪 嘉之, Mori Takeshi, Morioka Ichiro, Nishimura Noriyuki, Iijima Kazumoto, Yamada Hideto, Yakushijin Kimikazu, Matsuoka Hiroshi, Mori Yasuko

  第31回ヘルペスウイルス研究会, Jun. 2017, Japanese, 第31回ヘルペスウイルス研究会, 松江, Domestic conference

  Oral presentation


• メトトレキサート関連リンパ増殖性疾患により生じた下腿潰瘍の一例

  寒川 愛美, 濱岡 大, 小倉 香奈子, Kunisada Makoto, 村上 英毅, Yakushijin Kimikazu, Nishigori Chikako

  兵庫県皮膚科医会 第116回総会・学術集談会, Jun. 2017, Japanese, 兵庫県皮膚科医会, 神戸, Domestic conference

  Oral presentation


• MicroRNA-7 suppresses RB1 expression leading to chromosomal instability in leukemia cells harboring c-Kit mutation

  Keiji Kurata, Kawamoto Shinichiro, Ryota Masutani, Yakushijin Kimikazu, Katsuya Yamamoto, Matsuoka Hiroshi, Takayuki Takubo, Minami Hironobu

  Annual Meeting of the American Association for Cancer Research 2017, Apr. 2017, English, American Asociation for Cancer Research, Washington DC, USA, International conference

  Poster presentation


• A Case of Refractory Chronic GVHD of Lips Successfully Treated with Wrap Therapy

  市川 大哉, 奥野 真紀子, 坂井 里奈, 水谷 優, 倉田 啓史, 須藤 洋崇, 垣内 誠司, 北尾 章人, 宮田 吉晴, 眞田 幸尚, 乾 由美子, 瓜生 恭章, Saito Yasuyuki, Yakushijin Kimikazu, Kawamoto Shinichiro, 田村 恵利, 岸本 恵実, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu

  The 39th Annual Meeting of the Japan Socitey for Hematopoietic Cell Transplantation, Mar. 2017, Japanese, The Japan Society for Hematopoietic Cell Transplantation, 島根, Domestic conference

  Poster presentation


• 肝中心静脈閉塞症（VOD）モデルマウスを用いた肝静脈閉塞への好中球細胞外トラップ（NETs）関与の可能性

  河野麻理, 山本志緒里, 倉田啓史, Yakushijin Kimikazu, 西郷勝康, Kawano Seiji, Matsuoka Hiroshi

  第39回日本造血細胞移植学会総会, Mar. 2017, Japanese, 日本造血細胞移植学会, 松江, Domestic conference

  Oral presentation


• Defibrotide and Thrombomodulin Treatment for Late Onset Sinusoidal Obstruction Syndrome after allo-HSCT

  Yakushijin Kimikazu, 池添 隆之, 大和田 千桂子, 工藤 寿子, 岡村 浩史, 後藤 裕明, 矢部 普正, 安本 篤史, 桑原 英幸, 藤井 志朗, 賀川 久美子, 池邉 太一, 大西 康, 河野 彰夫, Katayama Yoshio, 吾郷 浩厚, 加藤 光次, 岡村 篤夫, 菊田 敦, 福田 隆浩

  The 39th Annual Meeting of the Japan Socitey for Hematopoietic Cell Transplantation, Mar. 2017, Japanese, The Japan Society for Hematopoietic Cell Transplantation, 島根, Domestic conference

  Oral presentation


• Effective immunosuppressive therapy with cyclosporine-A against relapsed pri mary cutaneous gamma/delta T-cell lymphoma after auto-PBSCT

  Kawamoto Shinichiro, 市川 大哉, 水谷 優, 北尾 章人, Yakushijin Kimikazu, 山本 克也, Matsuoka Hiroshi, Minami Hironobu

  第39回日本造血細胞移植学会総会, Mar. 2017, Japanese, 日本造血細胞移植学会, 松江, Domestic conference

  Poster presentation


• Early Initiation of Defibrotide or Thrombomodulin Treatment for Sinusoidal Obstruction Syndrome

  Yakushijin Kimikazu, 池添 隆之, 大和田 千桂子, 工藤 寿子, 岡村 浩史, 後藤 裕明, 矢部 普正, 安本 篤史, 桑原 英幸, 藤井 志朗, 賀川 久美子, 池邉 太一, 大西 康, 森下 剛久, Katayama Yoshio, 吾郷 浩厚, 加藤 光次, 岡村 篤夫, 菊田 敦, 福田 隆浩

  The 78th Annual Meeting of the Japanese Society of Hematology, Oct. 2016, Japanese, The Japanese Society of Hematology, 横浜, Domestic conference

  Oral presentation


• 抗ARS抗体陽性間質性肺炎と甲状腺機能低下症に合併した後天性血友病A

  坂井 里奈, Yakushijin Kimikazu, 王 康治, 西尾 智尋, 金子 正博, 小西 弘起

  The 78th Annual Meeting of the Japanese Society of Hematology, Oct. 2016, Japanese, The Japanese Society of Hematology, 横浜, Domestic conference

  Poster presentation


• The antiemetic effect of palonosetron in malignant lymphoma patients treated with the CHOP regimen

  宮田 吉晴, Yakushijin Kimikazu, 乾 由美子, 今村 善宣, 後藤 秀彰, 水谷 優, 倉田 啓史, 垣内 誠司, 眞田 幸尚, Minami Yosuke, Kawamoto Shinichiro, Ito Mitsuhiro, 富永 亮, 五明 広志, 水野 石一, 野村 哲彦, 喜多川 浩一, 杉本 健, 村山 徹, Matsuoka Hiroshi, Minami Hironobu

  The 78th Annual Meeting of the Japanese Society of Hematology, Oct. 2016, Japanese, The Japanese Society of Hematology, 横浜, Domestic conference

  Poster presentation


• Constitutional t(8;22)(q24;11.2) that mimics variant Burkitt-type translocation in Ph positive CML

  横路 優子, Kawamoto Shinichiro, 山本 克也, 坂井 里奈, 水谷 優, 北尾 章人, Toyoda Masanori, Yakushijin Kimikazu, Matsuoka Hiroshi, Minami Hironobu

  The 78th Annual Meeting of the Japanese Society of Hematology, Oct. 2016, Japanese, The Japanese Society of Hematology, 横浜, Domestic conference

  Poster presentation


• LONG-TERM FOLLOW-UP OUTPATIENT PROGRAM AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

  Hisayo Doi, Aya Okano, Mami Ishiyama, Masaaki Tanda, Junichiro Inoue, Keiji Kurata, Yoshiharu Miyata, Kawamoto Shinichiro, Yakushijin Kimikazu, Kayoko Ito

  21st Congress of APBMT, Oct. 2016, English, Asia-Pacific Blood and Marrow Transplantation Group, Singapore, Singapore, International conference

  Oral presentation


• Impact of TBI on engraftment and non-relapse mortality in unrelated HCT

  仲宗根 秀樹, Yakushijin Kimikazu, 藤 重夫, 鬼塚 真仁, 篠原 明仁, 荻野 剛史, 宮村 耕一, 内田 直之, 高梨 美乃子, 一戸 辰夫, 福田 隆浩, 熱田 由子, 緒方 正男

  The 78th Annual Meeting of the Japanese Society of Hematology, Oct. 2016, Japanese, The Japanese Society of Hematology, 横浜, Domestic conference

  Oral presentation


• EFFECTIVENESS OF THE HEMATOPOIETIC STEM CELL TRANSPLANTATION TEAM-BASED MEDICINE MEETINGS IN HYOGO PREFECTURE

  Mika Tsunogi, Hisayo Doi, Mayumi Matsumoto, Natsumi Ueda, Eri Ikezoe, Chinami Hino, Nobuhiro Hiramoto, Noboru Yonetani, Tohru Murayama, Yakushijin Kimikazu

  21st Congress of APBMT, Oct. 2016, English, Asia-Pacific Blood and Marrow Transplantation Group, Singapore, Singapore, International conference

  Poster presentation


• Early initiation of defibrotide or thrombomodulin treatment for sinusoidal obstruction syndrome

  Yakushijin Kimikazu, Takayuki Ikezoe, Chikako Ohwada, Kazuko Kudo, Hiroshi Okamura, Hiroaki Goto, Hiromasa Yabe, Atsushi Yasumoto, Hideyuki Kuwabara, Shiro Fujii, Kumiko Kagawa, Taichi Ikebe, Yasyshi Onishi, Yoshihisa Morishita, Katayama Yoshio, Hiroatsu Ago, Koji Kato, Atsuo Okamura, Atsushi Kikuta, Takahiro Fukuda

  第78回日本血液学会学術集会, Oct. 2016, Japanese, 一般社団法人 日本血液学会, 横浜, Domestic conference

  Oral presentation


• DEFIBROTIDE OR THROMBOMODULIN TREATMENT FOR SINUSOIDAL OBSTRUCTION SYNDROME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN AND ADULTS

  Yakushijin Kimikazu, Takayuki Ikezoe, Chikako Ohwada, Kazuko Kudo, Hiroshi Okamura, Hiroaki Goto, Hiromasa Yabe, Kumiko Kagawa, Atsushi Kikuta, Takahiro Fukuda

  21st Congress of APBMT, Oct. 2016, English, Asia-Pacific Blood and Marrow Transplantation Group, Singapore, Singapore, International conference

  Poster presentation


• Coexpression of NUP98/TOP1 and TOP1/NUP98 in de novo AML with t(11;20)(p15;q12) and t(2;5)(q33;q31)

  Katsuya Yamamoto, Minami Yosuke, Yakushijin Kimikazu, Yu Mizutani, Yumiko Inui, Kawamoto Shinichiro, Keiji Matsui, Yuji Nakamachi, Seiji Kawamo, Matsuoka Hiroshi, Minami Hironobu

  第78回日本血液学会学術集会, Oct. 2016, Japanese, 日本血液学会, 横浜市, Domestic conference

  Poster presentation


• BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia .

  Akihito Kitao, Yakushijin Kimikazu, Eriko Honda, Hiroya Ichikawa, Yu Mizutani, Yoshiharu Miyata, Kiyoaki Uryu, Yumiko Inui, Kawamoto Shinichiro, Matsuoka Hiroshi, Ito Mitsuhiro, Tomoo Ito, Minami Hironobu

  The 78th annual meeting of the japanese society of hematology, Oct. 2016, Japanese, Japanese Society of Hematology, 横浜, Domestic conference

  Poster presentation


• A REDUCED INTENSITY CONDITIONING REGIMEN USING FLUDARABINE AND BUSULFAN (FLU-BU2)

  Keiji Kurata, Yakushijin Kimikazu, Hiroya Ichikawa, Rina Sakai, Hirotaka Suto, Yumiko Inui, Atsuo Okamura, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu

  The 21st Annual Congress of Asia Pacific Blood and Marrow Transplantation Group 2016, Oct. 2016, English, Asia-Pacific Blood and Marrow Transplantation Group, Singapore, Singapore, International conference

  Poster presentation


• リンパ節生検で完全梗塞が認められ診断に難渋したホジキンリンパ腫の1例

  大國まりか, 須藤洋崇, 市川大哉, Yakushijin Kimikazu, 柳沢俊学, Sakai Yasuhiro, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu

  第213回日本内科学会近畿地方会, Sep. 2016, Japanese, 日本内科学会, 大阪, Domestic conference

  Oral presentation


• 発熱性好中球減少症における質量分析を用いた菌種同定の有用性についての検討

  水谷 優, Kawamoto Shinichiro, 市川 大哉, 西村 明子, 乾 由美子, 北尾 章人, Toyoda Masanori, Yakushijin Kimikazu, Matsuoka Hiroshi, Minami Hironobu

  第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference

  Oral presentation


• 同種造血幹細胞移植後のリンパ球回復と予後に関する後方視的解析

  倉田 啓史, Yakushijin Kimikazu, 乾 由美子, 岡村 篤夫, Kawamoto Shinichiro, Minami Yosuke, 山本 克也, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu

  第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference

  Oral presentation


• 造血器悪性腫瘍に対する化学療法中のD-indexと口腔内感染性合併症との関連についての検討

  Akashi Masaya, 岸本 恵実, 辻 和志, 楠元 順哉, Yakushijin Kimikazu, Kawamoto Shinichiro, 岡村 篤夫, Matsuoka Hiroshi, Furudoi Shungo, Komori Takahide

  第14回日本臨床腫瘍学会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸市, Domestic conference

  Oral presentation


• 急性骨髄性白血病に対するヘッジホッグ阻害薬投与の治療反応性バイオマーカーとしてのNANOG発現

  垣内 誠司, Minami Yosuke, 福島 庸晃, 水谷 優, 倉田 啓史, Kawamoto Shinichiro, Yakushijin Kimikazu, 直江 知樹, Matsuoka Hiroshi, Minami Hironobu

  第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference

  Oral presentation


• 肝移植後のリンパ増殖性疾患に対する治療戦略

  市川 大哉, 水谷 優, 乾 由美子, 北尾 章人, 瓜生 恭章, Yakushijin Kimikazu, Kuramitsu Kaori, Tanaka Motofumi, Matsuoka Hiroshi, Minami Hironobu

  第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference

  Oral presentation


• Treatment strategies for double primary neoplasm patients who develop malignant lymphoma and solid tumors

  北尾 章人, 水谷 優, 後藤 秀彰, 乾 由美子, Kawamoto Shinichiro, Yakushijin Kimikazu, Minami Yosuke, Matsuoka Hiroshi, Ito Mitsuhiro, Minami Hironobu

  第14回日本臨床腫瘍学会学術集会, Jul. 2016, English, 日本臨床腫瘍学会, 神戸, Domestic conference

  Oral presentation


• Quick detection of bacteria with mass spectrometry might reduce mortality in ferile neutropenia

  水谷 優, Kawamoto Shinichiro, 市川 大哉, 西村 明子, 乾 由美子, 北尾 章人, Toyoda Masanori, Yakushijin Kimikazu, Matsuoka Hiroshi, Minami Hironobu

  第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference

  Oral presentation


• Mycophenolate Mofetilを使用した造血幹細胞移植後に発症したHHV-6脳炎の治療経過

  乾 由美子, Yakushijin Kimikazu, 市川 大哉, 水谷 優, 北尾 章人, Kawamoto Shinichiro, 岡村 篤夫, 山本 克也, Matsuoka Hiroshi, Minami Hironobu

  第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference

  Oral presentation


• Delayed Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation with Mycophenolate Mofetil

  Keiji Kurata, Yakushijin Kimikazu, Ishikazu Mizuno, Yumiko Inui, Hiroshi Gomyo, Atsuo Okamura, Ryo Tominaga, Kawamoto Shinichiro, Minami Yosuke, Akio Maeda, Katsuya Yamamoto, Tohru Murayama, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu

  7th, JSH International Symposium, May 2016, English, Japan Society of Hematology, Awaji, Japan, International conference

  Poster presentation


• Nationwide Survey of Defbrotide and Recombinant Human Soluble Thrombomodulin for Treatment of Sinusoidal Obstruction Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation

  Yakushijin Kimikazu, Takayuki Ikezoe, Chikako Ohwada, Kazuko Kudo, Hiroshi Okamura, Hiroaki Goto, Hiromasa Yabe, Atsushi Yasumoto, Hideyuki Kuwabara, Shiro Fujii, Kumiko Kagawa, Taichi Ikebe, Yasushi Onishi, Yoshihisa Morishita, Koichi Watamoto, Nobuhiko Uoshima, Daisuke Nakamura, Shuichi Ota, Yasunori Ueda, Tatsuo Oyake, Kazutoshi Koike, Ishikazu Mizuno, Hiroatsu Iida, Katayama Yoshio, Ago Hiroatsu, Koji Kato, Atsuo Okamura, Atsushi Kikuta, Takahiro Fukuda

  42nd, Annual Meeting of the European Society for Blood and Marrow Transplantation, Apr. 2016, English, European Society for Blood and Marrow Transplantation, Valencia, Spain, International conference

  Oral presentation


• Absolute Lymphocyte Count Recovery Predicts Clinical Outcome after Allogeneic Hematopoietic Stem Cell Transplantation in a Japanese Population

  Keiji Kurata, Yakushijin Kimikazu, Ishikazu Mizuno, Yumiko Inui, Hiroshi Gomyo, Atsuo Okamura, Hiroya Ichikawa, Yu Mizutani, Seiji Kakiuchi, Yoshiharu Miyata, Ryo Tominaga, Akihito Kitao, Yukinari Sanada, Saito Yasuyuki, Minami Yosuke, Kawamoto Shinichiro, Akio Maeda, Katsuya Yamamoto, Tohru Murayama, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu

  42nd, Annual Meeting of the European Society for Blood and Marrow Transplantation, Apr. 2016, English, European Society for Blood and Marrow Transplantation, Valencia, Spain, International conference

  Poster presentation


• 自律神経ストームを伴った造血幹細胞移植後HHV-6脳炎

  乾 由美子, Yakushijin Kimikazu, 水谷 優, 市川 大哉, 倉田 啓史, 垣内 誠司, 宮田 吉晴, 眞田 幸尚, 北尾 章人, Minami Yosuke, Kawamoto Shinichiro, 田中 康博, 新里 偉咲, 山本 克也, 村山 徹, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu

  第38回日本造血幹細胞移植学会総会, Mar. 2016, Japanese, 日本造血細胞移植学会, 名古屋, Domestic conference

  Oral presentation


• 造血幹細胞移植患者への栄養管理の前後比較

  田渕 聡子, Takahashi Michiko, 生田 智子, 曽我 明弘, 永濱 郁代, Yakushijin Kimikazu, Kawamoto Shinichiro, 筒井 輪央, 内田 絢子, 脇田 久美子, 三ヶ尻 礼子, 山本 育子, 山本 将司, 戸田 明代, Usami Makoto

  第31回日本静脈経腸栄養学会学術集会, Feb. 2016, Japanese, 福岡, Domestic conference

  Oral presentation


• 造血幹細胞移植患者への栄養管理の前後比較

  田渕 聡子, Takahashi Michiko, 生田 智子, 曽我 明弘, 永濱 郁代, Yakushijin Kimikazu, Kawamoto Shinichiro, 筒井 輪央, 内田 絢子, 脇田 久美子, 三ヶ尻 礼子, 山本 育子, Yamamoto Masashi, 戸田 明代, Usami Makoto

  第19回日本病態栄養学会, Jan. 2016, Japanese, 日本静脈経腸栄養学会, 横浜, Domestic conference

  Oral presentation


• 造血幹細胞移植患者へのNEST介入前後の栄養評価

  田渕 聡子, Takahashi Michiko, 生田 智子, 丹田 雅明, 青木 紫織, 奥野 護, 永濱 郁代, 土井 久容, Yakushijin Kimikazu, Kawamoto Shinichiro, 筒井 輪央, 内田 絢子, 脇田 久美子, 三ヶ尻 礼子, 山本 育子, Yamamoto Masashi, 戸田 明代, Usami Makoto

  第31回日本静脈経腸栄養学会, Jan. 2016, Japanese, 日本静脈経腸栄養学会, 横浜, Domestic conference

  Oral presentation


• 造血幹細胞移植患者へのNEST介入前後の栄養評価

  田渕 聡子, Takahashi Michiko, 生田 智子, 丹田 雅明, 青木 紫織, 奥野 護, 永濱 郁代, 土井 久容, Yakushijin Kimikazu, Kawamoto Shinichiro, 筒井 輪央, 内田 絢子, 脇田 久美子, 三ヶ尻 礼子, 山本 育子, Yamamoto Masashi, 戸田 明代, Usami Makoto

  第19回日本病態栄養学会年次学術集会, Jan. 2016, Japanese, 日本病態栄養学会, 横浜, Domestic conference

  Oral presentation


• 超高齢で発症した発作性夜間血色素尿症の1例。

  鷹津 英, 乾 由美子, 水谷 優, 能勢 拓, 倉田 啓史, Yakushijin Kimikazu, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu

  第210回日本内科学会近畿地方, Nov. 2015, Japanese, 日本内科学会, 神戸, Domestic conference

  Oral presentation


• 診断に難渋したhairy cell leukemiaの一例。

  本多 瑛理子, 乾 由美子, 水谷 優, 北尾 章人, 瓜生 恭章, 市川 大哉, Yakushijin Kimikazu, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu

  第210回日本内科学会近畿地方, Nov. 2015, Japanese, 日本内科学会, 神戸, Domestic conference

  Oral presentation


• Retrospective Analysis of 384 Patients Diagnosed with Sinusoidal Obstruction Syndrome (SOS) who were not Treated with Defibrotide or Thrombomodulin: Historical Control Data for Prospective Trials of New Investigational Drugs for SOS

  Yakushijin Kimikazu, Yoshiko Atsuta, Noriko Doki, Akira Yokota, Heiwa Kanamori, Toshihiro Miyamoto, Hisashi Sakamaki, Yasuo Morishima, Ritsuro Suzuki, Takahiro Fukuda

  第20回アジア太平洋造血細胞移植学会年次学術集会, Oct. 2015, English, アジア太平洋造血細胞移植学会, 沖縄, International conference

  [Invited]

  Invited oral presentation


• Physical Functioning and Quality of Life of Patients Who Underwent Hematopoietic Stem Cell Transplantation: Impact of the Supports Provided at the Long-term Follow-up Unit

  Hisayo Doi, Mayo Nishikawa, Jyunichirou Inoue, Daisuke Makiura, Miura Yasushi, Atsuo Okamura, Kayoko Itou, Yakushijin Kimikazu

  第20回アジア太平洋造血細胞移植学会年次学術集会, Oct. 2015, English, アジア太平洋造血細胞移植学会, 沖縄, International conference

  Oral presentation


• Mixed phenotype acute leukemia with t(12;17)(p13;q21)/TAF15-ZNF384 and der(1;18)(q10;q10)

  山本 克也, Kawamoto Shinichiro, 水谷 優, Yakushijin Kimikazu, 倉田 啓史, 乾 由美子, 眞田 幸尚, 垣内 誠司, 宮田 吉晴, 山下 智江, 中町 祐司, Kawano Seiji, Matsuoka Hiroshi, Minami Hironobu

  第77回日本血液学会学術集会, Oct. 2015, English, 日本血液学会, 金沢, Domestic conference

  Poster presentation


• Herpesvirus 6 Encephalitis after Hematopoietic Stem Cell Transplantation with Administration of Mycophenolate Mofetil for Graft-versus-host Disease Prophylaxis in Japan: a Single Institution Experience.

  Yumiko Inui, Yakushijin Kimikazu, Yu Mizutani, Keiji Kurata, Yoshiharu Miyata, Yukinari Sanada, Kawamoto Shinichiro, Atsuo Okamura, Matsuoka Hiroshi, Minami Hironobu

  第20回アジア太平洋造血細胞移植学会年次学術集会, Oct. 2015, English, アジア太平洋造血細胞移植学会, 沖縄, International conference

  Poster presentation


• A case of scopulariopsis pneumonia with acute myeloid leukemia

  Kim S, Kurata K, Yokoro Y, Goto H, Mizutani Y, Takenaka K, Otera Hiroshi, Kawamoto Shinichiro, Yakushijin Kimikazu, Yamamoto Koji, Ito T, Matsuoka Hiroshi, Minami Hironobu

  第77回日本血液学会学術集会, Oct. 2015, English, 日本血液学会, 金沢, Domestic conference

  Poster presentation


• A case of myeloid sarcoma with myelofibrosis secondary to polycthemia vera

  Ohmiya S, Kurata K, Nose T, Kawamoto Teruya, Kawamoto Shinichiro, Yakushijin Kimikazu, Yamamoto Koji, Ito T, Matsuoka Hiroshi, Minami Hironobu

  第77回日本血液学会学術集会, Oct. 2015, English, 日本血液学会, 金沢, Domestic conference

  Poster presentation


• 造血幹細胞移植患者へのNST介入の評価

  田渕 聡子, Takahashi Michiko, 生田 智子, 曽我 明弘, 永濱 郁代, Yakushijin Kimikazu, Kawamoto Shinichiro, 山西 美沙, 脇田 久美子, 三ヶ尻 礼子, 山本 育子, 山本 将司, 戸田 明代, Usami Makoto

  第7回日本静脈経腸栄養学会近畿支部学術集会, Jul. 2015, Japanese, 京都, Domestic conference

  Oral presentation


• A phase 1b study of panobinostat and 5-azacitidine in Japanese patients with MDS, CMML, or AML

  Yakushijin Kimikazu, Minami Hironobu, Toshiki Uchida, Michinori Ogura, Masafumi Taniwaki, Tsutomu Kobayashi, Asuka Mori, Masataka Yonemura, Wataru Munakata, Yukio Kobayashi

  第13回日本臨床腫瘍学会学術集会, Jul. 2015, English, 日本臨床腫瘍学会, 札幌, Domestic conference

  Oral presentation


• Absolute Lymphocyte Count Recovery Predicts Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation

  Keiji Kurata, Yakushijin Kimikazu, Atsuo Okamura, Yukinari Sanada, Hideaki Goto, Yu Mizutani, Seiji Kakiuchi, Yoshiharu Miyata, Yumiko Inui, Yohei Funakoshi, Kiyoaki Uryu, Kawamoto Shinichiro, Minami Yosuke, Katsuya Yamamoto, Tohru Murayama, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu

  the 6th JSH International Symposium, May 2015, English, 日本血液学会, 軽井沢, Domestic conference

  Poster presentation


• 化学療法中の固形腫瘍患者に対するインフルエンザワクチン2回接種法の有効性と安全性.

  眞田 幸尚, Yakushijin Kimikazu, 野村 哲彦, Chayahara Naoko, Toyoda Masanori, Kiyota Naomi, Kawamoto Shinichiro, Mukohara Toru, Matsuoka Hiroshi, Minami Hironobu

  第112回日本内科学会総会, Apr. 2015, Japanese, 日本内科学会, 京都, Domestic conference

  Oral presentation


• 造血幹細胞移植患者に対する栄養管理への介入とその評価

  生田 智子, 丹田 雅明, 曽我 昭宏, 山岡 慶子, 青木 紫織, 田淵 聡子, Takahashi Michiko, 西岡 達也, 槇本 博雄, 久米 学, Hirano Takeshi, Kawamoto Shinichiro, Yakushijin Kimikazu, Usami Makoto, 平井 みどり

  日本薬学会第135年会, Mar. 2015, Japanese, 日本薬学会, 神戸, Domestic conference

  Poster presentation


• 骨髄非破壊的造血幹細胞移植後の非感染性心内膜炎

  眞田 幸尚, Yakushijin Kimikazu, 垣内 誠司, 宮田 吉晴, 船越 洋平, Minami Yosuke, Kawamoto Shinichiro, 山本 克也, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu

  第38回日本造血幹細胞移植学会総会, Mar. 2015, Japanese, 日本造血細胞移植学会, 名古屋, Domestic conference

  Oral presentation


• Nonbacterial thrombotic endocarditis after reduced-intensity conditioning for stem cell transplantation

  眞田 幸尚, Yakushijin Kimikazu, 垣内 誠司, 宮田 吉晴, 船越 洋平, Minami Yosuke, Kawamoto Shinichiro, 山本 克也, 伊藤 光宏, Matsuoka Hiroshi, Minami Hironobu

  The 37th Annual Meeting of the Japan Society for Hematoloietic Cell Transplantation, Mar. 2015, English, 日本造血細胞移植学会, 神戸, Domestic conference

  Oral presentation


• 胃がんに対する胃切除を含め積極的治療介入が奏功した高齢者血管内リンパ腫

  小牧 遼平, 倉田 啓史, 宮田 吉晴, 王 康治, 菅原 佳織, 池田 英司, 金田 俊彦, Yakushijin Kimikazu, 山下 幸政

  第207回近畿地方会, Mar. 2015, Japanese, 日本内科学会, 大阪, Domestic conference

  Poster presentation


• 『抗がん薬の安全な取り扱いと曝露対策に関するプロジェクト』の取り組み－散剤調剤時の曝露状況について－

  水田 直美, 和田 敦, 土井 久容, 黒川 敏子, 藤原 由佳, Yakushijin Kimikazu, Mukohara Toru, Minami Hironobu

  日本臨床腫瘍薬学会学術大会2015, Mar. 2015, Japanese, 日本臨床腫瘍薬学会, 京都, Domestic conference

  Oral presentation


• 急性骨髄性白血病に対して同種骨髄移植後にCandida Parapsilosis による横紋筋融解症を呈した1例

  垣内 誠司, Yakushijin Kimikazu, 山本 克也, 乾 由美子, 岡村 篤夫, Kawamoto Shinichiro, Minami Yosuke, 村山 徹, 伊藤 光宏, Matsuoka Hiroshi, Minami Hironobu

  第54回 神戸血液病研究会, Feb. 2015, Japanese, 神戸血液病研究会, 神戸, Domestic conference

  Oral presentation


• Efficacy of the Two-Dose Influenza Vaccine in Cancer Patients Receiving Chemotherapy: A Prospective Study.

  Yukinari Sanada, Yakushijin Kimikazu, Tetsuhiko Nomura, Katsuya Yamamoto, Keiji Kurata, Kei Takenaka, Seiji Kakiuchi, Yoshiharu Miyata, Yoshinori Imamura, Meiko Nishimura, Yohei Funakoshi, Yuriko Iwamoto, Chayahara Naoko, Toyoda Masanori, Minami Yosuke, Kiyota Naomi, Mukohara Toru, Kawamoto Shinichiro, Shimono Yohei, Mitsuhiro Ito, Matsuoka Hiroshi, Minami Hironobu

  56th Meeting of the American Society of Hematology, Dec. 2014, English, American Society of Hematology, サンフランシスコ, International conference

  Poster presentation


• Rapid recovery of lymphocyte counts after stopping MTX treatment might predict following regression of MTX-LPD.

  Yumiko Inui, Matsuoka Hiroshi, Takashi Shimada, Yakushijin Kimikazu, Atsuo Okamura, Mitsuhiro Ito, Tomoo Ito, Yukinari Sanada, Yoshiharu Miyata, Seiji Kakiuchi, Yuriko Kawamori, Shingo Yano, Yuichi Yahagi, Katsuki Sugiyama, Yoji Ogasawara, Shinobu Takahara, Takeshi Saito, Katsuya Yamamoto, Keisuke Aiba, Minami Hironobu

  The 76th Annual Meeting, the Japanese Society of Hematology, Nov. 2014, English, Japanese Society of Hematology, 大阪, Domestic conference

  Poster presentation


• MYC amplification in the form of double minute chromosomes in two cases of acute myeloid leukemia.

  Yamamaoto K, Yakushijin Kimikazu, Okamura A, Sanada Y, Kakiuchi S, Miyata Y, Iwamoto Y, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu

  第76回日本血液学会学術集会, Oct. 2014, English, 日本血液学会, 大阪, Domestic conference

  Poster presentation


• A case of spontaneous hemophilia B diagnoses in adulthood

  Miyata Y, Higasa S, Kakiuchi S, Sanada Y, Iwamoto Y, Kawamoto Shinichiro, Yakushijin Kimikazu, Yamamaoto K, Murayama T, Kuroki Y, Matsuoka Hiroshi, Minami Hironobu

  第76回日本血液学会学術集会, Oct. 2014, English, 日本血液学会, 大阪, Domestic conference

  Poster presentation


• 骨髄異形成症候群に結核性多発膿瘍を併発した1例。

  安部 祐子, 眞田 幸尚, 宮田 吉晴, 船越 洋平, Yakushijin Kimikazu, 杉本 健, 岡村 篤夫, 山本 克也, Matsuoka Hiroshi, Minami Hironobu

  第201回日本内科学会近畿地方会, Sep. 2014, Japanese, 日本内科学会, 京都, Domestic conference

  Oral presentation


• 当院における『抗がん薬の安全な取り扱いと曝露対策に関するプロジェクト』の取り組み

  水田 直美, 和田 敦, 土井 久容, 黒川 敏子, 藤原 由佳, Yakushijin Kimikazu, Mukohara Toru, Minami Hironobu

  第52回日本癌治療学会学術集会, Aug. 2014, Japanese, 日本癌治療学会, 横浜, Domestic conference

  Poster presentation


• 当院における『抗がん薬の安全な取り扱いと曝露対策に関するプロジェクト』の取り組み-散薬服用時の曝露状況について-

  水田 直美, 和田 敦, 土井 久容, 黒川 敏子, 藤原 由佳, Yakushijin Kimikazu, Mukohara Toru, Minami Hironobu

  第12回日本臨床腫瘍学会学術集会, Jul. 2014, Japanese, 日本臨床腫瘍学会, 福岡, Domestic conference

  Oral presentation


• 気道狭窄を伴う異なる頸部悪性腫瘍の2例

  岡田 希美, 眞田 幸尚, Yakushijin Kimikazu, 竹中 圭, 船越 洋平, Toyoda Masanori, Mukohara Toru, 大谷 恭子, Matsuoka Hiroshi, Minami Hironobu

  The 12th Annual Meeting of Japanese Society of Medical Oncology, Jul. 2014, Japanese, Japanese Society of Medical Oncology, 福岡, Domestic conference

  Poster presentation


• A prospective study of the efficacy of influenza vaccination for cancer patients receiving chemotherapy

  眞田 幸尚, Yakushijin Kimikazu, 山本 克也, 西村 明子, 船越 洋平, Chayahara Naoko, Toyoda Masanori, Kiyota Naomi, Mukohara Toru, Minami Hironobu

  The 12th Annual Meeting of Japanese Society of Medical Oncology, Jul. 2014, Japanese, Japanese Society of Medical Oncology, 福岡, Domestic conference

  Oral presentation


• 当院におけるゼヴァリンの初期経験

  西川 遼, Ejima Yasuo, Yoshida Kenji, Miyawaki Daisuke, Uezono Haruka, Ishihara Takeaki, ノルシャズリナ, Sasaki Ryohei, Matsuoka Hiroshi, Yakushijin Kimikazu

  第307回公益社団法人日本医学放射線学会関西地方会(第379回レントゲンアーベント), Jun. 2014, Japanese, 公益社団法人日本医学放射線学会関西地方会, 大阪, Domestic conference

  Oral presentation


• Poor Prognosis of Patients with Severe Sinusoidal Obstruction Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation in Japanese population: On Behalf of Complications Working Group of the Japan Society for Hematopoietic Cell Transplantation (J

  Yakushijin Kimikazu, Yoshiko Atsuta, Kazuteru Ohashi, Akira Yokota, Heiwa Kanamori, Toshihiro Miyamoto, Hisashi Sakamaki, Hiromasa Yabe, Yasuo Morishima, Koji Kato, Ritsuro Suzuki, Takahiro Fukuda

  EHA, Jun. 2014, English, EHA, ミラノ, イタリア, International conference

  Poster presentation


• 同種造血幹細胞移植後の類洞閉塞症候群の発症割合、リスク因子ならびに治療法に関する研究

  Yakushijin Kimikazu, 熱田 由子, 大橋 一輝, 横田 朗, 金森 平和, 宮本 敏浩, 坂巻壽, 矢部普正, 森島泰雄, 加藤剛二, 鈴木律朗, 福田隆浩

  第36回日本造血細胞移植学会総会, Mar. 2014, English, 日本造血細胞移植学会, 沖縄, Domestic conference

  Oral presentation


• Nationwide Survey of Sinusoidal Obstruction Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, and Outcome: On Behalf of Complications Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHC

  Yakushijin Kimikazu, Yoshiko Atsuta, Doki Noriko, Akira Yokota, Heiwa Kanamori, Toshihiro Miyamoto, Hisashi Sakamaki, Hiromasa Yabe, Yasuo Morishima, Koji Kato, Ritsuro Suzuki, Takahiro Fukuda

  ASH, Dec. 2013, English, American Society of Hematology, New Orleans, USA, International conference

  Poster presentation


• Gvhd Prophylaxis With Mycophenolate Mofetil and Clacineurin Inhibitor In Allogeneic Hematopoietic Cell Transplantation From HLA-Matche SibligsOr 7-8/8HLA-Matched Unrelated Volunteer Donors;A Japanese,Multicenter,Phase II Trial

  Takahiko Nakane, Hirohisa Nakamae, Saiko Kurosawa, Atsuo Okamura, Mchihiro Hidaka, Takuya Yamashita, Akiko Kohno, Takeshi Saito, Yasutaka Aoyama, Kzuo Hatanaka, Katayama Yoshio, Yakushijin Kimikazu, Tshimitsu Matsui, Akiyoshi Takami, Takuhiro Yamaguchi, Masayuki Hino, Takahiro Fukuda

  55th ASH Annual Meeting and Exposition, Dec. 2013, English, American Society of Hematology, New Orleans, USA, International conference

  Oral presentation


• Results of a retrospective study about MTX-LPD and a puestionnaire 'How I treat MTX-LPD'

  乾 由美子, Matsuoka Hiroshi, Yakushijin Kimikazu, 垣内 誠司, 眞田 幸尚, 宮田 吉晴, 船越 洋平, 川森 有里子, 岡村 篤夫, 山本 克也, 村山 徹, Minami Hironobu

  第75回日本血液学会学術集会, Oct. 2013, Japanese, 日本血液学会, 札幌, Domestic conference

  Poster presentation


• Extramedullary T-lymphoid crisis of ETV6/ABL1-positive myeloproliferative neoplasm with t(7;14)

  山本 克也, Yakushijin Kimikazu, 中町 祐司, 宮田 吉晴, 眞田 幸尚, 岩本 有里子, 岡村 篤夫, 松本 久幸, 村山 徹, Kawano Seiji, Hayashi Yoshitake, Matsuoka Hiroshi, Minami Hironobu

  第75回日本血液学会学術集会, Oct. 2013, Japanese, 日本血液学会, 札幌, Domestic conference

  Poster presentation


• A case of primary cardiac intermediate Burkitt / Diffuse large B cell lymphoma

  宮田 吉晴, 垣内 誠司, 倉田 啓史, 眞田 幸尚, 乾 由美子, 岩本 有里子, 富岡 秀夫, Yakushijin Kimikazu, 岡村 篤夫, 山本 克也, 村山 徹, Itoh Tomoo, Matsuoka Hiroshi, Minami Hironobu

  第75回日本血液学会学術集会, Oct. 2013, English, 日本血液学会, 札幌, Domestic conference

  Poster presentation


• 鼻腔原発NK／T細胞リンパ腫に対する放射線治療経験

  原田 文, Miyawaki Daisuke, 西村英輝, Ejima Yasuo, Yoshida Kenji, Yakushijin Kimikazu, Matsuoka Hiroshi, Doi Kiyoshi, Ohtsuki Naoki, Nibu Ken-ichi, Sasaki Ryohei

  第37回日本頭頸部癌学会, Jun. 2013, Japanese, 日本頭頸部癌学会, 新宿、東京（京王プラザホテル）, Domestic conference

  Poster presentation


• Tolvaptan as an alternative treatment for refractory fluid retention associated with sinusoidal obstruction syndrome after allogeneic stem cell transplantation

  Yakushijin Kimikazu, Kurata K, Miyata T, Kakiuchi S, Tomioka H, Kawamori-Iwamoto Y, Inui Y, Sanada Y, Okamura A, Yamamoto Koji, Murayama T, Matsuoka H, Minami Hironobu

  The 17th meeting of Asia Pacific Blood and Marrow Transplantation Group, Oct. 2012, English, Asia Pacific Blood and Marrow Transplantation Group, India, Tolvaptan as an alternative treatment for refractory fluid retention associated with sinusoidal obstruction syndrome after allogeneic stem cell transplantation, International conference

  Poster presentation


• Retrospective analysis of safety and efficacy of (R-) LEED and (R-) MCEC regimens followed by autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.

  Miyata T, Tominaga R, Gomyo R, Maeda A, Mizuno I, Yakushijin Kimikazu, Okamura A, Yamamoto Koji, Matsuoka H, Minami Hironobu, Murayama T

  The 17th meeting of Asia Pacific Blood and Marrow Transplantation Group, Oct. 2012, English, Asia Pacific Blood and Marrow Transplantation Group, India, Retrospective analysis of safety and efficacy of (R-) LEED and (R-) MCEC regimens followed by autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma., International conference

  Poster presentation


• Candica parapsilosis as a cause for rhabdomyolysis in a patient with acute myeloid leukemia after bone marrow transplantation.

  Kakiuchi S, Yakushijin Kimikazu, Tomioka H, Kawamori-Iwamoto Y, Inui Y, Okamura A, Yamamoto Koji, Murayama T, Matsuoka H, Minami Hironobu

  The 17th meeting of Asia Pacific Blood and Marrow Transplantation Group, Oct. 2012, English, Asia Pacific Blood and Marrow Transplantation Group, India, Candica parapsilosis as a cause for rhabdomyolysis in a patient with acute myeloid leukemia after bone marrow transplantation., International conference

  Poster presentation


• A novel TRB@/NOTCH1 fusion gene in T-cell lymphoblastic lymphoma with t(7;9)(q34;q34)

  Katsuya Yamamoto, Yuji Nakamachi, Yakushijin Kimikazu, Seiji Kakiuchi, Yumiko Inui, Yuriko Kawamori, Atsuo Okamura, Tohru Murayama, Itoh Tomoo, Kawano Seiji, Matsuoka Hiroshi, Minami Hironobu

  The 74th Annual meeting of the Japaneses society of Hematology, Oct. 2012, Japanese, Japaneses society of Hematology, 京都, Domestic conference

  Poster presentation


• 当科における悪性腫瘍に伴う静脈血栓塞栓症（VTE）の検討

  島田 貴信, Kiyota Naomi, 西村 明子, 今村 善宣, 船越 洋平, 富岡 秀夫, Chayahara Naoko, Toyoda Masanori, Yakushijin Kimikazu, 岡村 篤夫, Mukohara Toru, Matsuoka Hiroshi, Minami Hironobu

  第10回日本臨床腫瘍学会学術集会, Jul. 2012, Japanese, 日本臨床腫瘍学会, 大阪, cancer related VTEの現状, Domestic conference

  Poster presentation


• 当科においける静脈血栓塞栓症(VTE) 症例の検討

  島田 貴信, Kiyota Naomi, 藤原 豊, 西村 明子, 今村 善宣, 船越 洋平, 富岡 秀夫, Toyoda Masanori, Chayahara Naoko, Yakushijin Kimikazu, 岡村 篤夫, Mukohara Toru, Matsuoka Hiroshi, Minami Hironobu

  第10回日本臨床腫瘍学会学術集会, Jul. 2012, Japanese, 日本臨床腫瘍学会, 大阪, 当科においける静脈血栓塞栓症(VTE) 症例の検討, Domestic conference

  Poster presentation


• 切除不能神経内分泌腫瘍に対するダカルバジン単剤療法：後方視的解析

  今村 善宣, 藤原 豊, Toyoda Masanori, Chayahara Naoko, 西村 明子, 船越 洋平, 富岡 秀夫, 島田 貴信, Yakushijin Kimikazu, 岡村 篤夫, Kiyota Naomi, Mukohara Toru, Matsuoka Hiroshi, Minami Hironobu

  第10回日本臨床腫瘍学会学術集会, Jul. 2012, Japanese, 日本臨床腫瘍学会, 大阪, 切除不能神経内分泌腫瘍に対するダカルバジン単剤療法：後方視的解析, Domestic conference

  Poster presentation


• Secondary Phiradelphia-positive mixed-phenotype acute leukemia after adjuvant chemotherapy with S-1.

  Yumiko Inui, Atsuo Okamura, Atsushi Wada, Yakushijin Kimikazu, Matsuoka Hiroshi, Katsuya Yamamoto, Hirai Midori, Minami Hironobu

  第74回日本血液学会学術集会, Jun. 2012, English, 日本血液学会, 京都, Domestic conference

  Poster presentation


• Hyperglycaemia during the early phase after haematopoietic stem cell transplantation is caused by the elevation of insulin resistance

  Yakushijin Kimikazu, S.Fuji, S.Kim, Yoshimura Kenichi, S.Kurosawa, Y.Asakura, N.Ueno, K.Tada, T.Maeda, D.Nakamura, M.Nishinohara, K.Furuta, S.Mori, T.Tanosaki, Y.Heike, Y.Takaue, K.Tobinai, T.Fukuda

  38th Annual Meeting of the European Group for Blood and Marrow Transplantation, Apr. 2012, English, European Group for Blood and Marrow Transplantation, Geneva, Switzerland, International conference

  Poster presentation


• 皮疹を欠くもののHHV-6の再活性化と様々な症状発現を伴い、レクチゾールによるDIHS様変化を呈した1例

  辻本 昌理子, 山田 陽三, 濵岡 大, 清水 秀樹, 川森 有里子, Yakushijin Kimikazu, Arai Takashi, 平岡 栄治, Nishigori Chikako

  第41回日本皮膚アレルギー・接触皮膚炎学会総会・学術大会, Jul. 2011, Japanese, 日本皮膚アレルギー・接触皮膚炎学会, 山梨, Domestic conference

  Oral presentation


• Successful treatment with intravitreal injection of voricanazole in a patient with fungal endophthalmitis before cord blood transplantation

  船越 洋平, Yakushijin Kimikazu, 明石 梓, Kusuhara Sentaro, 土井 健史, 乾 由美子, Toyoda Masanori, 島田 貴信, Chayahara Naoko, 富岡 秀夫, Kiyota Naomi, 藤原 豊, Mukohara Toru, 岡村 篤夫, 山本 克己, Matsuoka Hiroshi, 村山 徹, Minami Hironobu

  第33回日本造血細胞移植学会総会, Mar. 2011, Japanese, 日本造血細胞移植学会, 松山, Domestic conference

  Poster presentation


• Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantaiton:results of elderly patients

  黒澤 彩子, Yakushijin Kimikazu, 山口 拓洋, 熱田 由子, 長村 登紀子, 秋山 秀樹, 谷口 修一, 宮村 耕一, 高橋 聡, 衛藤 徹也, 森島 泰雄, 坂巻 壽, 福田 隆浩

  第33回日本造血細胞移植学会総会, Mar. 2011, Japanese, 日本造血細胞移植学会, 愛媛, Domestic conference

  Oral presentation


• Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantaiton:results of younger patients

  Yakushijin Kimikazu, 黒澤彩子, 山口拓洋, 熱田由子, 長村登紀子, 秋山秀樹, 谷口修一, 宮村耕一, 高橋聡, 衛藤徹也, 森島泰雄, 坂巻壽, 福田隆浩

  第33回日本造血細胞移植学会総会, Mar. 2011, Japanese, 日本造血細胞移植学会, 愛媛, Domestic conference

  Poster presentation


• Optimal use of G-CSF after allogeneic hematopoietic stem cell transplantation under MMF dosing for GVHD prophylaxis

  岡村 篤夫, Yakushijin Kimikazu, 乾 由美子, 船越 洋平, 富岡 秀夫, 島田 貴信, Toyoda Masanori, Chayahara Naoko, Kiyota Naomi, 藤原 豊, Mukohara Toru, 山本 克也, Matsuoka Hiroshi, Minami Hironobu

  第33回日本造血細胞移植学会総会, Mar. 2011, Japanese, 日本造血細胞移植学会, 松山, Domestic conference

  Poster presentation


• Day +11 Methotrexate (MTX) might Reduce the Risk of Engraftment Syndrome (ES) and Acute Graftversus-Host Disease (GVHD) after Unrelated Bone Marrow Transplantation (U-BMT) with Reduced-Intensity Conditioning Regimens

  Yakushijin Kimikazu, 朝倉 義崇, 前田 猛, 黒澤 彩子, 平本 展大, 金成 元, 森 慎一郎, 田野崎 隆二, 平家 勇司, 高上 洋一, 飛内 賢正, 福田 隆浩

  BMT Tandem meetings, Feb. 2011, English, 米国骨髄移植学会, ホノルル, 米国, International conference

  Poster presentation


• Engraftment Syndrome (ES) After Reduced-Intensity Stem Cell Transplantation (RIST): ES May Have a Negative Impact on Survival In Standard-Risk Patients

  前田 猛, Yakushijin Kimikazu, 朝倉 義崇, 平本 展大, 黒澤 彩子, 神山 祐太郎, 福原 傑, 上野 二菜, 金成 元, 森 慎一郎, 田野崎 隆二, 平家 勇司, 飛内 賢正, 高上 洋一, 福田 隆浩

  第52回米国血液学会, Dec. 2010, English, 米国血液学会, オーランド, 米国, International conference

  Poster presentation


• Comparison of Outcomes After Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) In 73 Patients with Follicular Lymphoma (FL), Transformed Follicular Lymphoma (TL), or De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Favorable Outcome for TL Similar to

  多田 耕平, 金成 元, 朝倉 義崇, 平本 展大, Yakushijin Kimikazu, 黒澤 彩子, 上野 二菜, 神山 祐太郎, 福原 傑, 森 慎一郎, 平家 勇司, 田野 崎隆二, 飛内 賢正, 高上 洋一, 福田 隆浩

  第52回米国血液学会, Dec. 2010, English, 米国血液学会, オーランド, 米国, International conference

  Poster presentation


• Changes In Incidence and Causes of Non-Relapse Mortality (NRM) After Allogeneic Hematopoietic Cell Transplantation (allo-HCT): Are Transplants Improving?

  黒澤 彩子, Yakushijin Kimikazu, 山口 拓洋, 熱田 由子, 長村 登紀子, 秋山 秀樹, 谷口 修一, 宮村 耕一, 高橋 聡, 衛藤 徹也, 森島 泰雄, 坂巻 壽, 福田 隆浩

  第52回米国血液学会, Dec. 2010, English, 米国血液学会, オーランド, 米国, International conference

  Oral presentation


• MTX関連リンパ腫の2例

  乾 由美子, 船越 洋平, Yakushijin Kimikazu, 岡村 篤夫, Matsuoka Hiroshi, Minami Hironobu

  第94回近畿血液学地方会, Nov. 2010, Japanese, 近畿血液学地方会, 大津, Domestic conference

  Oral presentation


• フル移植とミニ移植の比較

  Yakushijin Kimikazu, 福田隆浩

  第72回日本血液学会総会, Sep. 2010, Japanese, 日本血液学会, 横浜, Domestic conference

  Others


• Therapy-related pure erythroid leukemia with hemophagocytic syndrome

  Yohei Funakoshi, Katsuya Yamamoto, Yumiko Inui, Hideo Tomioka, Chayahara Naoko, Yakushijin Kimikazu, Kiyota Naomi, Yutaka Fujiwara, Atsuo Okamura, Mukohara Toru, Matsuoka Hiroshi, Minami Hironobu

  第72回日本血液学会総会, Sep. 2010, Japanese, 日本血液学会, 横浜, Domestic conference

  Poster presentation


• Recent changes in non-relapse mortality after allogeneic hematopoietic cell transplantation

  中村 大輔, 黒澤 彩子, Yakushijin Kimikazu, 藤 重夫, 朝倉 義崇, 平本 展大, 金 成元, 森 慎一郎, 田野崎 隆二, 平家 勇司, 高上 洋一, 福田 隆浩

  第72回日本血液学会総会, Sep. 2010, Japanese, 日本血液学会, 横浜, Domestic conference

  Oral presentation


• Engraftment syndrome after reduced-intensity stem cell transplantation

  前田 猛, Yakushijin Kimikazu, 朝倉 義崇, 平本 展大, 黒澤 彩子, 神山 祐太郎, 福原 傑, 上野 二菜, 金 成元, 森 慎一郎, 田野崎 隆二, 平家 勇司, 高上 洋一, 福田 隆浩

  第72回日本血液学会総会, Sep. 2010, Japanese, 日本血液学会, 横浜, Domestic conference

  Oral presentation


• A novel dicentric chromosome, dic(9;9)(p12;q34), in follicular lymphoma withaut t(14;18)

  Katsuya Yamamoto, Manabu Shimoyama, Yohei Funakoshi, Yakushijin Kimikazu, Atsuo Okamura, Matsuoka Hiroshi, Itoh Tomoo, Minami Hironobu

  第72回日本血液学会総会, Sep. 2010, Japanese, 日本血液学会, 横浜, Domestic conference

  Poster presentation


• 造血幹細胞移植後の類洞閉塞症候群に対するデフィブロタイドの有効性の検討

  Yakushijin Kimikazu, Okamura Atsuo, Katayama Yoshio, Shimoyama Manabu, Matsui Toshimitsu

  第31回日本造血細胞移植学会総会, Feb. 2009, Japanese, 日本造血細胞移植学会, 札幌, Domestic conference

  Oral presentation


• Sequential measurement of portal flow is helpful for assessment of SOS treatment with defibrotide

  Yakushijin Kimikazu, Okamura Atsuo, Katayama Yoshio, Shimoyama Manabu, Matsui Toshimitsu

  第70回日本血液学会総会, Oct. 2008, Japanese, 日本血液学会, 京都, Domestic conference

  Poster presentation


• Effectiveness of cord blood transplant for adult acute lymphoblastic leukemia in CR

  Yakushijin Kimikazu, Okamura Atsuo, Katayama Yoshio, Shimoyama Manabu, Matsui Toshimitsu

  第70回日本血液学会総会, Oct. 2008, Japanese, 日本血液学会, 京都, Domestic conference

  Poster presentation


• Pure red cell aplasia with primary screlosing cholangitis improved after liver transplantation

  Yakushijin Kimikazu, Okamura Atsuo, Shimoyama Manabu, Katayama Yoshio, Matsui Toshimitsu, Ito Mitsuhiro, Ku Yonson

  第70回日本血液学会総会, Oct. 2008, Japanese, 日本血液学会, 京都, Domestic conference

  Poster presentation

• レパトア解析を利用した新規免疫反応評価法による網羅的免疫センシングの開発

  船越 洋平, 薬師神 公和, 大上 雅史

  日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, Apr. 2025 - Mar. 2028


• BCRレパトア解析を用いた造血幹移植後免疫再構築の解明

  薬師神 公和, 船越 洋平

  日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, Apr. 2024 - Mar. 2027